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MANDATE: European Collaborative Action “Urban Air, Indoor Environment and Human Exposure” 
(formerly "Indoor Air Quality & it's Impact on Man") 
 
For 25 years now the European Collaborative Action ECA "Indoor Air Quality & it's Impact on Man" has 
been implementing a multidisciplinary collaboration of European scientists the ultimate goal of which 
was the provision of healthy and environmentally sustainable buildings. To accomplish this task ECA is 
dealing with all aspects of the indoor environment including thermal comfort, pollution sources, the 
quality and quantity of chemical and biological indoor pollutants, energy use, and the ventilation 
processes which all may interact with indoor air quality. The work of ECA has been directed by a 
Steering Committee, which is hosted and managed by the European Commission’s Joint Research 
Centre.  
 
In order to provide a broader view on air pollution exposure in urban areas, both indoors and 
outdoors, the ECA Steering Committee decided to put more emphasis on the links between indoor and 
outdoor air quality and to focus its further work under a new title “Urban Air, Indoor Environment and 
Human Exposure”.  The focus of the renewed activity is urban & indoor air pollution exposure 
assessment, seen as part of environmental health risk assessment and also considering the needs of 
urban and indoor air quality management. The new approach is supported by those activities of the 
Joint Research Centre’s Institute for Health and Consumer Protection dealing with exposure to physical 
and chemical agents, chemical assessment and testing and associated health effects. 
 
This focussed activity proceeds within the broader framework of (i) health and comfort of the citizens, 
(ii) building technologies and source controls, and (iii) requirements of sustainability, energy 
efficiency and conservation of natural resources. 
 
Specific examples of the working areas of ECA are: 
- the relative importance of outdoor and indoor sources of pollution, 
- the building-related interaction between outdoor urban air and indoor air, 
- exposure to pollutants from the different urban outdoor and indoor sources and its relation to 
health and comfort. 
 
By addressing such topics ECA will lay the ground for air quality management to minimise exposures 
to air pollutants. It will thus continue to contribute to pre-normative research needed by EC services 
and national authorities responsible for preventing pollution and promoting health, comfort and 
quality of life.  
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Abstract 
 
ECA-IAQ (European Collaborative Action, Urban Air, Indoor Environment and Human 
Exposure), 2013. Harmonisation framework for health based evaluation of indoor 
emissions from construction products in the European Union using the EU-LCI concept, 
Report No 29. EUR 26168 EN. Luxembourg: Office for Official Publications of the 
European Communities 
 
This report describes a harmonised procedure for establishing a list of compounds and their associated LCI 
(Lowest Concentration of Interest) values for the evaluation of emissions from construction products (EU-LCI) 
taking into account existing procedures used in some Member States (i.e. ANSES in France and AgBB in 
Germany). It provides an appropriate health‐protective, science-based and transparent yet pragmatic approach 
with a flexible framework that enables review of the EU-LCI procedure to take into account new knowledge (e.g. 
data resulting from the REACH implementation process) for future revision of the EU-LCI master list in terms of 
both the compounds listed and their EU-LCI values. 
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EXECUTIVE SUMMARY 
 
The health based evaluation of chemical emissions from construction products is an 
integral part of the harmonisation framework for indoor products labelling schemes in 
the EU. The harmonisation process for the health based evaluation of gas-phase 
chemical emissions from construction products in Europe is based on the LCI (‘Lowest 
Concentration of Interest’) approach1, described fully in this report.  
The work was co-ordinated by the European Commission’s Directorate General Joint 
Research Centre (DG JRC) and performed in the context of the PILOT INDOOR AIR 
MONIT administrative arrangement with the Directorate General for Health and 
Consumers (SANCO) in liaison with experts from some EU Member States, the 
construction industry, the European Chemicals Industry (CEFIC), and also in 
consultation with the Directorate General for Enterprise and Industry (DG ENTR).   
The EU-LCI development work outlined in the present report builds on firm foundations 
of the existing national evaluation systems established by AgBB (German Committee for 
Health-related Evaluation of Building Products) in Germany and ANSES (French Agency 
for Food, Environmental and Occupational Health and Safety) in France that currently 
apply the LCI concept, the Danish Indoor Climate Labelling (DICL), the Finnish (M1) and 
Belgium labelling schemes, and from chemical emission test laboratories in the UK, 
France, Finland and Denmark. Ultimately, the harmonisation process and procedures 
described here will allow voluntary and mandatory labelling schemes to evaluate 
product emissions in the same way by using a robust health-based procedure. This work 
also supports the establishment of future emission classes for CE marking (Conformité 
Européenne) under the European Construction Products Regulation (CPR, 2011) with a 
harmonised list of LCI values (EU-LCIs).  
In the EU-LCI work performed to date, only volatile organic compounds (VOCs) have 
been considered. Very volatile organic compounds (VVOCs), semi-volatile organic 
compounds (SVOCs) and carcinogens were not considered at this stage of the process.   
This phase of the EU-LCI harmonisation process has established:   
1. A robust protocol for establishing a harmonised list of compounds and their 
associated EU-LCI values which takes into account the existing procedures used 
in some EU Member States. This procedure, based on sound toxicological and risk 
assessment principles, represents an appropriate health-protective, science-
based and transparent yet pragmatic approach for the evaluation of chemical 
emissions from construction products. 
2. A list of interim EU-LCI values for 82 compounds, which includes some of the 
compounds most relevant to DG ENTR’s ad hoc group on emission classes (i.e., 
acetaldehyde, toluene, xylene, 1,2,4-trimethylbenzene, 1,4-dichlorobenzene, 
ethylbenzene, 2-butoxyethanol and styrene) and two compounds of recent 
concern in Germany (ε-Caprolactam) and Belgium (α-pinene).  
3. A flexible framework that enables future revision of the content of the EU-LCI list 
in terms of both the type and number of compounds included and their 
                                                 
1
 LCI = Lowest Concentration of Interest (of individual VOCs). The LCI concept was first developed by the 
European Collaborative Action on ‘Indoor Air Quality and its Impact on Man’ when considering the best 
way to evaluate emissions from solid flooring materials. It was defined (see ECA Report No.18, 1997) as 
“the lowest concentration above which, according to best professional judgement, the pollutant may have 
some effect on people in the indoor environment”. 
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associated EU-LCI values. The framework provides the possibility of taking into 
account new knowledge (e.g. data resulting from the REACH implementation 
process or compounds identified and suggested by EU national authorities).  
The detailed protocol developed for the de novo derivation of EU-LCI values includes the 
following parts: 
a) Definition of EU-LCI  
EU-LCI values are health-based reference concentrations for inhalation exposure 
used to assess emissions after 28 days from a single product during a laboratory 
test chamber procedure as defined in the Technical Specification TS 16516 of the 
horizontal testing method developed by CEN TC 351/WG 2. EU-LCI values are 
applied in product safety assessment with the ultimate goal to avoid health risks 
from long-term exposure of the general population and they are usually 
expressed as μg/m3. 
b) Data Compilation Sheet 
All relevant toxicological data from different sources in the literature (indoor air 
quality guidelines, toxicological reference values or occupational exposure limits 
from established international and national committees and information 
available through the REACH process) for each compound are assimilated into 
one table. This simplifies the identification of commonalities and differences and 
also guarantees the fundamental principle of transparency in deriving the EU-LCI 
values.  
c) Fact Sheet 
To ensure that the derivation of EU-LCI values is transparent, a summary fact-
sheet with standardised format is generated for each compound. This comprises 
four main sections: a) general information; b) toxicological database (values 
derived from the data compilation process described above); c) assessment 
factors; and d) the derivation of the EU-LCI value. At the end of the factsheet the 
rationale for the derivation of the EU-LCI is given. This succinctly 
explains/justifies the selection and use of key data in the derivation of the EU-LCI 
value, in particular the selection of the key study used to determine the point-of-
departure value. It also, where necessary, explains/justifies the use of particular 
assessment factors, especially non-default factors. 
The protocol also provides guidance on applying a harmonised application of read-
across and assessment factors in EU-LCI derivation. 
Through application of the principles and rationale developed by the EU-LCI Working 
Group (EU-LCI WG) for the establishment of EU-LCI values, EU-LCI values have been 
established for a number of priority compounds. The EU-LCI WG compiled an EU-LCI 
master list containing a total of 177 compounds subdivided into two groups, the first 
containing 82 compounds with agreed interim EU-LCI values and the second containing 
95 compounds for which EU-LCI values are still to be derived.   
The practical application of the EU-LCI values and the necessary consideration of 
multiple sources that are normally present in real building scenarios are discussed and 
potential harmonisation issues related to the overall evaluation of emissions from 
construction products (for example, common criteria and threshold values for total 
volatile organic compounds (TVOC), R-value, SVOC, sensory evaluation and the sum of 
“not-yet-assessable” compounds) are identified.  
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Finally, developments concerning policies at both EU and national levels that have 
explicitly or implicitly considered and/or referred to the work of the EU-LCI WG are 
reported.  
In summary, this report presents the outcome of the preparatory work performed by the 
EU-LCI WG and represents a first consensus among the experts and representatives of 
the European Commission, some EU member states and the chemical and construction 
products industry who participated in the EU-LCI WG. The developed EU-LCI 
harmonisation framework is now open for a wider and formal consultation process at 
policy level which, however, is not yet in place.  
The EU-LCI work is considered an integral part of the harmonisation framework for 
indoor product labelling schemes in the EU which has potential for wide application 
across Europe, ensuring stronger protection of the health of European citizens from 
chemicals emitted from indoor products. 
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1. INTRODUCTION 
 
1.1 Background  
Since 2007, European experts in health related evaluation of construction materials and 
emissions testing have been working to establish a harmonised set of criteria for 
European construction material labelling schemes. The framework for harmonised 
criteria is set out in the report “Harmonised framework for indoor material labelling 
schemes” (ECA Report No. 27, 2012). Concerning the health based evaluation of 
emissions from construction materials the experts concluded that the “Lowest 
concentrations of interest” (LCI) approach is the most feasible strategy for assessing 
the health effects of compounds emitted from construction materials.  
The LCI strategy is used to assess the potential risks to health arising from inhalation 
exposure to individual VOCs. The ECA Report no. 18 on "Evaluation of VOC Emissions 
from Building Products – Solid Flooring Material" (1997) presented the key elements of 
this strategy. During the development of the national labelling approaches in Germany, 
France and Belgium, emphasis was put especially on the evaluation of individual 
compounds by consideration of LCI-values. Procedures have been developed in 
Germany and France that provide transparent systems for setting these values. The 
procedures and the main differences between these two approaches are outlined in ECA 
report no. 27.  
The need to harmonise the health based evaluation of emissions from construction 
products in Europe based on the LCI concept was discussed and consensus on the way 
forward achieved during the Workshop “Harmonisation of the health based evaluation 
of emissions from building products in the EU using the LCI concept” which was 
organised and hosted by the European Commission’s Joint Research Centre on 13-14 
September 2010 in Ispra (JRC Workshop report, 2010).  
Subsequently, in 2011 an EU-LCI working group comprising toxicologists and experts in 
chemical emission testing and product labelling was established and co-ordinated by 
JRC (as part of the PILOT INDOOR AIR MONIT administrative arrangement no. 
SI2.582843 with DG SANCO) with the objective to develop a harmonised framework for 
the health based evaluation of emissions from construction products in the EU using the 
LCI concept (the EU-LCI common list of compounds and values). Since December 2010, 
the EU-LCI work has been integrated into the activities on indoor air quality led by DG 
SANCO.  
This work is also linked to DG ENTR’s EGDS ad hoc group on emission classes for 
dangerous compounds under the remit of the Construction Products Directive 
(89/106/CE) (CPD, 1989). This group was set up by DG ENTR in November 2010 to 
develop a harmonised procedure for the classification of emission performance of 
construction products to be used in technical specifications and also included in the 
information provided with the CPD CE marking.   
Ultimately, the EU-LCI harmonisation framework will allow voluntary and mandatory 
labelling schemes to evaluate product emissions in the same way using a robust health-
based procedure and will support the establishment of future emission classes for CE 
marking under the European Construction Products Regulation (CPR, 2011) with a 
harmonised list of LCI values.  
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At this stage of the EU-LCI harmonisation work only volatile organic compounds (VOCs) 
have been considered. Other very volatile (VVOCs) and semi-volatile organic compounds 
(SVOCs) are to be addressed in the future.   
Nonetheless, in the context of the EU-LCI framework the starting list contains around 
177 VOCs commonly detected in emission tests of construction materials. The work 
builds on firm foundations laid by the labelling scheme and the protocol for qualifying 
emissions from construction products and decorating materials established by AgBB 
(German Committee for Health-related Evaluation of Building Products) and ANSES 
(French Agency for Environmental and Occupational Health and Safety) that currently 
apply the concept of LCI values, as well as schemes in Finland, Denmark and Belgium.  
The focus of the EU-LCI working group was the establishment of a harmonised and 
robust protocol for the derivation of EU-LCIs which is decribed in this report. It is based 
on sound toxicological and risk assessment principles and in accordance with REACH 
guidance on information requirements and chemical safety assessment (Chapter R.8: 
Characterisation of dose [concentration]-response for human health).  
 
1.2 The AgBB and ANSES lists of compounds as the starting point for 
EU-LCI harmonisation 
As mentioned in section 1.1 of the present report, the notified regulations of France and 
Germany constitute the basis for the harmonisation of LCIs.  The first AgBB LCI-list was 
adopted from ECA Report No. 18 (1997), which included 163 compounds. The 
respective LCI values were also adopted. The establishment of an expert group inside 
AgBB in 2001 with toxicologists from the Federal States regulators, and later also from 
industry along with representatives of manufacturing associations, provided a process 
to revise the German LCI-list taking into account current toxicological knowledge and 
the assumed or proven occurrence of particular compounds in construction products. 
Also new compounds were included, which was partly the result of new knowledge 
resulting from emission tests and partly due to the request from industry to develop LCI 
values for specific compounds (Däumling, 2012). 
In 2002, some compounds which were included in the ECA 18 list and usually 
considered as ‘pollutants’, were removed from the AgBB-list because they were not 
relevant for assessing emissions from construction products (e.g. dichloromethane, 
carbon tetrachloride, 1,4 dichlorobenzene). LCI-values for VVOC were also removed (e.g. 
formaldehyde, acetaldehyde, acetone, propanal) because the evaluation of VVOC 
emissions was postponed. In addition, the group of phthalates was removed for 
analytical reasons. Further reductions in the number of LCI-values resulted from the 
grouping and rearranging of compounds, especially in the group(s) of saturated aliphatic 
hydrocarbons and terpenes. A major increase in the number of compounds occurred 
between 2002 and 2004, when a large number of applications for establishing LCI values 
for additional compounds were submitted by different stakeholders: by the Federal 
Institute for Materials Research and Testing (BAM), the chemical industry (VCI – 
Verband der Chemischen Industrie), GUT (label for carpets) and also Umweltbundesamt 
– the German Federal Environment Agency (UBA). In 2003 alone, 16 compounds were 
added to the list (some glycols, some esters and others). 
In 2005, when the AgBB-Scheme became part of the approval requirements in Germany 
issued by Deutsches Institut für Bautechnik - German Institute for Building Technology 
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(DIBt), awareness of the possibility to apply for new or altered LCI values spread rapidly 
and the German LCI expert group also started receiving applications from foreign 
manufacturers for the determination of LCI-values (10 applications in 2008/2009 from 
‘Global Players’ affiliations in France and the Netherlands). After 2010 a large number of 
applications were submitted by the paint industry. One explanation for this increase in 
applications is the now completed revision of the evaluation criteria for the award of the 
Blue Angel UZ 12a. 
The development of the German LCI lists, from the former ECA report no. 18 LCI list in 
1997 to the most recent update of AgBB in 2012, is outlined in Table 1. 
 
           Table 1. Development of the AgBB-list of assessable compounds 
 
Assessable compounds in LCI lists  
from ECA 18 (1997) to AgBB (2012) 
ECA 18 (1997) 163 
AgBB 2001 163 
AgBB 2002 122 
AgBB 2003 138 
AgBB 2004 167 
AgBB 2005 167 
AgBB 2008 164 
AgBB 2010 170 
AgBB 2012 176 
 
In the framework of the 2004-2008 French National Environment and Health Action 
Plan (NEHAP), the French Agency for Environmental and Occupational Health Safety 
(AFSSET) established a health-related protocol for the evaluation of VOC and 
formaldehyde emissions from construction products. For the health based evaluation of 
the emissions of individual VOCs, AFSSET established a list of 165 LCIs in 2009.   
Subsequently, in the context of the mandatory labelling of volatile emission from 
construction products, floorings, wall coverings, paints and varnishes (which has been 
established in France by Decree n° 2011-321 (March 23, 2011) and Order of April 19, 
2011) focus was placed on emissions of 10 individual compounds and TVOC according 
to four emission classes (from very low emissions to high emissions). The 10 individual 
compounds2 were selected because of their occurrence indoors in French dwellings and 
their classification as dangerous compounds through inhalation according to EU 
classification. 
The definition of the LCI values and the corresponding decision trees for the LCI setting 
in the French and German schemes are reported and compared in the ECA report no. 27 
(2012). 
                                                 
2
 Formaldehyde, acetaldehyde, toluene, tetrachlorethylene, xylene, 1,2,4-trimethylbenzene, 1,4-
dichlorobenzene, ethylbenzene, 2-butoxyethanol, styrene, TVOC 
2002: removal of “general“pollutants (i.e. not found 
to be emitting from building materials) and VVOC 
2004: Addition of glycols 
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2. HARMONISATION FRAMEWORK FOR HEALTH BASED 
EVALUATION OF INDOOR EMISSIONS FROM CONSTRUCTION 
PRODUCTS IN THE EUROPEAN UNION BY USING THE EU-LCI 
CONCEPT  
 
 
2.1 Objectives of the EU-LCI harmonisation process  
The objectives of the EU-LCI harmonisation process, as proposed during the JRC 
Workshop on “Harmonisation of the health based evaluation of emissions from building 
products in the EU using the LCI concept” (September 2010, Ispra) and confirmed by the 
EU-LCI WG, are as follows:  
Objectives of the EU-LCI harmonisation process 
1. To devise a harmonised procedure for establishing a list of compounds and their 
associated EU-LCI values (including consideration of carcinogens) for the evaluation of 
emissions from construction products taking into account existing procedures used in some 
Member States (e.g. ANSES in France and AgBB in Germany) and to recommend an 
appropriate health‐protective, science based, transparent and yet pragmatic approach. 
2. To propose a flexible framework that enables future review of the procedure to take into 
account new knowledge (e.g. data resulting from the REACH implementation process) and 
revise the content of the EU-LCI list both in terms of number of compounds and EU-LCI 
values. 
3. To establish EU-LCI values for compounds on the EU-LCI list and new compounds. 
 
 
2.2 EU-LCI definition 
EU-LCI values serve a different purpose from classic IAQ guideline values. They are 
intended only for evaluating emissions from single products and not for evaluating 
indoor air quality. 
The EU-LCI refers to a 28-day test period, conforming to one of the testing times 
referred to in the Technical Specification TS 16516 of the horizontal testing method 
developed by CEN TC 351/WG 2. Since primary emissions decline with time, this time 
scale is considered to constitute a ‘worst case’ assumption for the long-term indoor air 
VOC emission scenario in the absence of oxidants.  
It is acknowledged that the test procedure (using chambers and correction factors 
relating to a ‘standard’ room) provides only an approximation to the situation in a real 
indoor environment; concentrations in actual rooms will depend on emission rates of 
products used in the specific indoor environment, the number of sources for a given 
chemical, variability of environmental conditions (i.e. temperature, humidity, air 
exchange rate), chemical transformation, sink effects (adsorption and desorption), etc. 
In determining appropriate maximum emissions from products through the application 
of EU-LCI values, and/or in product selection, account has to be taken of the emission 
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rates of individual compounds from multiple sources in a given indoor environment (see 
also chapter 5 of the present report). 
 
Definition of EU-LCI 
1. EU-LCIs are health-based values used to evaluate emissions after 28 days from a single 
product during a laboratory test chamber procedure (as defined in the Technical 
Specification, TS 16516 of the horizontal testing method developed by CEN TC 351/WG 2).  
2. EU-LCIs are applied in product safety assessment with the ultimate goal to avoid health 
risks from long-term exposure for the general population. 
3. EU-LCI values are usually expressed as µg/m3. 
4. Only values derived by application of the process established by the EU-LCI WG and 
described herein and ratified by the EU-LCI WG shall be called EU-LCIs. 
 
 
2.3 Principles and Rationale for the Establishment of EU-LCI values 
1. LCI values for a number of compounds have been produced independently by 
AgBB (Germany) and ANSES (France).  
2. Some of these values are the same (sometimes because they have a common 
source/origin), but many are different because of different methods of 
derivation, even when based on the same source/origin. 
3. The starting list for the EU-LCI setting process comprises those compounds that 
have been given LCI values by AgBB and ANSES (177 VOCs commonly detected in 
emission tests of construction materials). 
4. In case where a compound has, for whatever reason, identical or very similar 
(differing by 20% or less) ANSES and AgBB LCI values, the shared value or the 
lowest value for that compound in the two lists is termed the ‘ascribed interim’ 
EU-LCI. In due course, this compound will be re-evaluated using the EU-LCI 
agreed protocol to produce de novo ‘derived interim’ EU-LCI value. 
5. Compounds with different values in AgBB and ANSES will be assessed according 
to the EU-LCI WG’s agreed protocol to derive de novo EU-LCI values. These will be 
designated 'derived interim' EU-LCI values. Compounds awaiting assessment are 
termed EU-LCI ‘derivation pending’. 
6. When a formal process is set in place at EU level the ‘ascribed interim’ and 
‘derived interim’ EU-LCI values shall undergo a final evaluation and be assigned 
as ‘confirmed’ EU-LCI values.  
7. At any time, additional compounds (EU-LCI ‘candidate’ compounds, e.g. 
compounds identified by EU national authorities) may be added to the EU-LCI 
master list and subsequently evaluated. 
8. The EU-LCI master list comprises compounds with ‘confirmed’ EU-LCI values, 
‘interim’ (‘ascribed’ and ‘derived’) EU-LCI values, EU-LCI values ‘with derivation 
pending’, and ‘candidate compounds’. 
9. The EU-LCI ‘interim’ values (‘ascribed’ and ‘derived’) in the EU-LCI master list in 
the ECA report no. 29 will be the harmonised values that can be used by the EU 
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Member States and voluntary indoor air labelling schemes in the absence of any 
formal process underway at EU level to transform them into ‘confirmed’ EU-LCI 
values. 
10. There should be a periodic review of all EU-LCI values. This review may be 
accelerated in the event of significant new information (e.g. toxicity data) 
becoming available for any compound(s) on the EU-LCI master list. 
11. In due course, procedures shall be established for carcinogens (Category 1A and 
1B as defined in the CLP Regulation (EC) no. 1272/2008) and ultimately for ‘not 
yet assessable’ compounds. 
12. SVOC and VVOCs will not be considered at this stage of the process by the EU-LCI 
WG, with the exception of acetaldehyde and formaldehyde. 
13. To support the on-going activities of DG ENTR’s Expert Group on Dangerous 
Substances (EGDS), the EU-LCI WG will focus first on compounds under 
consideration by the EGDS ad hoc group on classes (AGC). 
 
2.4 Protocol for the de novo derivation of EU-LCI values 
With the clear and determined objective at the outset of establishing a robust scientific 
methodology, various alternative approaches for the EU-LCI setting process were 
discussed by the EU-LCI WG. The methodology was then developed through initial 
application to some compounds that have very different LCI values in the German AgBB 
and the French ANSES lists and which are also included in the “Individual substances 
list” in the DG ENTR’s EGDS ad hoc group’s proposal – namely toluene, xylene, 
ethylbenzene and styrene.   
Although these compounds are not very typical or prominent in product emissions, they 
served as examples for the establishment of a well documented toxicology-based 
assessment method. For these five compounds, values for Occupational Exposure Limits 
(OEL) and also Indoor Air Quality Guideline Values (IAQGV) were screened for their 
suitability for the evaluation of product emissions. The LCI derivations in the French and 
the German lists were then compared, but also a new evaluation conducted by going 
back to the critical effects, the key studies, the LOAELs (Lowest Observed Adverse Effect 
Levels) or NOAELs (No Observed Adverse Effect Levels) of suitable endpoints and 
applying appropriate assessment factors. In addition, compounds that appear in 
emission tests and for which such a broad background of toxicological evaluations does 
not exist had also to be considered. For all compounds a standard protocol for the de 
novo, transparent and harmonised derivation of EU-LCI values was developed by the EU-
LCI WG via an iterative process. 
The procedure for the de novo derivation of EU-LCI values consists of three main steps:  
 data compilation  
 data evaluation and  
 derivation of the EU-LCI value on the basis of a standardised factsheet generated 
for each compound.  
These steps are described in the remaining sections of chapter 2 of this report. 
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2.4.1 Data compilation 
Data compilation is an important prerequisite and the first step in deriving an EU-LCI 
value. Regarding the data sources to use, detailed consideration of available summarised 
information on indoor air quality guidelines, other toxicological reference values or 
occupational exposure limits from established international and national committees 
were considered. The EU-LCI WG agreed that evaluations for indoor air quality 
guidelines (e.g. by WHO) are a reliable information source, since they undergo an 
intense peer-review process. Also, documented derivations of occupational exposure 
limits by -authoritative committees and documentation for toxicological reference 
values are considered as good references for data mining. 
Furthermore, information available through the REACH process is also considered. A 
vast amount of registration data is published on the ECHA website in the form of IUCLID 
(International Uniform Chemical Information Database) datasets, where DNELs 
(Derived No Effect Levels) are also included. The EU-LCI WG agreed that only 
information from published reports (e.g. for compounds of very high concern/SVHC) 
could be used, or that access to registration dossiers should be arranged (via the 
respective EU competent bodies) so that the derivation of specific DNELs could be fully 
comprehended. 
Several aspects are considered when assessing and comparing data to be used as the 
basis for EU-LCI derivation, such as date of publication and type of key study, critical 
health endpoints assessed, the point of departure (such as NOAEL or LOAEL, benchmark 
dose), the assessment factors used, the species considered, and the duration and route of 
exposure.  
All relevant toxicological data retrieved for each compound shall then be assimilated 
into one table (the data compilation sheet). The data compilation simplifies the 
identification of common points and differences and guarantees the fundamental 
principle of transparency in deriving the EU-LCI value.  
Critical dose effects, key studies and critical dose values (NOAEL, LOAEL, benchmark 
dose (BMD)) shall be identified for each EU-LCI candidate compound by reviewing 
toxicological reference values (TRVs) from authoritative sources (where available) such 
as EU risk assessment reports (EU RARs), RIVM, Health Canada, US-EPA, ATSDR, 
OEHHA, ANSES and also indoor air quality guideline (e.g. by WHO) and/or occupational 
exposure limit documents (e.g. by SCOEL).  
It should be underlined that all relevant studies, including but not limited to the key 
study(ies)3 selected, along with the data compilation sheet and the standardised 
summary factsheet (see chapter 2.4.3.1 of the present report) are used for deriving the 
EU-LCI value for each compound of interest.  
 
 
                                                 
3
 The key study(ies) is (are) the one (s) selected as the starting point for the derivation of the EU-LCI 
value. Various criteria apply to the selection of the key study including endpoint(s), type of study, route of 
exposure, experimental design, and quality assurance aspects. 
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2.4.2 Data evaluation 
All relevant risk assessment reports shall be considered (including REACH Chemical 
Safety Reports), irrespective of publication date. With regard to individual studies, study 
design and quality is more important than the date of the study.  
Relevant key studies are to be listed in the data compilation sheet, unless the derivation 
of the EU-LCI is making use of published risk assessments, which already include and 
discuss the key-study(ies). 
The key study is chosen after thorough evaluation by the experts of the EU-LCI WG. 
Selection of the lowest reasonable point of departure (POD) of the key study (ies) will 
similarly be based on expert judgment. 
If the database reveals inconsistencies or lack of data, assessment of the original studies 
shall be undertaken. 
 
2.4.2.1 Studies and endpoints 
“Chronic”4 studies are generally preferred, except where a “short term” study provides 
valuable information about an important end point. 
Human studies are preferred to animal studies, provided the study design is robust. 
Inhalation studies are preferred to oral studies, although the latter can be used with an 
appropriate route-to-route extrapolation factor applied to the derived critical dose 
value. 
All specific endpoints relevant to EU-LCI setting will be documented, together with 
additional supporting information if needed. 
For all compounds, the associated REACH Chemical Safety Report(s) should be consulted 
and shall be taken into account provided that robust study summaries and/or raw data 
are available.  
 
2.4.2.2 Point of departure values 
NOAELs are normally preferred over LOAELs. If only a LOAEL is available then in line 
with REACH guidance a correction factor of 3 is generally applied. This factor will be 
addressed on a case by case basis and may vary from 1 to 10 depending on the type of 
effect and the shape of the dose-response curve. 
Benchmark dose (BMD) and physiologically based pharmacokinetic (PBPK) modelling 
data arealso considered if the quality of the data is sufficient. 
Assessment factors are applied to the point of departure (POD) to derive an EU-LCI 
value considered to be safe for humans (including children) following life-time exposure 
to VOCs emitted from a product. The use of assessment factors shall be in accordance 
with ECHA guidance5. Guidance on the application of read across for establishing EU-LCI 
values from data-poor compounds is given in chapter 2.5 of the present report. 
                                                 
4 For the definition of “chronic” studies please refer to section 2.5 of the current report. 
5 “Typically, the overall assessment factor is the product of the individual assessment factors, by assuming 
independency of the factors. It is to be realised that this multiplication is in general very conservative: 
when each individual assessment factor by itself is regarded as conservative, multiplication will lead to a 
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2.4.2.3 Other effects 
All other relevant information shall be recorded under ‘Other effects’. This will include, 
but not necessarily be limited to, information relating to odour, endocrine disrupting 
properties, known mixture effects, etc.  
 
 
2.4.3 EU-LCI derivation 
A key aspect of the EU-LCI setting process is the transparency of the process at all stages. 
This is achieved by the quality system applied by the EU-LCI WG which consists of: 
 Generating for each compound a summary factsheet with a standardised format 
(see section 2.4.3.1 of the present report) based on draft versions of the 
factsheets developed independently by at least two members of the EU-LCI WG 
(assessors). At the end of the draft summary factsheets a rationale is added 
explaining which study was used to derive the point-of-departure and how the 
assessment factors were applied. This allows potentially different approaches to 
be taken on board and maximises the possibility of obtaining an unbiased result 
when deriving the EU-LCI values. A final summary factsheet is produced after 
review of the draft factsheets by the entire EU-LCI WG. 
 Ensuring the harmonised application of assessment factors and read-across 
elaborated by the EU-LCI WG and described in sections 2.5 and 2.6 of the present 
report. This is facilitated by the ‘memorandum of decision’ which tabulates the 
assessment factors agreed upon for the compounds assessed (see table 7). The 
use of this table ensures the harmonised application of assessment factors and 
facilitates identification of potential outliers for further review.   
 Creating for each compound an EU-LCI “dossier” containing the final summary 
factsheet along with its associated data-collection sheet and a copy of the key-
study (ies) used for the derivation of the EU-LCI value.  
 
 
2.4.3.1 Standardised Summary Fact Sheet  
To ensure that the derivation of EU-LCIs is transparent, a summary fact-sheet with a 
standardised format is generated for each compound. This comprises four main 
sections:  
1. General information,  
2. Toxicological database (values derived from the data compilation process 
described in chapter 2.4.1),  
3. Assessment factors and  
4. The derivation of the EU-LCI value.  
Parameters in the factsheet are accompanied when necessary by an explanatory note.  
                                                                                                                                                        
piling up of conservatism. Hence, the more extrapolation steps are taken into account, the higher the level 
of conservatism”. (Source: Chapter R.8, page 67, ECHA Guidance on information requirements and 
chemical safety assessments, Version 2, December 2010). 
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A written ‘rationale’ explaining/justifying the selection of the key study(ies) and other 
key elements of the derivation of the EU-LCI value will always be provided and 
integrated into the standardised summary fact sheet.  
The standardised summary fact sheet template developed by the EU-LCI preparatory 
WG is shown in Table 2. 
 
 
Table 2. Standardised Summary Fact Sheet Template 
 
  Compound  NAME OF COMPOUND  Factsheet 
Parameter Note6 Comments Value / descriptor 
Please use the period (.) as decimal 
mark 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³]   
EU-LCI status 2 interim / confirmed   
 
  
EU-LCI year of issue 3 Year when the EU-LCI value  
has been issued 
  
General Information    
CLP-INDEX-Nr.  4  INDEX   
EC-Nr. 5  EINECS – ELINCS - NLP   
CAS-Nr. 6 Chemical Abstracts Service number   
Harmonised CLP classification 7 Human health risk related classification    
Molar mass  8 [g/mol]   
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
  
Read across compound 10 Where applicable  
Species 11 Rat,… human   
Route/type of study 12 Inhalation, oral feed, …   
Study length  13 Days, subchronic, chronic   
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of    
Point of departure (POD)  16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
  
POD  Value  17 [mg/m³] or [ppm]   
Assessment Factors (AF) 18   
Adjustment for exposure 
duration  
19 Study exposure 
hrs/day, days/week 
 
AF  
Study length 
20 sa sc c  
(R8-5) 
  
Route-to-route extrapolation 
factor 
21   
AF  22a Reliability of dose-response,    
                                                 
6 Explanation of notes are found at the end of section 2.4.3.1 
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Dose-response  LOAEL  NOAEL  
 22b Severity of effect (R 8-6d)  
Interspecies differences 23a Allometric  
Metabolic rate (R8-3) 
  
 23b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
  
AF  
Sensitive population 
25 Children or other sensitive groups   
Other assessment factors: 
quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)   
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
    ……………………..    µg/m3 
    ……………………..    ppb 
Molar adjustment factor  29 Used in read-across  
Rounded value (EU-LCI) 30 [µg/m3]  
Additional Comments 31  
 
 
 
 
RATIONALE Section 32  
 
 
 
 
Explanation of notes: 
 
1) EU-LCI value: numerical value of the LCI in µg/m3 (mass/volume) – transcript of line 30. 
 
2) EU-LCI status: interim or confirmed.  
 
Interim: approved by the EU-LCI WG 
Confirmed: approved by a formal body (potential future option) 
 
3) EU-LCI year of issue: year when the EU-LCI value has been issued by the EU-LCI WG (or the 
formal body). 
 
4) CLP Number: according to Regulation (EC) No 1272/2008 on classification, labelling and 
packaging (CLP) of substances and mixtures. Implementing the globally harmonized system of 
chemical classification or GHS.  
http://guidance.echa.europa.eu/docs/guidance_document/clp_introductory_en.pdf 
 
5) EC Number: under European Inventory of Existing Commercial chemical Substances (EINECS), 
ELINCS (European List of Notified Chemical Substances) in support of Directive 92/32/EEC, the 
7th amendment to Directive 67/548/EEC, NLP (No-Longer Polymers) 
See: ESIS:  European chemical Substances Information System: http://esis.jrc.ec.europa.eu/index.php?PGM=dat 
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6) CAS Number: collection of disclosed chemical compound information by Chemical Abstracts 
Service. Almost all molecule databases can be searched by CAS Registry Number. 
 
7) Harmonised CLP classification: CLP classification including CMR and other health relevant 
effects. In the case that classification is not harmonised, this should be stated. For self-
classifications by industry the ECHA- CLP inventory can be searched at: 
http://echa.europa.eu/web/guest/information-on-chemicals/cl-inventory-database  
 
8) Molar mass: symbol M, is a physical property characteristic of a given substance (chemical 
element or chemical compound), namely its mass per amount of substance [g/mol]. 
 
9) Key study, Authors, Year: bibliography (citation) including authors and year of publication of 
selected study demonstrating the toxic effect of concern and considered to be the most relevant 
and appropriate study selected for derivation of the EU-LCI. 
 
10) Read-across compound: compound on which read-across is based (reference compound). 
 
11) Species: animal species (rat, etc.), or human study. 
 
12) Type of study: type and circumstances of the study, indicating the route of exposure (e.g. 
occupational, inhalation study, oral study). Inhalation studies to be preferred if available. 
 
13) Study length: duration of the study in days  
 
a. Acute: Exposure by the oral, dermal, or inhalation route for 24 hours or less. 
b. Short-term: Repeated exposure(a) by the oral, dermal, or inhalation route for more than 
24 hours and, up to 30 days. 
c. Subchronic: Repeated exposure by the oral, dermal, or inhalation route for more than 30 
days, up to approximately 10 percent of the life span in humans (b) (more than 30 days 
and up to 90 days in typically used laboratory animal species(c)). 
d. Chronic: Repeated exposure by the oral, dermal, or inhalation route for more than 
approximately 10 percent of the life span in humans (more than approximately 90 days 
to 2 years in typically used laboratory animal species) 
 
14) Exposure duration: exposure conditions in hours per day and days per week. 
 
15) Critical endpoint: critical toxicological effect observed in the study and used for derivation of the 
limit value. A critical effect is described as “either the adverse effect that first appears in the dose 
response curve, or as a known precursor to the first adverse effect.” 
 
16) Point of departure (POD):  the dose corresponding to a given effect. Lowest concentration or 
dose at which the critical effect occurred or did not occur. The POD value is used for further 
derivation. POD will be mainly NOAEC*L, or LOAEC*L, BMD*L. It represents the lower confidence 
bound on the lowest experimental dose that showed an effect. Data from oral studies have to be 
converted to the corresponding inhalation dose data first (see note 21). 
 
17) POD value: numerical value of the POD in [mg/m³] or [ppm].  Use the unit given in study. 
 
18) Assessment Factors (AF): the numerical adjustment used to extrapolate from experimentally 
determined dose- response relationships to estimate the compound exposure at and above which 
adverse effects may occur in the population exposed. Assessment factors account for differences 
between species and variability within populations, as well as differences in study protocols and 
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exposure conditions (i.e. of the general population) and other uncertainties.  
 
Table 3. Default assessment factors7 
Assessment factor – accounting for differences in: Default value 
systemic effects 
Default value         
local effects 
Interspecies - correction for differences 
in metabolic rate per body 
weight 
- remaining differences 
ASa,b 
 
2.5 
- 
 
1f 
2.5g 
Intraspecies - worker  5 5 
- general population 10c 10c 
Exposure duration - subacute to subchronic 3 3h 
- subchronic to chronic 2 2h 
- subacute to chronic 6 6h 
Dose-response - issues related to reliability 
of the dose-response incl. 
LOAEL-NOAEL 
extrapolation and severity 
of effect 
1d 1d 
Quality of whole 
database 
- issues related to 
completeness and 
consistency of the 
available data 
- issues related to reliability 
of the alternative data 
1d 
 
 
1e 
1d 
 
 
1e 
 
 a AS = factor for allometric scaling (see Table 4) 
 b Caution should be taken when the starting point is an inhalation or diet study 
 c Not always covering for very young children; see text for deviations from default 
 d See text for deviation from default 
 e Special consideration needed on a case-by-case basis 
 f For effects on skin, eye and GI track via simple destruction of membranes 
 g For effects on skin, eye and GI track via local metabolism; for effects on respiratory tract 
 h For effects on respiratory tract 
 
 
 
 
                                                 
7 Source: Table R.8-6 from REACH guidance on information requirements and chemical safety assessment Chapter 
R.8: Characterisation of dose [concentration]-response for human health.  
http://echa.europa.eu/web/guest/guidance-documents/guidance-on-information-requirements-and-chemical-
safety-assessment  
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Table 4. Allometric scaling factors for different species as compared to humansa8 
Species Body weight (kg) AS factorb 
Rat 0.250 4 
Mouse 0.03 7 
Hamster 0.11 5 
Guinea pig 0.8 3 
Rabbit 2 2.4 
Monkey 4 2 
Dog 18 1.4 
                                      
                                   a Assuming the human body weight is 70 kg 
                                      b Not applicable when setting an inhalation DNEL based on an inhalation  
                                        animal study (see APPENDIX R. 8-2 of the following source: 
                                   http://echa.europa.eu/documents/10162/13632/information_requirements_r8_en.pdf)  
 
19) Adjustment for exposure duration: adjustment for the exposure duration setting in the critical 
study; a repeated exposure may be continuous, periodic, or intermittent.  
 
a. A continuous exposure is a daily exposure for the total duration of interest.  
b. A periodic exposure is one occurring at regular intervals (e.g. inhalation exposure 6 
hours/day, 5 days/week; or oral exposure 5 days/week).  
 
Note: After length and duration adjustment, the POD can be converted into a human equivalent 
concentration (HEC) from the experimental animal dose. The HEC is a human equivalent for 
24hrs, 7 days (assumed 70-year) of continuous exposure. 
 
20) AF Study length: adjustment for the study length, from short exposure periods to chronic 
exposure, i.e from s.a.,  s.c.  to c (subacute, subchronic, chronic).  
 
Acute: Exposure by the oral, dermal, or inhalation route for 24 hours or less. 
 
Subacute: Repeated exposure (a) by the oral, dermal, or inhalation route for more than 24 
hours, up to 30 days. 
 
Subchronic: Repeated exposure by the oral, dermal, or inhalation route for more than 30 
days, up to approximately 10 percent of the life span in humans (b) (more than 30 days up to 
90 days in typically used laboratory animal species(c)). 
 
                                                 
8 Source: Table R.8-3 from REACH guidance on information requirements and chemical safety assessment Chapter 
R.8: Characterisation of dose [concentration]-response for human health.  
http://echa.europa.eu/web/guest/guidance-documents/guidance-on-information-requirements-and-chemical-
safety-assessment  
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Chronic: Repeated exposure by the oral, dermal, or inhalation route for more than 
approximately 10 percent of the life span in humans (more than approximately 90 days to 2 
years in typically used laboratory animal species)  
 
Table 5. Assessment factors for duration extrapolation9 
Duration Default assessment factor 
Subchronic to chronic 2 
Subacute to chronic 6 
Subacute to subchronic 3 
                                     Note:  - ‘subchronic’ usually refers to a 90 day study 
- ‘subacute’ usually refers to a 28 day study 
- ‘chronic’ usually refers to a 1.5 – 2 years study (for rodents) 
                                          
21) Route-to-route extrapolation factor: approaches for deriving LCI using route-to-route 
extrapolation from non-inhalation studies. See for procedures: ECHA and IEH-IGHRC. See 
Guidelines on Route-to-Route Extrapolation of Toxicity Data when Assessing Health Risks of 
Chemicals (cr12) http://ieh.cranfield.ac.uk/ighrc/igpublications.html 
 
22) AF Dose response:  
 
      22a) relates to the reliability of the dose-response relationship and LOAEL to NOAEL extrapolation. 
        22b) relates to the severity of effect10 
 
                       The concept of severity of effect commonly used in toxicology is related to adversity and 
describes the severity of a particular outcome of exposure and the continuum of effects 
from physiological changes of uncertain significance to pathophysiological changes, 
morbidity, and finally, mortality. The reversibility of an outcome is often related to 
severity; generally, an outcome is considered more severe if it is irreversible. 
 
      Severity descriptors (ratings) commonly applied are: 
 No-effects 
 Mild effects that are reversible and do not interfere with normal function 
 Moderate effects that alter organ function or interfere with normal activity but are 
reversible or effects that are irreversible but do not alter organ function or interfere 
with normal activity. 
 Severe effects that are irreversible and alter organ function or interfere with normal 
activities 
The term "adverse" in LOAEL distinguishes between outcomes that are detrimental to an 
organism and outcomes that are temporary physiological responses with no detrimental impact. 
 
                                                 
9 Source: Table R.8-5 from REACH guidance on information requirements and chemical safety assessment Chapter 
R.8: Characterisation of dose [concentration]-response for human health.     
http://echa.europa.eu/web/guest/guidance-documents/guidance-on-information-requirements-and-chemical-
safety-assessment 
10Source: Assessment of Exposure-Response Functions for Rocket-Emission Toxicants. Subcommittee on Rocket-
Emission Toxicants, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission on Life 
Sciences, National Research Council, NATIONAL ACADEMY PRESS, Washington, D.C., 1998 
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23) Interspecies differences:  
 
       23a) interspecies extrapolation factor i.e. dosimetric adjustment,  uncertainty factor for allometric 
differences; 
       23b) kinetic and dynamic differences between the studied species and humans. 
 
24) Intraspecies differences: intraspecies extrapolation factor, variation within the human 
population, an uncertainty factor for kinetic and dynamic differences. 
 
25) AF (sensitive population): assessment factor for sensitive subgroups, which are not covered by 
the database and key study. Sensitive populations such as neonates and genetically sensitive 
subgroups, and also fetuses and children which may be particularly vulnerable during 
development and maturation. 
 
26) Other adjustment factors (quality of the whole database): used to compensate for lack of 
knowledge and quality of whole database. Relates to completeness and consistency of the 
available data and reliability of alternative data on a case-by-case basis. 
  
27) Summary of assessment factors: Total Assessment Factor (TAF)  product of all single factors 
used in the process (usually between 100 and 3000). 
 
28) POD/TAF: numerical value in µg/m3 and ppbV (Conversion at 23 °C and 101.3 KPa) 
1 mol ≈ 24.295084 liter 
Conc.[µg/m3] = (Conc[ppbV] * M[g/mol]) / 24.295084 liter 
 
29) Molar adjustment factor: only necessary if read-across is used. Factor used to adjust difference 
in molecular weight between the compound for which the LCI is derived and the compound on 
which read-across is based.   
 
30) Rounded value: value of the EU-LCI rounded according to rounding rules in µg/m3. 
Table 6. Rounding rules 
 
Value size-range Rule Example 
 
  Before rounding After Rounding 
Tens: 10–50 Rounded to 5 13 15 
Tens: 50–100 Rounded to tens 53 50 
Hundreds Rounded to fifties 123 100 
Thousands Rounded to hundreds 1568 1600 
Ten thousands and 
twenty thousands 
Rounded to thousands 17856 18000 
 
               Rounding rules: 
 The EU-LCI calculation shall be rounded only at the end of the EU-LCI derivation process.  
 Rounding is to be applied to EU-LCI values expressed as µg/m3   
 All newly derived EU-LCI values shall be rounded as from the Table 6.   
31) Additional Comments: additional relevant information from the data compilation sheet (e.g. 
odour, endocrine disrupting effects, known mixture effects). 
32) RATIONALE for derivation of the EU-LCI value: The rationale section succinctly explains the 
the selection and use of key data in the derivation of the EU-LCI value, in particular the selection 
of the key study used to determine the point-of-departure value. It also, where necessary, explains 
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the use of particular assessment factors, especially non-default factors. The rationale normally 
comprises between half a page and a page of text.   
 
 
2.5 Application of assessment factors in EU-LCI derivation 
Assessment factors (AFs) are applied to the point of departure (POD) value to derive an 
EU-LCI value considered to be safe for humans (including children) following life-time 
exposure to VOCs emitted from a product. The selection of assessment factors is in 
accordance with REACH guidance on information requirements and chemical safety 
assessment (ECHA, 2012). The total assessment factor (TAF) value depends on whether 
the data are from human or animal studies, the duration of exposure in the study that 
supplies the POD, the type of POD used, and the completeness of the database that 
supports the POD. The TAF value may range from 1 to 3000 depending on the nature of 
the data used in the assessment. 
 
2.5.1 Assessment factor for interspecies differences 
 
This factor is applied when the POD is derived from experimental data from studies 
performed on animals. Assessment factors for interspecies differences cover 
uncertainties related to kinetic and dynamic differences between the studied species 
and humans. The dynamic differences can be related to anatomical differences, local 
metabolic effects and remaining species-specific differences. To account for differences 
in metabolic rate, allometric scaling factors as recommended in the ECHA Guidance are 
used (ECHA, Table R. 8.3) and for the remaining differences a default factor of 2.5 is 
applied.  
Exposure to respiratory toxicants may cause adverse effects on the respiratory system 
(nose, pharynx, trachea, bronchi, and lungs). Respiratory toxicity includes a variety of 
acute and chronic pulmonary conditions, including local irritation, bronchitis, 
pulmonary edema, emphysema, and cancer. 
In the case of respiratory toxicants, only limited data are available for the purpose of 
quantitative interspecies comparison. However the small data set available has not 
produced any evidence of rodents being generally more sensitive to irritants than 
humans. Differences between rodent and human effect levels observed with some 
compounds may be interpreted as a tendency for somewhat greater sensitivity toward 
respiratory tract irritants in humans (Kalberlah et al., 2002). 
When the POD is derived from inhalation studies for systemic effects, no correction 
needs to be made for allometric differences (metabolic rate), because extrapolation is 
already based on the toxicological equivalence of concentration of a compound in the 
air: animals and humans breathe at a rate depending on their caloric requirements 
(allometric dose adjustment).  
When the POD is related to local effects, no correction has to be made for differences in 
systemic metabolism.  
For remaining specific differences, a default value of 1 is used for effects on skin, eye and 
GI tract if the mode of action implies only a simple destruction of membranes, and a 
default value of 2.5 is used for effects on the skin, eye and GI tract if local metabolism or 
  
Page 29 
 
  
receptor binding reactions are involved. A factor of 2.5 is also applied for local effects on 
the respiratory tract (ECHA, Table R. 8.6)  
For compounds for which specific data are available, other values may be applied based 
on a case by case approach and expert judgment.  
 
 
2.5.2 Assessment factor for intraspecies differences 
 
The response of humans to exposure of xenobiotic compounds may vary because of a 
number of biological factors such as age, sex, genetic composition, disease status, etc. To 
account for this variability, a default factor of 10 is generally considered conservative 
enough for the general population but not always covering for very young children 
according to the ECHA guidance (Table R. 8.6). A case by case value would be thus 
preferred.  
When the POD is derived from human occupational data, since some intraspecies 
variability between workers is already included (if the number of workers is sufficient 
to be representative of this population), the EU-LCI WG recommends applying a default 
factor of 5 to take into account vulnerable population including children. When the POD 
is derived from a single human study in a test chamber, as population variability is not 
covered, a factor of 10 should be applied as default. In the case of a sensory irritation 
chamber study with a sufficient number of subjects (men and women) a smaller factor of 
5 might be selected, based on a case by case evaluation.  
Concern has been raised about the special susceptibility of children to the toxicity of 
chemicals. To take into account the potential increased susceptibility of children to 
chemicals, due to their biological differences from adults, the application of an extra 10-
fold inter individual factor is recommended by some organizations (e.g. US-EPA’s Food 
Quality Protection Act, 1996). Concerning the susceptibility of some vulnerable 
populations such as elderly or early infancy in general, it is assumed that the default 
factor of 10 for intraspecies (human to human) variations is sufficient to account for 
differences between general population and vulnerable groups in most cases. Renwick 
et al. (2000), considers that available data do not provide a scientific rationale for an 
extra factor for children. Recently, Ginsberg et al. (2010) analysed information regarding 
child/adult intake and dosimetry differences for particles and gases for potential 
application to risk assessment. They concluded that these differences exist and are not 
usually captured by standard interspecies adjustment factors. However, for a life time 
risk assessment, incorporation of children’s inhalation intake to the assessment would 
lead to an effective increase in exposure and risk of 1.6 fold. The EU-LCI WG considers 
that this value is already covered by the intraspecies assessment factor and no specific 
extra factor for children is by default needed.  
If, for a specific compound, effects on the reproductive, endocrine, immune or nervous 
systems are suspected, then a specific assessment factor for children might be used, 
based on a case by case approach (Kemi, 2003; ECHA, 2012; RIVM report 613340005, 
2002). Factors of 3 or 10 could then be used in those cases when there are reasons for 
concern for these severe effects in children. 
A specific assessment factor for children might also be used in case the database for a 
compound is considered too poor for evaluation of the toxicity to children. In this case a 
factor of 1-10 may be applied to compensate. 
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For compounds for which specific data are available, other values may be applied based 
on a case by case approach and expert judgment. It is considered that information on 
intraspecies variation for local (concentration-dependent) effects is very scarce and no 
attempt has therefore been made to refine the default intraspecies factors already used 
for systemic effects. 
For local effects, the assessment factors to be used for intraspecies differences are 
therefore the same as those proposed above for systemic effects. 
It is to be noted that, as is the case for interspecies assessment factors, relevant 
substance-specific information on intraspecies variations should always be used to 
adjust or substitute the default factors (WHO/IPCS, 2005). 
 
 
2.5.3 Extrapolation from short exposure periods to chronic exposure 
 
LCIs are used to assess lifetime exposure to emitted compounds from a product, 
corresponding to a “chronic exposure”. The EU-LCI WG considers that in this context of 
deriving EU-LCI values, an exposure of 10 years or more would be considered as a 
chronic exposure and no adjustment for time duration of the key study is required. 
The assessment factor for study length concerns the adjustment for the study length, 
from short exposure periods to chronic exposure (subacute, subchronic, chronic). These 
latter terms are defined below (see also Table R.8-5 of the ECHA Guidance (ECHA, 
2012)): 
 Acute: Exposure by the oral, dermal, or inhalation route for 24 hours or less. 
 
 Subacute: Repeated exposure (a) by the oral, dermal, or inhalation route for more 
than 24 hours, up to 30 days. 
 
 Subchronic: Repeated exposure by the oral, dermal, or inhalation route for more 
than 30 days, up to approximately 10 percent of the life span in humans (b) 
(more than 30 days up to 90 days in typically used laboratory animal species(c)). 
 
 Chronic: Repeated exposure by the oral, dermal, or inhalation route for more 
than approximately 10 percent of the life span in humans (more than 
approximately 90 days to 2 years in typically used laboratory animal species).  
 
When only subacute or subchronic data are available, an assessment factor is applied to 
take into account duration.  The default values for this factor are based on Table R.8-5 of 
the ECHA Guidance (ECHA, 2012): 
 Subacute to chronic: AF = 6 
 Subchronic to chronic: AF = 2 
For compounds for which specific data are available, other values may be applied based 
on a case by case approach and expert judgment. In particular, whether this assessment 
factor also applies to inhalation and dermal studies is questionable. It might be possible 
that the exposure period influences the toxicological effects that depend on the route of 
exposure.  In the absence of compound-specific data, or in cases where the data cannot 
be readily assessed, available data supports default time extrapolation factors for local 
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(respiratory) effects similar to those proposed for systemic effects (Kalberlah et al., 
2002). 
 
2.5.4 Assessment factor to adjust for exposure duration 
 
Characterizing the hazards of inhaled toxicants generally includes extrapolation from 
observations on animals that are subjected to intermittent or subchronic exposures, to a 
human environmental context of usually continuous exposure.  
Adjustment of duration to a lifetime continuous exposure is currently applied as a 
default assumption to derive inhalation non-cancer reference values in risk assessment. 
This accounts for differences in the exposure pathway (for example, in laboratory 
assays, rodents are usually exposed for several hours a day, five days a week for several 
months, whereas workers are exposed for 8 hours a day for five days a week). The 
exposure duration adjustment factor is calculated using a simple linear relationship. 
This assumes, for a given chemical compound, that the same calculated values of the 
concentration of exposure multiplied by the duration of exposure will yield the same 
biological response (Haber’s rule) (Belkebir et al., 2011). 
After duration adjustment, the POD will be converted into a human equivalent 
concentration (HEC) from the experimental animal dose. The HEC is a human equivalent 
for 24 hrs, 7 days a week of continuous exposure. 
For compounds for which specific data are available, other adjustments may be applied 
based on a case by case approach and expert judgment. For example, where toxicity 
depends on the (peak) concentration rather than on the exposure duration, a time 
adjustment based on the experimental data for short term exposure could lead to an 
overestimation of risks. It may be assumed that the effects induced by direct contact 
with the respiratory tract are directly related to the concentration of exposure. Exposure 
duration would in this case exert a relatively weak influence on the induction of these 
lesions.  
 
2.5.5 Assessment factor for dose-response 
 
When no data are available to identify a clear NOAEL, a LOAEL may be used as a POD to 
derive an EU-LCI. An assessment factor may then be applied to the LOAEL to estimate 
the NOAEL. However, there is no guarantee that extrapolation of a LOAEL with any 
chosen factor will yield a true estimate of the NOAEL. The ratio between LOAEL and 
NOAEL is strongly linked to the dose spacing used. Therefore this factor can only be 
assigned using expert judgment in which the shape of the dose-response curve and the 
magnitude of the effect at the LOAEL is considered (Vermeire et al., 1999). By default 
and in line with REACH guidance, a tentative factor of 3 is applied in the EU- LCI setting 
process. 
Besides the use of a LOAEL or NOAEL a benchmark dose approach (e.g. BMD10 as LOAEL 
and BMDL5 as NOAEL) can be used to determine the POD (EFSA, 2009). The selection of 
the most appropriate POD is done by expert judgement. 
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2.5.6 Other assessment factors 
 
Factors to consider with regard to missing data:  
 In cases where animal bioassays are missing from a complete data base, the 
critical NOAEL needs to be adjusted to account for the impact of the missing 
bioassay(s). (Evans and Baird, 1998).  Such adjustment depends on the definition 
of a “sufficient” database (and the quality of the data) in the context of deriving 
the EU-LCI, the data already available and those missing. Evans and Baird have 
shown that both the number of bioassays available and the specific bioassay(s) 
available may influence the estimate of the critical NOAEL from an incomplete 
data set. When it is considered necessary, the EU-LCI WG will apply a default 
value of 3 for this factor.  
Severity of effects:  
 Factors to consider concerning the severity of effect: The type of critical effect on 
which the EU-LCI is based should be taken into account. Depending on the 
severity of the effect for human health (e.g. severe and irreversible), extra 
assessment factors may be applied by expert judgment on a case by case 
approach. Therefore, the EU-LCI WG considers that no extra default correction 
factor is necessary. 
 The extent and severity of the effects seen at the LOAEL in reproductive toxicity 
studies may in some cases be significant (e.g. extensive foetal or offspring death, 
major malformations, severe functional defects in the offspring, infertility or 
severe effects on the reproductive system). This should be reflected in the use of 
an appropriate assessment factor to account for the uncertainty related with the 
'dose-response relationship' (ECHA section R.8.4.3.1). 
An overview on the harmonised application of assessment factors in the context of the 
EU-LCI setting is given in Table 7 for the priority compounds treated by the EU-LCI WG 
and reported in chapter 3 of the present report. 
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Table 7. Overview table on harmonised application of assessment factors in the context of the EU-LCI setting  
 
 
 
VERSION: 07 
January 2013 
 
 
 Trimethyl-
benzenes 
Xylenes Butoxyethanol Acetaldehyde Styrene p-Dichlorobenzene Toluene 
Ethyl-  
benzene 
n-Butanal ε-Caprolactam a-Pinene 
  
Compounds assessed with priority (1) 
 
 
Additionally assessed compounds (2) 
STANDARDISED 
SUMMARY 
FACTSHEET’S 
PARAMETERS 
STANDARDISED 
SUMMARY 
FACTSHEET 
LINE 
           
Critical effect 15 
Neurotox 
and local 
effects on 
lungs 
Irritation 
Hematology, 
hemolysis, liver 
hemosiderin 
deposition 
Nasal 
irritation, 
(olfact 
damage?) 
Neurotox, 
genotox & 
hearing loss 
Carcinogenic, 
respiratory 
effects/damage 
Neurological 
effects      
(color vision 
impairment) 
Ototoxicity   
(outer hair 
cells of the 
cochlear) 
Irritation 
(squamous 
metaplasia of the 
nasal cavity) 
Irritation of 
respiratory tissues 
Bladder epithelial 
changes 
LOAEL/NOAEL 16 NOAEC LOAEC NOAEC NOAEC LOAEC NOAEC LOAEC LOAEC NOAEC NOAEC NOAEC 
Species 11 Rat 
Human 
(workers) 
F344-Rat Rat 
Human 
(workers) 
Rodents 
Human 
(workers) 
Rat Rat Rat Mouse 
ASSESSMENT 
FACTORS 
            
Adjustment  for 
exposure 
duration 
[h/d, d/w] 
19 5.6 4.2 5.6 5.6 4.2 5.6 4.2 4.7 5.6 5.6 5.6 
AF Study Length                                     
[sa --> sc --> c] 
20 2 2 2 2    2 2 3 2 
Route-to-route 
extrapolation 
factor 
21            
AF Dose 
Response: 
reliability of 
dose-response    
LOAEL--> NOAEL 
22a  3   3  2 3    
AF Dose 
Response: 
severity of effect 
22b    2 3 5      
Interspecies: 
allometric 
metabolic rate 
23a            
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VERSION: 07 
January 2013 
 
 
 Trimethyl-
benzenes 
Xylenes Butoxyethanol Acetaldehyde Styrene p-Dichlorobenzene Toluene 
Ethyl-  
benzene 
n-Butanal ε-Caprolactam a-Pinene 
  
Compounds assessed with priority (1) 
 
 
Additionally assessed compounds (2) 
STANDARDISED 
SUMMARY 
FACTSHEET’S 
PARAMETERS 
STANDARDISED 
SUMMARY 
FACTSHEET 
LINE 
           
ASSESSMENT 
FACTORS 
            
Interspecies: 
kinetic+dynamic 
23b 2.5     2.5  3.6    
Intraspecies: 
kinetic+dynamic 
/ Worker - 
General 
Population 
24 10 5 10 10 5 10 5 10 10 5 10 
AF Sensitive 
population 
25            
Other 
assessment 
factors: quality 
of whole 
database 
26         2   
Total 
Assessment 
Factor (TAF) 
27 280 126 112 224 189 700 42 1015 224 84 112 
Point of 
Departure 
(POD) Value 
17 123 mg/m3 14.2 ppm 25 ppm 275 mg/m3 10 ppm 20 ppm 123 mg/m3 200 ppm 50 ppm 24 mg/m3 50 ppm 
EU-LCI Value 
[µg/m3] 
1 & 30 450 500 1100 1200 250 150 2900 850 650 300 2500 
                
(1) Compounds in the EU-LCI masterlist list  which were assessed with priority and with ‘derived interim’ EU-LCI values 
(2) Compounds in the EU-LCI masterlist with ‘derived interim’ EU-LCI values which were assessed additonally to those under (1)     
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2.6 Read-across guidance for EU-LCI derivation 
For some chemicals, because of lack of adequate studies and experimental data, the EU-
LCI value cannot be derived directly. In these cases hazard assessment within REACH 
may rely upon predictive approaches such as read-across and grouping of substances 
(ECHA, 2008). If test data are available on a range of chemicals with similar structure, it 
is possible to extrapolate, with confidence, from data-rich compounds to data-poor 
compounds provided that they are structurally closely related. As subtle changes in 
chemical structure can have a significant impact on biological activity, especially if the 
toxicity is mediated by binding to a receptor, certain minimum criteria need to be 
considered when undertaking hazard assessment using predictive approaches. It is 
important to be aware of the limitations of predictive approaches and the basic 
requirements associated with their use in human health hazard assessment (IGHRC, 
2013). 
2.6.1 General considerations 
For data poor compounds, LCIs have been established by AgBB (60 compounds in 2012) 
and ANSES (50 compounds) by applying read-across on the basis of chemical structural 
similarity. 
A major difference between the ANSES and the AgBB LCI lists is that AgBB applies molar 
adjustment to the read-across derived LCI values whereas ANSES does not. This results 
in different LCI values between these two lists as can be seen in Figure 1. 
 
 
Figure 1. Differences of read-across derived LCIs in AgBB (NIK) and ANSES (CLI) due to 
molar adjustment 
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When EU-LCIs are established for data-poor compounds by read-across, a justification is 
provided, including the argumentation for grouping or identification of homologue 
compounds – e.g. structural similarities between homologue compounds (common 
functional groups, or common precursors or breakdown products).  
In the context of the EU-LCI work, derivation of an EU-LCI value for a data poor 
compound is thus based on read-across of information from one or several data- rich 
homologue compound(s). The justification shall contain a clear explanation to be 
transparent, consistent and traceable. Any points of uncertainty should be mentioned.  
Application of read-across can only be justified if there is a reasonable indication that 
the homologue compounds have the same health endpoint(s). This is assessed and 
documented before the read-across is carried out. Although standardization of methods 
for read-across would benefit consistency, experience from read-across applied in 
similar contexts (e.g. LCI setting in the German AgBB scheme; use of read-across in 
setting OEL values11) has shown that the applicability of read-across methods needs to 
be evaluated on a case-by-case basis and requires expert judgment. 
Nonetheless, a degree of standardization for read-across of EU-LCI values can be 
achieved by adopting the following approaches: 
 Whenever possible, the EU-LCI value is derived by read-across from a compound 
with an existing EU-LCI value within the same chemical class. 
 If no EU-LCI value is available for a homologue of the compound of interest then 
read-across is not possible, unless sufficient toxicological information is available to 
firstly derive a de novo EU-LCI value for a close homologue according to the EU-LCI 
procedure, which can then be used for the read-across process to derive an EU-LCI 
value for the compound of interest.   
 When EU-LCI values are available for more than one compound within the same 
chemical class, read-across uses as a starting point the EU-LCI value for that 
homologous compound within the category which has the closest analogy in 
structure, functional groups and molecular weight and assuming the same endpoint 
as the compound for which the EU-LCI value is to be derived. Identification of the 
‘closest homologue’ is based on expert judgment, preferably supported by existing 
tools and guidelines (e.g. by ECHA12, Organisation for Economic Co-operation and 
Development (OECD) QSAR toolbox13, European Centre for Ecotoxicology and 
Toxicology of Chemicals (ECETOC), etc.) on how to undertake read-across. In the 
case that there is no unequivocal choice of compound having the ‘closest homology 
to the compound for read-across’ among the different compounds in the same 
category, read-across shall start from the compound with the lowest EU-LCI value. 
However, deviations from this rule of thumb may be possible, so long as a 
justification is provided.  
 If QSAR analysis or specific functional groups indicate that the toxicity of the 
compound could be higher, or that endpoints different from those of the compounds 
on which the read-across might dominate, an additional uncertainty factor (AF) shall 
                                                 
11 ECETOC Technical Report 101: Guidance for setting Occupational Exposure Limits (OELs): emphasis on 
data-poor substances. 
12 REACH – Guidance on information requirements and chemical safety assessment Chapter R.6: QSARs 
and grouping of chemicals 
13 http://www.oecd.org/env/existingchemicals/qsar 
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be applied, or the decision may be taken that no EU-LCI value by read-across can be 
derived.  
 When performing read-across, the molar adjustment principle and rules shall be 
applied (see below).  
 Certain quality criteria about the key study should be applied prior to carrying out 
read-across.  
 
2.6.2 Molar adjustment 
Molar adjustment in read-across accounts for the fact that the activity of a compound in 
air (or in solution) is driven by the number of molecules per unit air (or solution), rather 
than by the mass of the compound per unit air (or solution) (concentration – expressed 
as µg/m³ or mg/m³). Thus, read-across from one homologue to another should be done 
on a molarity basis, or, when read-across is on a µg/m³ basis, by applying a molar 
adjustment factor accounting for differences in molecular weight (MW) between the two 
homologues. This approach recognizes that a common functional group(s) of the 
homologues is driving the health effect, and not – or to a lesser extent - the difference in 
(aliphatic saturated) chain length between the homologues.     
In addition, the reactivity of functional groups may be counteracted by steric and 
electronic factors in larger molecules. Conversely, larger lipophilic residues may 
facilitate intracellular bioavailability and, hence, increase toxicological activities. 
Sometimes toxicological properties may be mediated by the whole molecule rather than 
by a prominent functional group (e.g. local irritation by hydrocarbons) and in such cases 
it may be inappropriate to extrapolate on a molar basis. The complexity of these issues 
indicates that the approach employed should not be too formalistic, and that read-across 
from compounds with a short aliphatic chain to a large aliphatic chain should be 
performed with caution.  
The EU-LCI WG working group considers that if read-across is applied for homologues 
beyond two additional CH2 groups per aliphatic chain, molar adjustment for larger 
molecules shall be confined to an arbitrary cut-off of two additional CH2 groups per 
aliphatic chain compared to the homologue compound from which the read-across 
starts (cut-off rule). 
When applying read-across, the unrounded EU-LCI value of the homologue compound, 
which serves as the basis for the read-across, is used.  
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2.6.3 Examples of read-across used in the derivation of EU-LCI Values 
 
Example 1:  n-Propylbenzene 
 
 Data poor compound: no adequate toxicological data for n-propylbenzene; de novo 
derivation of EU-LCI for n-propylbenzene is not possible. 
 Read across from EU-LCI value of ethylbenzene: within the chemical class ‘saturated 
aromatic hydrocarbons’, ethylbenzene is the closest homologue compound with an 
EU-LCI value: one additional CH2 group in the aliphatic side chain of n-
propylbenzene. 
 
 Toxicological critical endpoint for ethylbenzene: ototoxicity. 
 The key assumption underlying the read across of the EU-LCI value from 
ethylbenzene to propylbenzene is that both compounds have the same critical 
endpoint (ototoxicity) and this is caused by the common functional group (and not 
by the additional CH2 group). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
n-Propylbenzene  120.19  ?   
(read-across to be used) 
 
950 µg/m³ 
Ethylbenzene  106.17 850 µg/m3 
(de novo protocol)  
Unrounded value:  
860.6 µg/m³ or 197 ppb 
 
 Unrounded EU-LCI value ethylbenzene: 197 ppb  to be used for read across EU-LCI 
of n-propylbenzene. 
     No cut-off rule in place: difference in change length between the two homologue 
compounds is smaller than two CH2 groups per aliphatic chain. 
 Thus, EU-LCI value for n-propylbenzene is 197 ppb.  After MW conversion: EU-LCI n-
propylbenzene = 974.3 µg/m³  rounded to 950 µg/m³. 
 
 
  
H3C
CH3
  
Page 39 
 
  
Example 2:  Diisopropylbenzene (1,3-, 1,4-) 
 Data poor compound: no adequate toxicological data for diisopropylbenzene (1,3-, 
1,4-); de novo derivation of EU-LCI diisopropylbenzene is not possible. 
 Read-across candidate compounds for starting value: within the chemical class of 
‘saturated aromatic hydrocarbons’ xylene and ethylbenzene are two compounds 
with  EU-LCI values and having similar ‘closest homologue’ to diisopropylbenzene 
(1,3-, 1,4). Cumene (=isopropylbenzene) is another possible homologue, but it has no 
EU-LCI value. 
 Toxicological critical endpoints for homologue compounds:  
o xylene: effects on central nervous system (CNS) (and irritation);  
o ethylbenzene: ototoxicity. 
 Of these compounds, xylene has the lowest EU-LCI value (112.6 ppb). Thus, as a 
conservative approach, xylene is used as most appropriate homologue compound as 
starting point for the read across. 
 The key assumption underlying the read across of the EU-LCI value from xylene to 
diisopropylbenzene (1,3-, 1,4-) is that both compounds have the same critical 
endpoint (CNS effects) and  this endpoint is caused by the common functional group 
(and not by the additional CH2 groups). 
   
Compounds Structure MW 
[g/mol] 
EU-LCI value 
Diisopropylbenzene 
(1,3-, 1,4-) 
 162.27 ?   
(read-across to be 
used) 
750 µg/m³ 
 
Xylene  106.17 500 µg/m³ 
(de novo protocol) 
Unrounded value: 
491.9 µg/m³ or 
112.6 ppb  
Ethylbenzene 
 
106.17 850 µg/m3  
(de novo protocol)  
Unrounded value: 
860.6 µg/m³ or 197 
ppb 
 
 
 No cut-off rule in place: difference in change length between the two homologue 
compounds is smaller than two CH2 groups per aliphatic chain. 
H3C
H3C
CH3
CH3
CH3
CH3 CH3 CH3
CH3
CH3
CH3
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 Thus, the EU-LCI value for diisopropylbenzene (1,3-, 1,4-) is 112.6 ppb. After MW 
conversion : EU-LCI diisopropylbenzene (1,3-, 1,4-) = 751.8 µg/m³ to be rounded 
to 750 µg/m³. 
 
 
Example 3:  Phenyl octane and isomers 
 
 Data poor compound: no adequate toxicological data for phenyl octane; de novo 
derivation of phenyl octane not possible. 
 Read-across candidate compounds for starting value: within the chemical class of 
‘saturated aromatic hydrocarbons’ ethylbenzene is the closest homologue with an  
EU-LCI value; phenyl octane having additional (CH2)6 groups in the aliphatic chain 
compared to ethylbenzene. EU-LCI value for ethylbenzene: 197 ppb. 
 Toxicological critical endpoints for homologue compounds:  
Ethylbenzene: ototoxicity, assuming the critical endpoint for phenyl octane is 
ototoxicity. 
 
Compound Structure MW  
[g/mol] 
EU-LCI value 
Phenyl octane and 
isomers 
 190.32 ?   
(read-across to be used) 
1100 µg/m³ 
 
ethylbenzene  106.17 850 µg/m²  
(de novo protocol)  
Unrounded value: 860.6 
µg/m³ or 197 ppb 
 
 The key assumption underlying the read across of the EU-LCI value from 
ethylbenzene to phenyl octane is that both compounds have the same critical 
endpoint (ototoxicity) and that this endpoint is caused by the common functional 
group (and not by the additional CH2 groups). 
 The cut-off rule on the molar adjustment factor is applicable: difference in change 
length between the two homologue compounds is larger than two CH2 groups per 
aliphatic chain. 
 Thus after applying the MW conversion: EU LCI phenyl octane= 1088.0 µg/m³  to 
be rounded to 1100 µg/m³. 
 
EU-LCI values were derived by applying read-across for the following compounds listed 
in the EU-LCI master list (table 9): n-propylbenzene, diisopropylbenzene (1,3-, 1,4-), 
phenyloctane and isomers, pentanal, hexanal, heptanal, octanal, nonanal, decanal, 2-
ethylhexanal. The factsheets for these compounds are reported in Appendix A.   
H3C
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3. EU-LCI DERIVATION FOR PRIORITY COMPOUNDS  
 
To start with deriving EU-LCI values and also to support the harmonisation activities of DG 
ENTR’s ad hoc group on classes and CEN/TC 351/WG 2, the EU-LCI WG treated with priority 
the compounds listed in Table 8. 
 
Table 8. Prioritised compounds for deriving EU-LCIs 
 
Compound CAS No. 
1,2,4-Trimethylbenzene 95-63-6 
2-Butoxyethanol 111-76-2 
Toluene 108-88-3 
Xylene 1330-20-7 
1,4-Dichlorobenzene 106-46-7 
Ethylbenzene 100-41-4 
Styrene 100-42-5 
Acetaldehyde 75-07-0 
Tetrachloroethylene 127-18-4 
Formaldehyde 50-00-0 
ε-Caprolactam 105-60-2 
α-Pinene 80-56-8 
n-Butanal 123-72-8 
 
These 13 compounds (with their associated data) also served the purpose of testing, 
improving and finalising the protocol for the de novo derivation of EU-LCI values.   
In Table 8, LCI values for the compounds shaded in blue are very similar (or equal) in the 
AgBB and ANSES lists. LCI values for the compounds shaded in green differ significantly 
between these two systems.  
With regard to formaldehyde (shaded in red in Table 8), the de novo derivation of an EU-LCI 
value was postponed until a decision was made on its European harmonised classification and 
labelling. It is noted that based on a REACH Annex XV dossier, the ECHA Committee for Risk 
Assessment (RAC) in December 2012 (i.e. since the last meeting of the EU-LCI WG) adopted an 
opinion on a European harmonised classification and labeling for formaldehyde14 classifying 
it as category 1B carcinogen and not as 1A category which proposed by France. The future de 
novo derivation of an EU-LCI value for formaldehyde will take into consideration the 
aforementioned ECHA opinion.  Tetrachloroethylene is among the compounds for which their 
EU-LCI derivation is pending. 
The compounds shaded in orange in Table 8 are compounds of recent concern in Germany (ε-
caprolactam) and Belgium (α-Pinene). An EU-LCI value for n-butanal (shaded in yellow) was 
also derived as it served as starting value for read-across derivation of EU-LCIs for 
homologous aldehydes. 
The data collection sheets and the summary factsheets of the compounds which were treated 
with priority by the EU-LCI WG are reported in Appendix A.  
                                                 
14 http://echa.europa.eu/view-article/-/journal_content/c89bdb13-09e9-497c-8e73-ddae13a842c8  
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4. EU-LCI MASTER LIST 
 
Following the principles and rationale for the establishment of EU-LCI values (chapter 2.3) 
and the application of the protocol for the de novo derivation of EU-LCI values (chapter 2.4) 
for the priority compounds (chapter 3), an EU-LCI master list was compiled by the EU-LCI WG 
in 2013.  
The EU-LCI master list contains a total of 177 compounds and is subdivided  into two groups, 
the first containing 82 compounds with agreed interim (‘ascribed’ or ‘derived’) EU-LCI values 
and the second containing 95 compounds for which EU-LCI values are still to be derived.   
 
82 compounds with agreed interim (‘ascribed’ or ‘derived’) EU-LCI values 
 
 21 compounds with interim ‘derived’ EU-LCI values according to the de novo EU-LCI 
protocol and the procedure for read-across. 
 61 compounds with interim ‘ascribed’ EU-LCI values according to the rationale for 
derivation of EU-LCIs (same or very similar (difference within 20%) NIK (Niedrigste 
Interessierende Konzentration) / CLI (Concentration Limite d’Intérêt) values in the 
German and French lists). 
 
95 compounds with EU-LCI values ‘with derivation pending’  
 
 40 compounds for which EU-LCI values should be derived by read-across  
 29 compounds with different LCI values in AgBB and ANSES lists due to different 
derivation basis  
 24 compounds which are only present in either the AgBB or the ANSES list  
 1 compound with same key study for LCI derivation in both AgBB and ANSES but 
different LCI values due tothe application of different assessment factors (2-
Ethylhexanoic acid) 
 1 compound for which an EU-LCI value currently cannot be derived (Benzaldehyde) 
due to limitations of underlying human and animal studies and lack of a sufficient and 
transparent database.   
 
The composition of the EU-LCI master list (version as of July 2013) is graphically presented in 
Figure 2. 
 
The content of the EU-LCI master list (as of July 2013) is reported in Table 9. 
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Figure 2. The composition of the EU-LCI master list (as of July 2013) 
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Table 9. The content of the EU-LCI Master List (as of July 2013) 
 
EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
 
Version: July 2013 
 
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
                    
1   AROMATIC HYDROCARBONS                
1-1 108-88-3 Toluene 2900 1900 
EU: Repr. 2; Individ. 
substance evaluation  
300 
VG Index 2005; 
EU Repr. Cat. 3 
  
‘Derived’ 
Interim EU-LCI  
1-2 100-41-4 Ethylbenzene 850 880 OEL D 750 VTR RIVM   
‘Derived’ 
Interim EU-LCI  
1-3 
1330-20-7 
106-42-3 
108-38-3 
95-47-6 
Xylene (o-, m-, p-) and mix of o-, m- 
and p-xylene isomers 
500 2200 EU-OEL 200 VG Index   
‘Derived’ 
Interim EU-LCI  
1-4 98-82-8 Isopropylbenzene (Cumene)  1000 EU-OEL/OEL D 400 VTR IRIS US EPA   
EU-LCI  
‘with derivation 
pending’ 
1-5 103-65-1 n-Propylbenzene 950 1000 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
EU-OEL/OEL D 
200 
Analogy xylene 
1-3; VG Index  
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
1-6 
108-67-8 
95-63-6 
526-73-8 
Trimethylbenzene  
(1,2,3-;1,2,4-;1,3,5-) 
450 1000 EU-OEL/OEL D 1000 OEL F   
‘Derived’ 
Interim EU-LCI  
1-7 611-14-3 2-Ethyltoluene  1000 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
EU-OEL/OEL D 
200 
Analogy 1-3;  
VG Index 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
1-8 
527-84-4 
535-77-3 
99-87-6 
25155-15-1 
Cymene (o-,m-,p-) (1-Isopropyl-
2(3,4)-methylbenzene) and mix of  
o-,m- and p-cymene  
1000 1100 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
conversion via 
molecular weight; 
EU-OEL/OEL D 
1000 OEL Belgium 
Precautionary 
approach by 
adopting the 
lower value 
‘Ascribed’ 
Interim EU-LCI  
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
  
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
1  AROMATIC HYDROCARBONS        
1-9 95-93-2 1,2,4,5-Tetramethylbenzene  1100 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
conversion via 
molecular weight; 
EU-OEL/OEL D 
200 
Analogy 1-3;  
VG Index 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
1-10 104-51-8 n-Butylbenzene  1100 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
conversion via 
molecular weight; 
EU-OEL/OEL D 
200 
Analogy 1-3;  
VG Index 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
1-11 
99-62-7 
100-18-5 
Diisopropylbenzene (1,3-;1,4-) 750 1400 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
conversion via 
molecular weight; 
EU-OEL/OEL D 
200 
Analogy 1-3;  
VG Index 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
1-12 2189-60-8 Phenyl octane and isomers 1100 1600 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
conversion via 
molecular weight; 
EU-OEL/OEL D 
200 
Analogy 1-3;  
VG Index 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
1-13 104-72-3 Phenyl decane and isomers  1800 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
conversion via 
molecular weight; 
EU-OEL/OEL D 
200 
Analogy 1-3;  
VG Index 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
1  AROMATIC HYDROCARBONS        
1-14 6742-54-7 Phenyl undecane and isomers  1900 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
conversion via 
molecular weight; 
EU-OEL/OEL D 
200 
Analogy 1-3;  
VG Index 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
1-15 4994-16-5 4-Phenyl cyclohexene (4-PCH)  1300 
cf. styrene (1-16); 
conversion via 
molecular weight; 
OEL D 
250 
Analogy 1-3;  
VG Index 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
1-16 100-42-5 Styrene 250 860 OEL D 250 VG Index  
‘Derived’ 
Interim EU-LCI  
1-17 98-83-9 
2-Phenylpropene  
(α-Methylstyrene) 
 2500 EU-OEL/OEL D 1200 OEL F  
EU-LCI  
‘with derivation 
pending’ 
1-18 637-50-3 
1-Propenyl benzene  
(ß-methyl styrene) 
 2400 
EU-OEL for α-methyl 
styrene (1-17): 
246000 µg/m³ 
1200 
Analogy 1-17;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
1-19 536-74-3 Phenyl acetylene  840 
cf. Styrene (1-16); 
conversion via 
molecular weight; 
OEL D 
250 
Analogy 1-16;  
VG Index 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
1-20 
611-15-4 
100-80-1 
622-97-9 
25013-15-4 
Vinyl toluene (o-, m-, p-) and mix 
of o-,m- and p-vinyl toluene 
 4900 OEL D 2400 OEL F  
EU-LCI  
‘with derivation 
pending’ 
1-21 
1074-17-5 
1074-43-7 
1-Methyl-2(3)-propylbenzene       200 
Analogy 1-3;  
VG Index 
 
EU-LCI  
‘with derivation 
pending’ 
1-22   
Other alkylbenzenes, as long as 
indiv. isomers have not to be 
evaluated differently 
  1000 
cf. lowest LCI of 
saturated 
alkylbenzenes 1-6; 
EU-OEL/OEL D 
     
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
1  AROMATIC HYDROCARBONS        
1-23 91-20-3 Naphthalene  5 
EU: Carc. 2; OEL D; 
LCI value changed 
10 
VG AFSSET;  
EU Carc. Cat. 3 
 
EU-LCI  
‘with derivation 
pending’ 
1-24 91-17-8 Decahydronaphthalene       1000 OEL Poland   
EU-LCI  
‘with derivation 
pending’ 
1-25 95-13-6 Indene 450 450 
OEL Denmark, F: 
45000 µg/m³ 
450 OEL F   
‘Ascribed’ 
Interim EU-LCI  
2   
SATURATED ALIPHATIC 
HYDROCARBONS 
(n-, iso- and cyclo-) 
             
2-1 110-54-3 n-Hexane   72 
EU-OEL;  
EU: Repr. 2 
700 
VTR IRIS US EPA;  
EU Repr. Cat. 3  
  
EU-LCI 
‘with derivation 
pending’ 
2-2 110-82-7 Cyclohexane 6000 7000 EU-OEL/OEL D 6000 VTR IRIS US EPA 
Precautionary 
approach by 
adopting the 
lower value 
‘Ascribed’ 
Interim EU-LCI  
2-3 108-87-2 Methyl cyclohexane 8100 8100 OEL D 8100  MAK-DFG   
‘Ascribed’ 
Interim EU-LCI  
2-4 142-82-5 n-Heptane   21000 EU-OEL       
EU-LCI  
‘with derivation 
pending’ 
2-5   
Other saturated aliphatic 
hydrocarbons until C8 
  15000 OEL D 10000 OEL F   
EU-LCI 
‘with derivation 
pending’ 
2-6   
Other saturated aliphatic 
hydrocarbons higher than C9 
6000 6000 OEL D 6000 MAK-DFG   
‘Ascribed’ 
Interim EU-LCI  
3   TERPENES              
3-1 498-15-7 3-Carene 1500 1500 
cf. 3-2 to 3-5;  
OEL Sweden 
1500 OEL Sweden   
‘Ascribed’ 
Interim EU-LCI  
3-2 80-56-8 α-Pinene 2500 1500 
OEL Sweden: 
150000 µg/m³ 
450 VG Index   
‘Derived’ 
Interim EU-LCI  
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
3  TERPENES        
3-3 127-91-3 β-Pinene 1400 1500 
OEL Sweden: 
150000 µg/m³ 
1400 OEL Denmark 
Precautionary 
approach by 
adopting the 
lower value 
‘Ascribed 
Interim EU-LCI  
3-4 138-86-3 Limonene   1500 
OEL Sweden: 
150000 µg/m³ 
450 VG Index   
EU-LCI  
‘with derivation 
pending’ 
3-5   Other terpene hydrocarbons 1400 1500 
OEL Sweden: 
150000 µg/m³ (This 
group includes all 
mono-terpenes, 
sesquiterpenes and 
their oxygen 
containing 
derivatives) 
1400 OEL Denmark 
Precautionary 
approach by 
adopting the 
lower value 
‘Ascribed’ 
Interim EU-LCI  
4   ALIPHATIC ALCOHOLS               
4-1 75-65-0 
2-Methyl-2-propanol  
(tert-butanol) 
620 620 OEL D 600 MAK-DFG 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
4-2 78-83-1 2-Methyl-1-propanol   3100 OEL D 1500 OEL F  
EU-LCI  
‘with derivation 
pending’ 
4-3 71-36-3 1-Butanol 3000 3100 OEL D 3000 
OEL USA;  
PEL OSHA 
Precautionary 
approach by 
adopting the 
lower value 
‘Ascribed’ 
Interim EU-LCI  
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
4  ALIPHATIC ALCOHOLS        
4-4 
71-41-0 
30899-19-5 
94624-12-1 
6032-29-7 
584-02-1 
137-32-6 
123-51-3 
598-75-4 
75-85-4 
75-84-3 
1-Pentanol (all isomers) 730 730 
MAK-DFG:  
73000 µg/m³  
700 MAK-DFG 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
4-5 111-27-3 1-Hexanol 2100 2100 OEL D 2100 OEL D   
‘Ascribed’ 
Interim EU-LCI  
4-6 108-93-0 Cyclohexanol 2000 2100 
TLV (ACGIH): 
206000 µg/m3 
2000 OEL F 
Precautionary 
approach by 
adopting the 
lower value 
‘Ascribed’ 
Interim EU-LCI  
4-7 104-76-7 2-Ethyl-1-hexanol  540 
MAK-DFG;  
LCI value changed 
due to changed 
MAK-DFG value 
1100 MAK-DFG  
EU-LCI 
‘with derivation 
pending” 
4-8 111-87-5 1-Octanol 1100 1100 OEL D 1100 OEL D  
‘Ascribed’ 
Interim EU-LCI  
4-9 123-42-2 
4-Hydroxy-4-methyl-pentane-2-on 
(diacetone alcohol) 
960 960 OEL D 950 MAK-DFG 
Precautionary 
approach by 
adopting the 
lower value 
‘Ascribed’ 
Interim EU-LCI  
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
4  ALIPHATIC ALCOHOLS        
4-10   
Other C4 - C13 saturated alcohols 
n- and iso- 
  1100 
cf. 4-7 and 4-8; 
saturated cyclic 
alcohols are 
excluded; OEL D 
     
EU-LCI  
‘with derivation 
pending’ 
5   AROMATIC ALCOHOLS               
5-1 108-95-2 Phenol   10 
EU: Muta. 2; Individ. 
substance evaluation  
20 
VTR RIVM;  
EU: Mut. Cat. 3 
 
EU-LCI  
‘with derivation 
pending’ 
5-2 128-37-0 
BHT  
(2,6-di-tert-butyl-4-methylphenol) 
100 100 
OELs Denmark, 
Finland, France, 
Great Britain:  
10000 µg/m³ 
100 OEL F  
‘Ascribed’ 
Interim EU-LCI  
5-3 100-51-6 Benzyl alcohol 440 440 
WEEL (AIHA): 
44000 µg/m³ 
450 
TWA WEEL 
(AIHA) 
No rounding 
‘Ascribed’ 
Interim EU-LCI  
6   GLYCOLS, GLYCOETHERS               
6-1 107-21-1 Ethandiol (Ethylenglycol)   260 OEL D 400 VTR OEHHA  
EU-LCI 
‘with derivation 
pending’ 
6-2 96-49-1 Ethylene carbonate  370 
cf. Ethanediol  
(6-1); conversion via 
molecular weight; 
OEL D 
400 
Analogy 6-1;  
VTR OEHHA 
Procedure for 
read-across to be 
applied 
EU-LCI 
‘with derivation 
pending’ 
6-3 7397-62-8 Butyl glycolate  550 
cf. glycolic acid, 
metabolite of 
ethanediol (6-1); 
conversion via 
molecular weight; 
OEL D 
1300 OEL Denmark 
Procedure for 
read-across to be 
applied or derive 
new EU-LCI ? 
EU-LCI  
‘with derivation 
pending’ 
  
Page 53 
 
  
EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
6  GLYCOLS, GLYCOETHERS          
6-4 111-46-6 Diethylene glycol 440 440 OEL D 450 MAK-DFG/OEL D 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
6-5 57-55-6 
Propylene glycol  
(1,2-Dihydroxypropane) 
  2500 
Individ. compound 
evaluation 
100 
TWA WEEL 
(AIHA) 
 
EU-LCI  
‘with derivation 
pending’ 
6-6 108-32-7 Propylene carbonate   250 
Individ. compound 
evaluation 
     
EU-LCI  
‘with derivation 
pending’ 
6-7 623-84-7 Propylene glycol diacetate  5300 
cf. propylene glycol 
(6-5); conversion via 
molecular weight 
6500 OEL Denmark 
Procedure for 
read-across to be 
applied or derive 
new EU-LCI ? 
EU-LCI  
‘with derivation 
pending’ 
6-8 
110-98-5 
25265-71-8 
Dipropylene glycol 670 670 
OEL D;  
(CAS 25265-71-8) 
650 OEL D No rounding 
‘Ascribed’ 
Interim EU-LCI  
6-9 110-63-4 1,4-Butanediol 2000 2000 OEL D 2000 OEL D  
‘Ascribed’ 
Interim EU-LCI  
6-10 107-41-5 
Hexylene glycol  
(2-methyl-2,4-pentanediol) 
  490 
MAK-DFG:  
49000 µg/m³ 
     
EU-LCI  
‘with derivation 
pending’ 
6-11 6846-50-0 
2,2,4-Trimethylpentanediol 
diisobutyrate (TXIB) 
450 450 
Individ. compound 
evaluation 
450 NIK AgBB  
‘Ascribed’ 
Interim EU-LCI  
6-12 109-86-4 
Ethylene glycol monomethyl ether 
(2-Methoxyethanol) 
  3 
EU: Repr. 1B; 
EU-OEL 
20 
VTR IRIS US EPA; 
EU: Repr. Cat. 2 
 
EU-LCI  
‘with derivation 
pending’ 
6-13 110-49-6 2-Methoxyethyl acetate   5 
EU: Repr. 1B; 
EU-OEL 
90 
VTR OEHHA;  
EU: Repr. Cat. 2 
 
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
 
 Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
6  GLYCOLS, GLYCOETHERS          
6-14 110-71-4 1,2-Dimethoxyethane  4 
EU: Repr. 1B;  
cf. 2-methoxyethanol 
6-12 (metabolite 
methoxyacetic acid); 
conversion via 
molecular weight; 
EU-OEL 
20 
Analogy 6-12;  
VTR IRIS US EPA; 
EU: Repr. Cat. 2 
Procedure for 
read-across to be 
applied 
EU-LCI 
‘with derivation 
pending’ 
6-15 111-96-6 
Diethylene glycol dimethyl ether  
(1-Methoxy-2-(2-methoxy-ethoxy)-
ethane) 
28 28 
EU: Repr. 1B;  
OEL D 
30 
MAK-DFG/OEL D 
EU: Repr. Cat. 2 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
6-16 25265-77-4 
2,2,4-Trimethyl-1,3-pentanediol 
monoisobutyrate (Texanol®) 
600 600 
Individ. compound 
evaluation 
600 NIK AgBB  
‘Ascribed’ 
Interim EU-LCI  
6-17 109-59-1 
Ethylene glycol isopropylether  
(2-Methylethoxyethanol) 
220 220 OEL D 200 MAK-DFG/OEL D 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
6-18 112-49-2 Triethylene glycol-dimethyl ether  7 
EU: Repr. 1B; cf. 2-
methoxy-ethanol  
6-12 (metabolite 
methoxyacetic acid); 
conversion via 
molecular weight; 
EU-OEL 
20 
Analogy 6-12;  
VTR IRIS US EPA; 
EU: Repr. Cat. 2 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
6-19 110-80-5 
Ethylene glycol monoethyl ether  
(2-Ethoxyethanol) 
  8 
EU: Repr. 1B;  
EU-OEL;  
70 
VTR OEHHA;  
EU: Repr. Cat. 2 
 
EU-LCI  
‘with derivation 
pending’ 
6-20 111-15-9 2-Ethoxyethyl acetate   11 
EU: Repr. 1B;  
EU-OEL; 
300 
VTR OEHHA;  
EU: Repr. Cat. 2 
 
EU-LCI  
‘with derivation 
pending’ 
6-21 629-14-1 1,2-Diethoxyethane  10 
cf. 2-ethoxyethanol 
6-19 (metabolite 
ethoxyacetic acid); 
conversion via 
molecular weight; 
EU-OEL 
70 
Analogy 6-19; 
VTR OEHHA 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
 
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
6  GLYCOLS, GLYCOETHERS          
6-22 111-90-0 
Diethylene glycol monoethyl ether  
(2-(2-ethoxyethoxy)ethanol) 
350 350 OEL D 350 OEL D  
‘Ascribed’ 
Interim EU-LCI  
6-23 2807-30-9 
Ethylene glycol monoisopropyl 
ether (2-Propoxyethanol) 
860 860 OEL D 850 MAK-DFG/OEL D 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
6-24 111-76-2 
Ethylene glycol monobutylether  
(2-butoxyethanol) 
1100 490 OEL D 1000 VTR ATSDR  
‘Derived’ 
Interim EU-LCI  
6-25 112-07-2 2-Butoxyethyl acetate   1300 EU-OEL/OEL D 150 OEL F  
EU-LCI  
‘with derivation 
pending’ 
6-26 112-34-5 Diethylene glycol monobutylether 670 670 EU-OEL 650 EU-OEL 
EU-OEL value 
already rounded, 
no double 
rounding 
‘Ascribed’ 
Interim EU-LCI  
6-27 124-17-4 
Diethylene glycol monomethyl 
ether acetate 
(Butyldiglykolacetate, 2-(2-
butoxyethoxy) ethyl acetate) 
850 850 
MAK-DFG:  
85000 µg/m³  
850 MAK-DFG  
‘Ascribed’ 
Interim EU-LCI  
6-28 122-99-6 2-Phenoxyethanol 1100 1100 OEL D 1100 MAK-DFG/OEL D  
‘Ascribed’ 
Interim EU-LCI  
6-29 112-25-4 
Ethylene glycol n-hexyl ether  
(2-Hexoxyethanol) 
 1200 
cf. ethylene glycol 
monobutyl ether  
6-24; conversion via 
molecular weight; 
EU-OEL 
1000 
Analogy 6-24;  
VTR ATSDR 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
6-30 112-59-4 
Diethylene glycol n-hexyl ether  
(2-(2-Hexoxyethoxy)-ethanol) 
 740 
cf. diethylene glycol-
monobutyl ether  
6-26; conversion via 
molecular weight; 
EU-OEL 
650 
Analogy 6-26;  
EU-OEL 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
6-31 107-98-2 
Propylene glycol monomethyl 
ether (1-Methoxy-2-propanol) 
  3700 EU-OEL/OEL D 2000 VTR IRIS US EPA  
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
 
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
6  GLYCOLS, GLYCOETHERS          
6-32 1589-47-5 
1-Propylene glycol 2-methyl ether  
(2-Methoxy-1-propanol) 
19 19 
EU: Repr. 1B;  
OEL D 
20 
MAK-DFG/OEL D 
EU: Repr. Cat. 2 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
6-33 70657-70-4 
1-Propylene glycol 2-methyl ether 
acetate  
(2-Methoxy-1-propyl acetate) 
28 28 
EU: Repr. 1B;  
OEL D 
30 
MAK-DFG/OEL D 
EU: Repr. Cat. 2 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
6-34 7777-85-0 
1,2-Propylene glycol dimethyl 
ether 
 25 
cf. 2-methoxy-1-
propanol 6-32 
(metabolit 
methoxypropionic 
acid); conversion via 
molecular weight; 
OEL D 
20 
Analogy6-32;  
MAK-DFG/OEL D 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
6-35 34590-94-8 
Dipropylene glycol monomethyl 
ether 
3100 3100 EU-OEL/OEL D 3100 EU-OEL  
‘Ascribed’ 
Interim EU-LCI 
6-36 88917-22-0 
Dipropylene glycol monomethyl 
ether acetate 
 3900 
cf. dipropylene 
glycol monomethyl 
ether 6-35; 
conversion via 
molecular weight; 
EU-OEL 
3100 
Analogy 6-35;  
EU-OEL 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
6-37 29911-27-1 
Dipropylene glycol mono-n-
propylether 
 740 
cf. diethylene glycol 
monobutyl ether  
6-26; conversion via 
molecular weight; 
EU-OEL 
650 
Analogy 6-26;  
EU-OEL 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
6-38 
29911-28-2 
35884-42-5 
132739-31-2 
Dipropylene glycol mono-n(t)-
butylether 
 810 
cf. diethylene glycol 
monobutyl ether  
6-26; conversion via 
molecular weight; 
EU-OEL 
650 
Analogy 6-26;  
EU-OEL 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
6-39 
20324-33-8 
25498-49-1 
Tripropylene glycol mono-
methylether 
 2000 
Individ. compound 
evaluation;  
LCI value changed 
1000 NIK AgBB  
EU-LCI 
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
6  GLYCOLS, GLYCOETHERS          
6-40 
63019-84-1 
89399-28-0 
111109-77-4 
Dipropylene glycol dimethyl ether  1300 1300 
Individ. compound 
evaluation 
1300 NIK AgBB   
‘Ascribed’ 
Interim EU-LCI  
6-41 2517-43-3 3-Methoxy-1-butanol   500 
Individ. compound 
evaluation;  
New LCI value  
     
EU-LCI  
‘with derivation 
pending’ 
6-42 
1569-01-3 
30136-13-1 
1,2-Propylene glycol n-
propylether 
  1400 
Individ. compound 
evaluation;  
New LCI value 
     
EU-LCI  
‘with derivation 
pending’ 
6-43 
5131-66-8 
29387-86-8 
15821-83-7 
63716-40-5 
1,2-Propylene glycol n-butylether   1600 
Individ. compound 
evaluation;  
New LCI value 
     
EU-LCI  
‘with derivation 
pending’ 
6-44 104-68-7 Diethylene glycol phenylether   1450 
cf. 2-Phenoxy-
ethanol; conversion 
via molecular 
weight; New LCI 
value 
     
EU-LCI  
‘with derivation 
pending’ 
6-45 126-30-7 Neopentyl glycol   1000 
Individ. compound 
evaluation; 
New LCI value 
     
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
7  ALDEHYDES        
7-1 50-00-0 Formaldehyde    VVOC 10 
VGAI AFSSET;  
EU: Carc. Cat. 3  
 
EU-LCI  
‘with derivation 
pending’ 
7-2 75-07-0 Acetaldehyde 1200   VVOC 200 
VG Index; NF 
16000-3; EU: 
Carc. Cat. 3 
  
‘Derived’ 
Interim EU-LCI  
7-3 123-38-6 Propanal     VVOC 8 
VTR US EPA;  
NF 16000-3 
 
EU-LCI  
‘with derivation 
pending’ 
7-4 123-72-8 Butanal 650 640 
VVOC;  
OEL D: 64000 µg/m³ 
650 
MAK-DFG/OEL D 
NF 16000-3 
 
‘Derived’ 
Interim EU-LCI 
7-5 110-62-3 Pentanal 800 1700 
OEL Denmark, F; 
TLV (ACGIH):  
175000 µg/m³ 
1700 OEL F 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
7-6 66-25-1 Hexanal 900 890 
cf. Butanal 7-4; 
conversion via 
molecular weight; 
OEL D 
650 
Analogy 7-4;  
MAK-DFG/OEL D 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
7-7 111-71-7 Heptanal 900 1000 
cf. Butanal 7-4; 
conversion via 
molecular weight; 
OEL D 
650 
Analogy 7-4;  
MAK-DFG/OEL D 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
7-8 123-05-7 2-Ethyl-hexanal 900 1100 
cf. Butanal 7-4; 
conversion via 
molecular weight; 
OEL D 
650 
Analogy 7-4;  
MAK-DFG/OEL D 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
7-9 124-13-0 Octanal 900 1100 
cf. Butanal 7-4; 
conversion via 
molecular weight; 
OEL D 
650 
Analogy 7-4;  
MAK-DFG/OEL D 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
7  ALDEHYDES        
7-10 124-19-6 Nonanal 900 1300 
cf. Butanal 7-4; 
conversion via 
molecular weight; 
OEL D 
650 
Analogy 7-4;  
MAK-DFG/OEL D 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
7-11 112-31-2 Decanal 900 1400 
cf. Butanal 7-4; 
conversion via 
molecular weight, 
OEL D 
650 
Analogy 7-4;  
MAK-DFG/OEL D 
Procedure for 
read-across 
applied 
‘Derived’ 
Interim EU-LCI 
7-12 
4170-30-3 
123-73-9 
15798-64-8 
2-Butenal (Crotonaldehyde)  1 
EU: Muta. 2;  
former OEL D 
6 
OEL F   
EU. Mut. Cat. 3;  
NF 16000-3 
 
EU-LCI 
“with 
derivation 
pending” 
7-13 
1576-87-0 
764-39-6 
31424-04-1 
2-Pentenal  12 
cf. 2-butenal 7-12, 
but no EU 
classification as 
mutagen; conversion 
via molecular 
weight; OEL D 
6 
Analogy 7-12;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
7-14 
6728-26-3 
505-57-7 
16635-54-4 
1335-39-3 
73543-95-0 
Hexenal  14 
cf. 2-pentenal 7-13; 
conversion via 
molecular weight; 
OEL D 
6 
Analogy 7-13;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
7-15 
2463-63-0 
18829-55-5 
57266-86-1 
29381-66-6 
2-Heptenal  16 
cf. 2-pentenal 7-13; 
conversion via 
molecular weight; 
OEL D 
6 
Analogy 7-13;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
7-16 
2363-89-5 
2548-87-0 
25447-69-2 
20664-46-4 
2-Octenal  18 
cf. 2-pentenal 7-13; 
conversion via 
molecular weight; 
OEL D 
6 
Analogy 7-13;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
7  ALDEHYDES        
7-17 
2463-53-8 
18829-56-6 
60784-31-8 
2-Nonenal  20 
cf. 2-pentenal 7-13; 
conversion via 
molecular weight; 
OEL D 
6 
Analogy 7-13;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
7-18 
3913-71-1 
2497-25-8 
3913-81-3 
2-Decenal  22 
cf. 2-pentenal 7-13; 
conversion via 
molecular weight; 
OEL D 
6 
Analogy 7-13;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
7-19 
2463-77-6 
53448-07-0 
1337-83-3 
2-Undecenal  24 
cf. 2-pentenal 7-13; 
conversion via 
molecular weight, 
OEL D 
6 
Analogy 7-13;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
7-20 98-01-1 Furfural   20 
EU: Carc. 2; Individ. 
compound 
evaluation  
8 
OEL ACGIH;  
EU: Carc. Cat. 3 
 
EU-LCI  
‘with derivation 
pending’ 
7-21 111-30-8 Glutaraldehyde   2 OEL D 0.08 
Sensitizer,  
VTR OEHHA;  
NF 16000-3 
 
EU-LCI  
‘with derivation 
pending’ 
7-22 100-52-7 Benzaldehyde  90 
WEEL (AIHA):  
8800 µg/m³ 
90 
TWA WEEL 
(AIHA) 
 
EU-LCI 
‘with derivation 
pending’ 
8   KETONES              
8-1 78-93-3 2-Butanone (ethylmethylketone) 5000 6000 EU-OEL/OEL D 5000 VTR IRIS US EPA  
‘Ascribed’ 
Interim EU-LCI  
8-2 563-80-4 3-Methyl-2-butanone 7000 7000 
OELs Denmark, F: 
705000 µg/m³ 
7000 OEL F  
‘Ascribed’ 
Interim EU-LCI  
8-3 108-10-1 
4-Methyl-2-pentanone 
(methylisobutylketone) 
  830 EU-OEL/OEL D 3000 VTR IRIS US EPA  
EU-LCI  
‘with derivation 
pending’ 
8-4 120-92-3 Cyclopentanone 900 900 
OEL Denmark: 
90000 µg/m³ 
900 OEL Denmark  
‘Ascribed’ 
Interim EU-LCI  
8-5 108-94-1 Cyclohexanone 410 410 EU-OEL 410 OEL F  
‘Ascribed’ 
Interim EU-LCI  
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
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Remarks /  
derived from 
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  Interim AgBB   
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ANSES 
    
 
  2012 2012   2009       
8  KETONES        
8-6 1120-72-5 2-Methylcyclopentanone  1000 
cf. Cyclopentanone 
8-4; conversion via 
molecular weight; 
OEL Denmark 
900 
Analogy 8-4;  
OEL Denmark 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
8-7 583-60-8 2-Methylcyclohexanone 2300 2300 
OELs Denmark, F, 
Finland:  
230000 µg/m³ 
2300 OEL F  
‘Ascribed’ 
Interim EU-LCI  
8-8 98-86-2 Acetophenone 490 490 
TLV (ACGIH):  
49000 µg/m³  
500 TLV ACGIH No rounding 
‘Ascribed’ 
Interim EU-LCI  
8-9 116-09-6 
1-Hydroxyacetone  
(1-hydroxy-2-propanone) 
 2400 
oxidation product of 
propylene glycol 6-5; 
conversion via 
molecular weight  
400 
Analogy VTR 
OEHHA 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
9   ACIDS             
9-1 64-19-7 Acetic acid   1250 
Individ. compound 
evaluation;  
LCI value changed 
250 EU-OEL  
EU-LCI 
‘with derivation 
pending’ 
9-2 79-09-4 Propionic acid 310 310 EU-OEL/OEL D 300 OEL F 
OEL values 
already rounded, 
no double 
rounding 
‘Ascribed’ 
Interim EU-LCI  
9-3 79-31-2 Isobutyric acid  370 
cf. propionic acid  
9-2; conversion via 
molecular weight; 
EU-OEL/OEL D 
300 
Analogy 9-2;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
9-4 107-92-6 Butyric acid  370 
cf. propionic acid  
9-2; conversion via 
molecular weight; 
EU-OEL/OEL D 
300 
Analogy 9-2;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
9-5 75-98-9 
2,2-Dimethylpropanoic aicd 
(pivalic acid) 
 420 
cf. propionic acid  
9-2; conversion via 
molecular weight; 
EU-OEL/OEL D 
300 
Analogy 9-2;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
 
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
9  ACIDS        
9-6 109-52-4 n-Pentanoic acid (valeric acid)  420  
cf. propionic acid  
9-2; conversion via 
molecular weight; 
EU-OEL/OEL D 
300 
Analogy 9-2;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
9-7 142-62-1 n-Hexanoic acid (caproic acid)  490 
cf. propionic acid  
9-2; conversion via 
molecular weight;  
EU-OEL/OEL D 
300 
Analogy 9-2;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
9-8 111-14-8 n-Heptanoic acid  550 
cf. propionic acid  
9-2; conversion via 
molecular weight; 
EU-OEL/OEL D 
300 
Analogy 9-2;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
9-9 124-07-2 n-Octanoic acid  600 
cf. propionic acid  
9-2; conversion via 
molecular weight; 
EU-OEL/OEL D 
300 
Analogy 9-2;  
OEL F 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
9-10 149-57-5 2-Ethylhexanoic acid   50 
EU: Repr. 2;  
TLV (ACGIH):  
5000 µg/m³ 
5 
TLV (ACGIH);  
EU: Repr. Cat. 3 
 
EU-LCI  
‘with derivation 
pending’ 
10   ESTERS              
10-1 108-21-4 Propyl acetate (n-, iso-) 4200 4200 
OEL Finland, MAK-
DFG: 420000 µg/m³  
4200 MAK-DFG  
‘Ascribed’ 
Interim EU-LCI  
10-2 108-65-6 2-Methoxy-1-methylethyl acetate  2700 2700 EU-OEL/OEL D 2700 MAK-DFG/OEL D  
‘Ascribed’ 
Interim EU-LCI  
10-3 107-31-3 Methylformiate 1200 1200 OEL D 1200 MAK-DFG  
‘Ascribed’ 
Interim EU-LCI  
10-4 592-84-7 n-Butyl formiate  2000 
cf. Methylformiate 
10-3; conversion via 
molecular weight; 
OEL D 
1200 
Analogy 10-3;  
MAK-DFG/OEL D 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
10-5 80-62-6 Methyl methacrylate   2100 EU-OEL/OEL D 50 VTR Canada  
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
 
 Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
10  ESTERS        
10-6   Other methacrylates  2100 
cf. Methyl 
methacrylate 10-5; 
OEL D 
50 
Analogy 10-5;  
VTR Canada 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
10-7 110-19-0 Isobutyl acetate 4800 4800 
OEL D;  
 
4800 MAK-DFG/OEL D  
‘Ascribed’ 
Interim EU-LCI  
10-8 123-86-4 n-Butyl acetate 4800 4800 
OEL D;  
 
4800 MAK-DFG/OEL D  
‘Ascribed’ 
Interim EU-LCI  
10-9 103-09-3 2-Ethylhexyl acetate  690 
cf. 2-ethyl-1-hexanol 
4-7; conversion via 
molecular weight; 
MAK-DFG;  
LCI value changed 
1100 
Analogy 4-7;  
MAK-DFG/OEL D 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
10-10 96-33-3 Methyl acrylate 180 180 EU-OEL/OEL D 200 MAK-DFG/OEL D 
MAK/EU-OEL 
value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
10-11 140-88-5 Ethyl acrylate 200 210 EU-OEL/OEL D 200 OEL F 
Precautionary 
approach by 
adopting the 
lower value 
‘Ascribed’ 
Interim EU-LCI  
10-12 141-32-2 n-Butyl acrylate 110 110 EU-OEL/OEL D 100 OEL  F 
Same value of 
origin, no 
rounding 
‘Ascribed’ 
Interim EU-LCI  
10-13 103-11-7 2-Ethylhexyl acrylate 380 380 OEL D 400 MAK-DFG/OEL D 
MAK value already 
rounded, no 
double rounding 
‘Ascribed’ 
Interim EU-LCI  
10-14   
Other acrylates  
(acrylic acid esters) 
110 110 
cf. n-butyl acrylate 
10-12;  
EU-OEL/OEL D 
110 
Analogy 10-12;  
OEL D 
 
‘Ascribed’ 
Interim EU-LCI  
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
10  ESTERS        
10-15 627-93-0 Dimethyl adipate 50 50 
Dicarbonic acid (C4-
C6)-dimethylester, 
mixture MAK-DFG: 
5000 µg/m³; Individ. 
compound 
evaluation 
50 NIK AgBB  
‘Ascribed’ 
Interim EU-LCI  
10-16 106-65-0 Dimethyl succinate 50 50 
Dicarbonic acid (C4-
C6)-dimethylester, 
mixture MAK-DFG: 
5000 µg/m³; Individ. 
compound 
evaluation 
50 NIK AgBB  
‘Ascribed’ 
Interim EU-LCI  
10-17 1119-40-0 Dimethyl glutarate 50 50 
Dicarbonic acid (C4-
C6)-dimethylester, 
mixture MAK-DFG: 
5000 µg/m³; Individ. 
compound 
evaluation 
50 NIK AgBB   
‘Ascribed’ 
Interim EU-LCI  
10-18 71195-64-7 Diisobutyl glutarate   100 
Individ. compound 
evaluation 
      
EU-LCI  
‘with derivation 
pending’ 
10-19 925-06-4 Diisobutyl succinate   100 
Individ. compound 
evaluation 
      
EU-LCI  
‘with derivation 
pending’ 
10-20 105-75-9 Dibutyl fumarate 50 50 
Individ. compound 
evaluation 
50 NIK AgBB   
‘Ascribed’ 
Interim EU-LCI  
10-21 105-76-0 Maleic acid dibutylester 50 50 
Individ. compound 
evaluation 
50 NIK AgBB   
‘Ascribed’ 
Interim EU-LCI  
10-22 13048-33-4 Hexamethylene diacrylate 10 10 
WEEL (AIHA)  
1000 µg/m³  
10 
TWA WEEL 
(AIHA) 
  
‘Ascribed’ 
Interim EU-LCI  
10-23 96-48-0 Butyrolactone   2700 
Individ. compound 
evaluation 
1800 OEL Denmark   
EU-LCI  
‘with derivation 
pending’ 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
10   ESTERS              
10-24 115-95-7 Linalool  acetate       200 
Analogy vinyl 
acetate; OEL D 
  
EU-LCI  
‘with derivation 
pending’ 
11  CHLORINATED HYDROCARBONS        
11-1 127-18-4 Tetrachloroethene15    
Compound has been 
deleted from the 
German list, no 
relevance 
250 
AQG WHO;  
EU Carc. Cat. 3 
 
EU-LCI  
‘with derivation 
pending’ 
11-2 56-23-5 Tetrachloromethane       35 
VTR AFSSET;  
EU Carc. Cat. 3 
  
EU-LCI  
‘with derivation 
pending’ 
11-3 106-46-7 1,4-Dichlorobenzene 150     60 
VTR ATSDR;  
EU Carc. Cat. 3 
  
‘Derived’ 
Interim EU-LCI 
12   OTHERS              
12-1 123-91-1 1,4-Dioxane   73 
EU: Carc. 2;  
OEL D 
3000 
VTR OEHHA;  
EU Carc. Cat. 3 
  
EU-LCI  
‘with derivation 
pending’ 
12-2 105-60-2 ε-Caprolactam 300 240 
Individ. compound 
evaluation 
100 OEL Denmark   
‘Derived’ 
Interim EU-LCI 
12-3 872-50-4 N-Methyl-2-pyrrolidon 400 400 
EU: Repr. 1B;  
EU-OEL; Individ. 
compound 
evaluation 
400 
EU-OEL;  
EU: Repr. Cat. 2 
  
‘Ascribed’ 
Interim EU-LCI  
12-4 556-67-2 Octamethylcyclotetrasiloxane (D4) 1200 1200 
EU: Repr. 2; Individ. 
compound 
evaluation 
1200 
NIK AgBB;  
EU: Repr. Cat. 3 
  
‘Ascribed’ 
Interim EU-LCI  
12-5 541-02-6 
Decamethylcyclopentasiloxane 
(D5) 
  1500 
cf. Octamethylcyclo-
tetrasiloxane; 
conversion via 
molecular weight  
      
EU-LCI  
‘with derivation 
pending’ 
                                                 
15 Compound otherwise known, and frequently referred to, as tetrachloroethylene 
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EU-LCI 
no. 
CAS no. Compound EU-LCI 
NIK 
(µg/m³) 
Remarks /  
derived from 
CLI 
(µg/m³) 
Remarks / 
derived from 
Explanatory note  
 
Status 
of 
EU-LCI values 
 
  
Version: July 2013 
   
  Interim AgBB   
AFSSET/ 
ANSES 
    
 
  2012 2012   2009       
12  OTHERS        
12-6 540-97-6 
Dodecamethylcyclohexa-siloxane 
(D6) 
  1200 
cf. Octamethylcyclo-
tetrasiloxane; 
Individ. compound 
evaluation 
      
EU-LCI  
‘with derivation 
pending’ 
12-7 100-97-0 Hexamethylenetetramine 30 30 
OEL Norway, 
Sweden:  
3000 µg/m³ 
30 
Sensitizer;  
OEL Sweden 
  
‘Ascribed’ 
Interim EU-LCI  
12-8 96-29-7 2-Butanonoxime   20 
EU: Carc. 2; Individ. 
compound 
evaluation 
90 
OEL Denmark;  
EU Carc. Cat. 3 
  
EU-LCI  
‘with derivation 
pending’ 
12-9 126-73-8 Tributyl phosphate    
SVOC, no LCI value 
EU: Carc. 2 
2 OEL F  
EU-LCI  
‘with derivation 
pending’ 
12-10 78-40-0 Triethyl phosphate   75 
cf. tributyl 
phosphate 12-9; 
MAK: 11000 µg/m³; 
conversion via 
molecular weight;  
LCI value changed 
2 
Analogy 12-9;  
OEL France 
Procedure for 
read-across to be 
applied 
EU-LCI  
‘with derivation 
pending’ 
12-11 26172-55-4 
5-Chloro-2-methyl-2H-isothiazol-
3-one (CIT)  
1 1 
Individ. compound 
evaluation 
1 NIK AgBB   
‘Ascribed’ 
Interim EU-LCI  
12-12 2682-20-4 
2-Methyl-4-isothiazolin-3-one 
(MIT) 
100 100 
Individ. compound 
evaluation 
100 NIK AgBB   
‘Ascribed’ 
Interim EU-LCI  
12-13 121-44-8 Triethylamine   42 OEL D 7 VTR US EPA   
EU-LCI  
‘with derivation 
pending’ 
12-14 109-99-9 Tetrahydrofuran   1500 
EU-OEL/OEL D 
New LCI value 
     
EU-LCI  
‘with derivation 
pending’ 
12-15 68-12-2 Dimethylformamide   15 
EU: Repr. 1B;  
MAK-DFG;  
New LCI value 
     
EU-LCI 
‘with derivation 
pending’ 
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Note: the French list was filed in 2009, classifications given in the corresponding column are based on the dangerous substances directive (67/548/EEC), and not 
according to  the CLP regulation (Regulation (EC) No 1272/2008). 
 
  COLOUR CODING DEFINITION 
 
STATUS OF 
EU-LCI VALUES 
 
  Yellow 
 
- Compounds for which EU-LCI were derived 
according to the de novo protocol (11) and the 
procedure for read across (10) 
 
 
‘Derived’ Interim 
EU-LCI 
 
  Red 
 
- Compounds with different LCI values in 
AgBB/ANSES due to different derivation basis (29) 
 
- Compounds for which EU-LCIs to be derived by 
read across (40) 
 
EU-LCI 
‘with derivation pending’ 
 
  Green 
Compounds in AgBB/ANSES with same/similar 
(within 20% difference) LCI values (61) 
‘Ascribed’ Interim 
EU-LCI 
 
  Blue 
 
- Compounds on either the AgBB-list or the ANSES-
list (24) 
 
- Compounds in AgBB/ANSES for which same 
derivation basis for the LCIs but different values 
due to different safety/extrapolation factors (1 case, 
see No 9-10) 
 
EU-LCI 
‘with derivation pending’ 
 
  Grey 
 
Limitations of underlying human and animal 
studies and lack of a sufficient and transparent 
database currently does not allow the de novo 
derivation of  an EU-LCI value (1) 
 
EU-LCI 
‘with derivation pending’ 
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5. PRACTICAL APPLICATION OF EU-LCIs AND THE NECESSARY 
CONSIDERATION OF MULTIPLE SOURCES  
 
                
As previously explained, EU-LCI values are, by definition, health-based values used to evaluate 
emissions after 28 days from a single product during a laboratory test chamber procedure (as 
defined in the Technical Specification TS 16516 of the horizontal testing method developed by 
CEN TC 351/WG 2). EU-LCIs are applied in product safety assessment with the ultimate goal 
to avoid health risks from long-term exposure16 for the general population. 
EU-LCI values serve a different purpose from IAQ guideline values. They are intended only for 
evaluating emissions from single products, not for evaluating indoor air quality. 
It is clear that achieving appropriate low levels of hazardous compounds in any particular 
indoor environment through the control of emissions requires account to be taken of the 
presence of all sources of those compounds.  
Thus whenever a product is selected and used in a building it must always be kept in mind 
that the resulting indoor air concentrations of a particular volatile organic compound will 
depend upon the amounts emitted from that product as well as from other possible sources of 
that compound. The resulting indoor air concentration in buildings will also depend on the 
ventilation rate and any other processes such as chemical reactions, sorption to surfaces, and 
air temperature. Compared with the test chamber scenario the real room situation is complex 
and more dynamic in nature. Therefore the selection of ‘approved’ construction products with 
emissions satisfying the EU-LCI criteria does not necessarily guarantee good indoor air quality 
in buildings.  
There are several conceivable ways of addressing the multiple sources issue: 
1. Determine the appropriate emission rate of a compound from a particular product 
based on the likely presence of other sources of that compound in typical use 
conditions. In this case the EU-LCI value could be adjusted by application of a ‘multiple 
sources factor’ to give the target highest product emission rate.17  
2. Provide quantitative emission information on product approval documents (i.e. 
specifying the Ri value18) or limit the emission for a single compound to 50% of the R-
value19 (ceiling value) for example. 
3. When selecting a particular construction product with a determined and declared 
emission rate of a compound, consider the possible presence of other emitting sources 
of that same compound in a given environment. In this situation the consideration (and 
                                                 
16
 By inhalation in indoor environments, not taking into consideration other exposure routes (dietary, dermal 
etc.) 
17 It is suggested that in this scenario the default multiple sources factor (MSF) applied to the EU-LCI should be 2, 
which would effectively halve the LCI value in the default situation. In the situation where the compound is 
rare/unusual then this factor might be changed to 1. Where it is known, or there is good reason to believe, that 
there are likely to be numerous sources of that compound then the MSF could be raised to 5. 
18
 Ri value: Ratio Ci/LCIi where Ci is the mass concentration of the compound in air and LCIi is the LCI value of 
compound i.  
19
 R value: sum of all Ri values 
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avoidance) of multiple sources of the same compound would be done by 
planning/building professionals.   
The knowledge of, and access to, construction product emission information within the 
approval process is beyond the remit of the EU-LCI Working Group. The Working Group will 
derive EU-LCI values solely on a toxicological basis with no inherent consideration of possible 
multiple sources or other modifying factors.  
It is recommended that the decision on approving a particular construction product and 
providing appropriate information on emission behaviour (e.g. emission classes) should rest 
with the approving agencies, and that the selection of products and/or technical solutions 
within a building process should rest with the planner, who must be given access to adequate 
information to make these decisions. 
 
 
6. POTENTIAL HARMONISATION ISSUES   
 
Concerning the overall evaluation of chemical emissions from construction products, certain 
additional aspects are considered to require further development and potential 
harmonisation. These are related to:  
(a) The evaluation of compounds for which currently no LCI values can be derived (“not-
yet-assessable” compounds) 
(b) Assessment concept for semi-volatile organic compounds (SVOCs), very volatile 
organic compounds (VVOCs) and carcinogens. 
(c) Reviewing the EU-LCI concept by considering combined effects of chemicals 
(d) Common criteria and threshold values for total volatile organic compounds (TVOC) 
and sensory evaluation 
Once these potential harmonisation issues have been addressed, the health-based evaluation 
of emissions from construction products using the EU-LCI approach can be broadened by 
considering, for example, common criteria and threshold values for TVOC, SVOC, sensory 
evaluation and the sum of “not-yet-assessed” compounds) and R-value <1. 
 
 
6.1 Evaluation of “not-yet-assessable” compounds  
 
The central goal of the EU-LCI concept is to assess as many emitted compounds as possible in 
order to enable a real health-based evaluation of product emissions. This can reduce 
uncertainty for consumers and for product manufacturers. A limitation of this concept is that 
there are still remaining gaps due to lack of approaches and adequate data for other 
potentially relevant compounds to derive EU-LCI values. Also, compounds whose health 
effects are poorly understood and compounds which cannot be identified with existing 
analytical capabilities cannot be evaluated using the EU-LCI concept. Additional criteria and 
measurement methods are needed to tackle this problem. 
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Some compounds are currently measured, at least semi-quantitatively by the sampling and 
analytical methods currently prescribed but not assessed according to EU-LCI values. Two 
strategies have been used to limit the potential problems with these compounds: 
 The AgBB and ANSES schemes restrict "not-yet-assessable" compounds to 10% of the 
threshold value for the TVOC amount (ECA report 18, 1997). 
 The M1-scheme in Finland has a low allowed total amount of VOC emission (TVOC 0.2 
mg/m2.h) including assessed and "not-yet-assessable" compounds. The idea behind 
this approach is the following: low TVOC assumes low emission of the individual 
compounds that constitute the TVOC. 
More toxicological information about the "not-yet-assessable" compounds is expected in the 
course of the REACH process. However, degradation or reaction products and odorous 
compounds – not falling under the REACH regulation – will still need to be tackled. 
 
 
6.2 Health-based evaluation of emissions for SVOCs, VVOCs and 
carcinogens  
Besides the VOCs that have already been accommodated in the EU-LCI harmonisation 
framework and the “not-yet-assessable” compounds, there is a need to consider the inclusion 
and development of protocols for assessing carcinogens, SVOC (e.g. phthalates, flame 
retardants) and VVOCs for which European harmonised test methods are not yet available. 
The Technical Specification TS 16516 of the horizontal testing method developed by CEN TC 
351/WG 2 provides emission data for carcinogens within the VOC range, for some of the most 
volatile of SVOCs and some VVOCs including formaldehyde. 
 
 
6.3 Considering the EU-LCI in relation to combined effects of chemicals 
The application of NIK/LCI-values in the registration of construction products relates to the 
concentration of VOCs obtained in emission chamber testing. In general construction product 
emissions contain several VOCs from different chemical classes. 
The existing schemes in Germany (AgBB) and France (ANSES) make use of the R-value 
approach (Risk-value) to determine whether the concentration of multiple compounds 
emitted from a construction product is in compliance with the approval requirements. The R-
value is derived by summarizing the individual Ri-values. The Ri value is the ratio of the 
emission concentrations of individual compounds in the mixture divided by the 
corresponding LCI value (Ci/LCIi). 
R-value = Ri + …Rn 
While the limitations of the current R-value approach assuming dose additivity of all 
compounds in a chemical mixture irrespective of their health effects is recognised in the EU-
LCI work, current knowledge does not allow the practical use of health end-point dedicated R-
values.    
At this stage of development of the EU-LCI harmonization exercise, therefore, the R-value 
approach shall be adopted as it is currently used by the AgBB and ANSES schemes (i.e. as a 
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pragmatic approach). However, in the light of any new evidence, the definition and/or 
application of the R-value concept should be re-considered. In this perspective, the outcome of 
EU activities (DG ENV and DG SANCO)20  on a new approach to assessing combined health 
effects of chemicals, as well as of other international initiatives such as those being taken by 
the World Health Organisation (WHO)/International Programme on Chemical Safety (IPCS) 
and the OECD, need also to be considered21.  
 In conclusion, at present, applying the existing R-value concept - as opposed to several health 
end-point dedicated R-values - is considered to provide a pragmatic and, from a toxicological 
perspective, conservative approach.  
 
6.4 Harmonisation needs for TVOC and sensory evaluation 
TVOC is an air pollution parameter that summarises the amounts of VOCs collected by an air 
sampler containing the sorbent Tenax TA that is determined by thermal desorption and gas 
chromatography (TD/GC) analysis. It refers to those compounds defined as VOCs that elute 
during the GC analysis between the C6 to C16 chromatographic retention window. TVOC is 
determined as the total integrated peak area that is calibrated with use of toluene as reference 
compound. 
Alternatively, the sum of VOCs (TVOCSUM) may be determined by summing the individual 
concentrations of every identified and unidentified component eluting between n-hexane and 
n-hexadecane inclusively, at a concentration above 5 μg.m-3, after subtracting non-interfering 
VOC artefacts. 
It can be deduced from the aforementioned definition of TVOC/ TVOCSUM that TVOC is not a 
health based indicator. Any assumption that all VOCs within the TVOC window have the same 
health endpoint and thus can be treated in the same manner and be added together, cannot be 
supported from a toxicological standpoint. Moreover, TVOC cannot reflect perceived intensity 
of olfaction by nature of the diversity of the odor thresholds of VOCs. 
As far as the relevance of using TVOC in assessing the emissions of construction products is 
concerned, the following points should be underlined: 
 TVOC represents a narrow chromatographic window that excludes, for example, the 
lower aldehydes, e.g. formaldehyde 
 Poly-oxygenated VOCs may be underestimated, i.e. low detector response 
 Certain biologically reactive VOCs are not measured 
 VOCs with low odour thresholds may not be measured 
 A high TVOC value may be harmless, while a low TVOC value may result in poor IAQ, 
e.g. as a result of strong odour perception. 
                                                 
20 At request of DG ENV, the DG SANCO’s Scientific Committee on Health and Environmental Risks (SCHER), the 
Scientific Committee on Emerging and Newly Identified Risks (SCENIR) and the Scientific Committee on 
Consumer Products (SCCP) prepared an opinion on mixture toxicity/combination effects of chemicals.   
 
21 “RISK ASSESSMENT OF COMBINED EXPOSURES TO MULTIPLE CHEMICALS: A WHO/IPCS FRAMEWORK.” The 
project was conducted within the WHO-IPCS project on the Harmonization of Approaches to the Assessment of 
Risk from Exposure to Chemicals. 
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The EU-LCI WG recognises that TVOC is widely established and accepted in Europe in 
connection with product emissions and indoor air quality. Although TVOC has no direct 
relevance to health, it is used as an indicator to quantify VOC emissions and often as one of the 
criteria when assessing indoor air quality. Assessing the emission behaviour of products via 
TVOC as the one and only criterion is certainly unacceptable. However, when evaluating the 
emissions of construction products, TVOC does provide supplementary information when 
combined with the health-based evaluation using the EU-LCI concept and the limitation of 
CMR compounds.   
Harmonisation of the TVOC concept and the setting of a possible upper concentration limit 
was not within the remit of the EU-LCI WG but will be the responsibility of a new group which 
was recommended to be established by European Commission according to the resolutions of 
ECA WG 27 (ECA report no. 27, 2012). 
As far as the sensory evaluation (sensory irritation and odour perception) of the emissions is 
concerned, this is considered to be an important aspect of the assessment of construction 
product emissions. Results have shown that chemical characterisation of emissions is not a 
good predictor of sensory effects. Therefore it is important to complement the chemical 
assessment of product emissions with sensory evaluation. ECA WG 27 (ECA report no. 27, 
2012) supports the work of ISO TC 146/SC6 in creating a standard for sensory evaluation. The 
ISO 16000-28 on “Indoor Air - Determination of odour emissions from construction products 
using test chambers” includes both acceptability evaluation using an untrained panel and 
perceived intensity measurement with a trained panel. It also combines the odour evaluation 
chamber technique with Technical Specifications TS 16516 of the horizontal testing method 
developed by CEN TC 351/WG 2(reference room). 
 
 
6.5 References 
CEN TC 351/WG 2 technical specification TS 16516. 
(http://www.cen.eu/CEN/Sectors/TechnicalCommitteesWorkshops/CENTechnicalCommitte
es/Pages/WP.aspx?param=510793&title=CEN%2FTC+351). 
ECA report no. 27 (2012). “Harmonisation framework for indoor products labelling schemes 
in the EU”. EUR 25276 EN, ISBN 978-92-79-22535-2. Publications Office of the European 
Union, Luxembourg. 
ECA report no. 18 (1997). Evaluation of VOC emissions from building products – Solid flooring 
materials. EUR 17334/EN, ISBN 92-828-0384-8, Office for Official Publications of the 
European Communities, Luxembourg.    
ISO 16000-28:2012. “Indoor air – Part 28: Determination of odour emissions from building 
products using test chambers”.  
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7. EU-LCI IN RELATION TO EXISTING POLICIES   
 
The EU-LCI harmonisation framework cuts across a number of EU legislative mandates and 
standardization activities, and its implemention is to be seen strictly in relation to them. It is 
important to implement the EU-LCI framework in a wider and integrated context of safe, 
healthy, energy efficient and sustainable buildings in EU. This, in line with the Europe 2020 
Strategy, implies the efficient alignment and implementation of various legislative mandates 
the Construction Products Regulation (Regulation (EU) No 305/2011), the Energy 
Performance of Buildings Directive – EPBD (2002/91/EC), the EC Lead Market Initiative 
(COM(2007)860), the Integrated Product Policy (IPP), the Chemicals Policy (REACH), Green 
Public Procurement, and the Integration of Environmental Aspects into European 
Standardisation (COM(2004)206).  
In the following sections of chapter 7, developments concerning some of the policies which 
have explicitly or implicitly considered and/or referred to the EU-LCI work are reported. 
 
7.1 EU-LCI in relation to CE marking  
Since 2013-07-01, the European Construction Products Regulation (Regulation (EU) No 
305/2011) replaced the former Construction Products Directive (CPD, 89/106/EEC). The goal 
of the CPR is to facilitate cross-border trade and over-come trade barriers in the form of 
national rules and standards. The CPR aims to provide a common technical language in 
harmonised European product performance standards, for use by both manufacturers and 
regulators.  
The CPR contains a chapter defining the framework of European or national requirements for 
hygiene, health and the environment for construction works. Amongst other things, the 
giving-off of toxic gas, or the presence of dangerous particles or gases in the air has been 
identified as specific criteria. The translation into limit values for relevant compounds is left 
to each EU Member State and is currently implemented on a mandatory basis only in France 
and Germany, while Belgium has recently notified a similar mandatory regulation.  
The purpose of the CPR is not to influence the level of protection but to harmonise the 
technical description of products and to facilitate cross-border trade. CE marking could 
(wherever relevant) be accompanied by performance classes that cover all national 
regulations in Europe. Then each EU Member State could specify which performance classes a 
product shall fulfil for being accepted into that national market. The intention is that this CE 
marking will substitute any national law.  
This topic acquired high relevance for Europe when the French system was recently 
introduced, as this system is based on performance classes whereas the German system and 
the upcoming Belgium system is based on pass/fail criteria. The German system with its 
pass/fail scheme defines a product as being safe or not safe for an assumed concentration 
according to the exposure scenario in a standard room described in the technical 
specification. Moreover, it applies to indoor environments which are commonly occupied by 
people for a prolonged time. In the construction sector in general, the principle of classes 
(stability, durability, fire resistance, etc.) is applied depending on the type of building that is 
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constructed. It is not always necessary to use the best performing material. Products 
belonging to different performance classes can be combined. However, it should be 
underlined that a product cannot be considered as being unsafe or safe per se. It depends on 
the use of the product. Products could in principle be safe, per se. It depends on the use of the 
product. Products could in principle be safe, as long as they are used correctly in relation to 
the exposure scenario defining appropriate use in a given building. Moreover, the issue of 
potential multiple sources for a given compound opens the possibility of classes below that 
deemed ‘safe’ according to the single material exposure scenario used. Therefore, the 
challenge is how the information about a given product can be most effectively applied to fit-
for-purpose, safe and cost-optimised building constructions.  
The current effort by DG ENTR’s Expert Group on Dangerous Substances (EGDS) is to bring 
both systems into an EU harmonised classification system which should be transparent in the 
communication to end users in the market, require less expert knowledge for interpretation, 
and be consistent with the EU-LCI harmonisation work. This will decrease existing burdens 
for the construction industry in producing and certifying safe construction materials and 
products and will also help remove barriers to trade across the European market.   
 
 
7.2 EU-LCI in relation to the REACH process  
In the derivation of the EU-LCI values information from the European chemical substances 
information system, the Annex VI on hazardous substances of the Classification, Labelling and 
Packaging Directive ((EC) No 1272/2008)) and the REACH process is fully considered. Via the 
European Chemicals Agency (ECHA) website (http://echa.europa.eu), a vast amount of 
registration data is published, where DNELs (Derived No Effect Levels) are also included. As 
mentioned in section 2.4.1 the EU-LCI WG considers only information from published reports 
(e.g. already published info for compounds of very high concern/SVHC), or if access to 
registration dossiers can be arranged (via the respective EU competent bodies or the 
registrant on a voluntary basis) so that the derivation of particular DNELs could be fully 
comprehended. 
Comparing the long-term inhalation DNELs for workers (DNELw) with the DNELs for the 
general population (DNELp) for 120 compounds relevant to indoor air (Figure 3), it can be 
seen that on average the DNELw is four times greater than the DNELp, with minimum and 
maximum ratios being in the range 1 to 23. 
Table 10 shows wide differences between DNELs and the EU-LCI values derived for several 
compounds emitted from construction products in the context of the  EU-LCI harmonisation 
framework, even though the REACH Guidance on information requirements and the chemical 
safety assessment (Chapter R.8) was used as the basis in the derivation of the EU-LCI values. 
This may be due to a number of reasons, such as non-harmonised application of assessment 
factors and read-across, assumption of short-term exposure scenarios for consumers, etc. The 
reasons for such discrepancies should be explored and alignment of DNELs and EU-LCIs 
should be sought where appropriate. Disclosure of the approach and associated data used for 
the derivation of DNELs would greatly facilitate this. The importance of the findings of the EU-
LCI work in relation to the requirements of the REACH legislation is reflected in the 
Commission’s Staff Working document (SWD(2013)0025, page 16) companion to the EC’s 
report “Review of REACH”. 
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(COM(2013)0049)(http://ec.europa.eu/enterprise/sectors/chemicals/documents/reach/rev
iew2012/index_en.htm). 
 
 
Figure 3. DNELs for workers versus DNELs for general population 
 
 
Table 10. Comparison of EU-LCI, NIK, CLI and DNEL values for some compounds in the EU-LCI 
master list 
 
Compound EU-LCI 
[µg/m3] 
NIK 
[µg/m3] 
CLI 
[µg/m3] 
 DNEL* 
[µg/m3] 
Trimethylbenzenes 450 1000 1000  29400 
Xylenes** 500 2200 200  14800 
2-Butoxyethanol 1100 490 1000  49000 
Styrene 250 860 250  10200 
Toluene 2900 1900 300  56500 
Ethylbenzene 850 880 750  15000 
              * Long-term inhalation DNEL, general population: systemic effects 
                     ** CAS 1330-20-7 
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Moreover, it would be useful to revise chapter R.8 of the ECHA guidance on information 
requirements and chemical safety assessment concerning sensory irritation, and also to have 
additional data requirements concerning odour threshold as part of the REACH 
documentation according to a harmonised test.  
 
 
7.3 EU-LCI in relation to consumer product policies 
There are a number of EU policies that impact on the use of ingredients in consumer products, 
either by prohibiting the use of certain compounds or by imposing restrictions on the content 
of chemicals in product composition: the REACH regulation (EC 1907/2006), the General 
Product Safety Directive (GPSD, 2001/95/EC), the regulation on classification, labelling and 
packaging of substances and mixtures ((EC) No 1272/2008) and the Biocidal Products 
Regulation (BPR, 2012). Specific sectorial policies exist for various categories of consumer 
products such as cosmetics (Cosmetics Products Regulation EC 1223/2009), detergents and 
toys (Toys Safety Directive 2009/48/EC), etc. In terms of health risk assessment, most 
existing product policies focus on chemical content rather than emissions. Risk health 
assessment in relation to emissions, exposure patterns and health effects of consumer 
products in the EU was recently undertaken in the context of the EU funded EPHECT project 
(Emissions, Exposure Pattern and Health Effects of Consumer products in the EU, 
https://sites.vito.be/sites/ephect). The outcome of EPHECT shows that many of the 
compounds emitted from the products studied in this project (i.e., personal care products, air 
fresheners, cleaning agents and sprays, etc.) are common with those emitted from 
construction products and are considered in the EU-LCI harmonisation framework. From a 
health risk assessment point of view, a new holistic approach for health based evaluation of 
emissions from construction products (based on the EU-LCI concept) and consumer products 
is considered a challenging development. Such an approach should account for differences 
between construction and consumer products in terms of typologies of pollution sources and 
emissions (constant sources and long term emissions as opposed to short and temporary 
emissions), different use and exposure patterns and risk assessment procedures. 
 
7.4 EU-LCI in relation to national legislation 
The development of the EU-LCI harmonisation framework has been positively received and 
supported by a wide range of stakeholders (European Commission, EU Member States and the 
European Chemicals Industry). However, in terms of its implementation into national policies 
in the EU Member States, there is a need for further discussion and definition of how the on-
going work and procedures of national committees (e.g., the German NIK Committee) will be 
aligned to the outcome of the EU-LCI work (i.e. adopting the harmonised protocol for deriving 
EU-LCI values and the master list of EU-LCI values). This requires a transition phase in which 
the EU Member States that do not have in place a national procedure for deriving LCI values 
may wish to proactively adopt the EU-LCI framework even if it is not formally required by the 
European legislation. An example of such a proactive adoption of the EU-LCI framework (with 
interim solution the German NIK values) is the stated intention of Belgium via its Belgian 
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Royal Decree which aims at establishing threshold levels for the emissions to the indoor 
environment from construction products. 
(http://ec.europa.eu/enterprise/tris/pisa/app/search/index.cfm?fuseaction=pisa_notif_over
view&sNlang=EN&iyear=2012&inum=568&lang=en&iBack=3).  
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2008 on classification, labelling and packaging of substances and mixtures, amending and 
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8. GLOSSARY  
 
AFSSET: Agence Francaise de Sécurité Sanitaire de l’Environment et du Travail (French agency for 
environmental and occupational health and safety; now ANSES). 
ANSES: Agence nationale de sécurité sanitaire de l’alimentation, de l’environment et du travail (French 
agency for food, environmental and occupational health and safety). 
AgBB: Ausschuss zur gesundheitlichen Bewertung von Bauprodukten (Committee for Health-related 
Evaluation of Building Products). 
Assessment Factor: A numerical factor (multiplier) used at various stages of the extrapolation from 
an experimentally determined toxicological point-of-departure to the estimated level of exposure 
below which an adverse effect is unlikely to occur. Sometimes referred to as an ‘uncertainty factor’ or, 
historically, a ‘safety factor’. 
ATSDR: [US] Agency for Toxic Substances and Disease Registry. 
BMD: Benchmark Dose – The dose or exposure of a compound associated with a specified low 
incidence of risk, generally in the range of 1% to 10%, of a health effect, or the dose associated with a 
specified measure or change of a biological effect. Thus BMD10, for example, is the dose of the test 
material that leads to a 10% increase in effect. The BMD approach provides a more quantitative 
alternative to the first step in the dose-response assessment than the NOAEL/LOAEL process for non-
cancer health effects. 
Category 1A and 1B carcinogens and mutagens: Compounds that are classified in accordance with 
the provisions of Regulation (EC) No 1272/2008 as a carcinogen or mutagen category 1A or 1B (based 
on the Globally Harmonized System). A Category 1 compound is known or presumed to have 
carcinogenic/mutagenic potential for humans. For Category 1A the assessment is based primarily on 
human evidence; for Category 1B the assessment is based primarily on animal evidence. 
CEN/TC 351 horizontal standard: Horizontal testing procedure being developed by the CEN/TC 351 
working group 2 and published as Technical Specification TS 16561 for the determination of emissions 
into indoor air of regulated dangerous substances from construction products that can be used for all 
types of substances and construction products deemed relevant under the essential requirements of 
the Construction Products Directive (89/106EEC). 
CLI: Concentration Limite d’Intérêt– the French (Afsset/Anses) LCI. 
CLP: Classification, Labelling and Packaging. The classification, labeling and packaging of substances in 
the EU is regulated under EU Regulation 1272/2008 on Classification, Labelling and Packaging and, 
until 1st June 2015, Directive 67/548 EEC on Classification, Labelling and Packaging. 
CMR: Carcinogenic, mutagenic or toxic to reproduction – meeting the criteria for classification in 
category 1 or 2 in accordance with Directive 67/548/EEC. This directive was recently replaced by the 
new EU regulation (EC) No 1272/2008 on classification, labelling and packaging of chemical 
substances and mixtures, the so-called CLP Regulation. According to the new CLP Regulation these 
substances shall be classified as 1A or 1B (see definition above). 
CPD: The ‘Construction Products Directive’ 89/106/EEC of 21 December 1988 on the approximation 
of laws, regulations and administrative provisions of the member states relating to construction 
products. The ‘Construction Products Directive’ (CPD) aims to ensure the free movement of all 
construction products within the European Union by introducing a common technical language, 
consisting of harmonised standards and European technical approvals, in which manufacturers can 
express the performance of the products that they place on the market. This Directive will be replaced 
by the Construction Products Regulations (CPR) on 1st July 2013. 
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CPR: The Construction Products Regulation (EU) No 305/2011 of the European Parliament and of the 
Council of 9 March 2011 laying down harmonised conditions for the marketing of construction 
products and repealing Council Directive 89/106/EEC. This regulation aims to ensure reliable 
information on construction products in relation to their performance. This is achieved by providing a 
“common technical language" offering uniform assessment methods of the performance of 
construction products. The Construction Products Regulation entered into force on the 24th of April 
2011 and will replace the Construction Products Directive (CPD) completely on 1st July 2013. 
Critical effect: The first adverse effect that appears when the threshold (critical) concentration or 
dose is reached in the critical organ. 
Critical dose: The dose of a substance at and above which adverse functional changes, reversible or 
irreversible, occur in a cell or an organ. In the EU-LCI process it may also refer to the lowest dose or 
exposure level at which the identified important (critical) toxic effect occurs in the chosen study(ies).  
CSR: Chemical Safety Report (produced as part of the substance registration process under REACH). 
DG ENTR: The European Commission’s Directorate General for Enterprise and Industry. 
DG JRC: The European Commission’s Joint Research Centre. 
DG SANCO: The European Commission’s Directorate General for Health and Consumers. 
DIBT: Deutsches Institut für Bautechnik (German Institute for Building Technology). 
DNEL: Derived No-Effect Level – in REACH, the level of exposure below which no adverse effects are 
expected to occur and therefore the level above which humans should not be exposed. A DNEL is a 
derived level of exposure because it is normally calculated on the basis of available dose descriptors 
such as NOAELs or BMDs  from animal studies. 
ECETOC: European Centre for Ecotoxicology and Toxicology of Chemicals. 
ECHA: The European Chemicals Agency. 
EFSA: The European Food Safety Agency. 
EGDS: The DG Enterprise Expert Group on Dangerous Substances. 
Emission rate: The mass of chemical emitted from a specific unit area of product surface per unit time 
– [mg/m2/h] or [mg/item/h]. 
Endpoint: In biological and clinical research, a disease, symptom or sign that constitutes one of the 
target outcomes of the experiment or trial. 
EU-LCI: The EU-LCI value for a compound (‘ascribed interim’, ‘derived interim’, ‘with derivation 
pending’) agreed by the EU-LCI working group or formally endorsed by the EU Member States 
(‘confirmed’). 
EU-LCI ‘ascribed interim’ value: The EU-LCI value given to a compound that, for whatever reason, 
has identical or very similar (differing by 20% or less) LCI values in the ANSES and AgBB lists.  
EU-LCI ‘candidate’ compound: A compound under consideration for inclusion into the EU-LCI master 
list and subsequent evaluation (e.g. compounds identified by EU national authorities).  
EU-LCI ‘derived interim’ value: The EU-LCI value of a compound derived de novo using the EU-LCI 
protocol.  
EU-LCI ‘interim’ value: The ‘ascribed’ or ‘derived’ EU-LCI value in the EU-LCI master list to be used as 
the harmonised value by the EU Member States, as long as no formal process is underway to transform 
it into a ‘confirmed’ EU-LCI value. 
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EU-LCI ‘with derivation pending’: The EU-LCI value (for compounds with different LCI values in 
AgBB and ANSES lists) for which de novo derivation (by applying the EU-LCI protocol) has not been 
initiated.  
EU-LCI WG: The expert group (established by the European Commission’s DG JRC in the context of the 
PILOT INDOOR AIR MONIT administrative arrangement with DG SANCO) responsible for developing 
the EU-LCI framework, deriving EU-LCI values and preparing the EU-LCI master list.  
EU-LCI master list: a list comprising compounds with ‘confirmed’ and ‘interim’ EU-LCI values, EU-LCI 
values ‘with derivation pending’ and EU-LCI ‘candidate’ compounds.  
EU-RAR: European Union Risk Assessment Report. These reports were produced in accordance with 
Council Regulation (EEC) 793/93 on the evaluation and control of the risks of “existing” substances - 
chemical substances in use within the European Community before September 1981 and listed in the 
European Inventory of Existing Commercial Chemical Substances. 
HEC: The human equivalent concentration represents the equivalent human exposure concentration 
adjusted to a continuous basis. 
IAQG: Indoor Air Quality Guideline(s). 
LOAEL: Lowest Observed Adverse Effect Level - the lowest dose or exposure level at which there is a 
statistically or biologically significant increase in the frequency or severity of an adverse effect 
compared with the unexposed control group. 
LCI: Lowest Concentration of Interest - The LCI concept was first developed by the ‘European 
Collaborative Action on ‘Indoor Air Quality and its Impact on Man’ when considering the best way to 
evaluate emissions from solid flooring materials. It was defined (see ECA Report No.18, 1997) as “the 
lowest concentration above which, according to best professional judgement, the pollutant may have 
some effect on people in the indoor environment”.  
Molar adjustment: The multiplicative factor, based on relative molecular weight, applied to the value 
derived by read-across, generally from a smaller molecular entity to a larger molecule, assuming the 
same active moiety. When applying molar adjustment in a homologous series of compounds, the molar 
adjustment factor rapidly increases. It is considered appropriate, therefore, to apply a cap or ‘cut-off’ 
(e.g. 1.5 x base value; two CH2 group per aliphatic chain) to limit the maximum adjustment made and 
achieve an appropriate level of safety in the risk assessment procedure. 
MRL (Chronic Minimal Risk Level): An estimate of daily human exposure to a dose of a chemical that 
is likely to be without an appreciable risk of adverse noncancerous effects over a lifetime of exposure 
(based on chronic studies of 365 or more days). Used by ATSDR. 
NIK: Niedrigste Interessierende Konzentration – the German (AgBB) LCI. 
NOAEL: No Observed Adverse Effect Level - An exposure level at which there are no statistically or 
biologically significant increases in the frequency or severity of adverse effects compared to those 
observed in the control group; some effects may be produced at this level, but they are not considered 
as adverse or precursors to adverse effects. The NOAEL is thus generally taken as the highest exposure 
without adverse effect. 
OECD: Organization for Economic Co-operation and Development. 
OEL: Occupational Exposure Limit. 
PBPK: Physiologically based pharmacokinetic [modelling] - Mathematical modeling of the kinetic 
behavior of a substance in the body, based on measured physiological parameters (Also known as 
physiologically based toxicokinetic modelling). 
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Point-of-departure value: The point on a toxicological dose-response curve established from 
experimental data generally corresponding to an estimated low effect level, based for example on the 
benchmark dose or a LOAEL or NOAEL.  
Primary emission: The release of volatile compounds contained in the material from manufacture in 
free form. The rate of emission will normally decay continuously up to and beyond the standard 28-
day chamber testing period. 
QSAR: Quantitative Structure-Activity Relationship - The relationship between the physical and/or 
chemical properties of a substance and its ability to cause a particular effect. ‘QSARs’, as commonly 
referred to, are the mathematical models developed to predict the properties of a substance from its 
molecular structure. In toxicology the aim of QSARs is to predict the toxicity of a substance by analogy 
with the properties of other toxic substances of known structure and toxic properties. 
R-Value: R is the sum of the ratio of individual VOCi concentrations to their respective LCIi values, i.e. R 
=  (Ci/LCIi) of assessable VOCs. In both the AgBB scheme and the ANSES protocol, the limit value of 
“exposure concentration” is R ≤ 1 after 28 days.  
Read-across: The technique used to predict endpoint information for one chemical by using data on 
the same endpoint from another chemical which is considered to be similar - e.g. on the basis of 
structural similarity and similar properties and/or activities. The approach can be qualitative or 
quantitative. 
REACH: Registration, evaluation, authorisation and restriction of chemicals – the European regulatory 
framework for chemicals (Regulation (EC) No 1907/2006). 
RfC (Reference Concentration)/RfD (Reference Dose): An estimate of the daily exposure 
concentration/dose to/of a substance for a human population, including sensitive subgroups, that is 
likely to be without an appreciable risk of deleterious effects during a lifetime. 
RIVM: Rijksinstituut voor Volksgezondheid en Milieu (Dutch national institute for public health and 
the environment). 
Risk value (inhalation): A concentration of chemical (usually expressed as µg/m³) that for noncancer 
toxicity is generally considered to be without adverse effects in populations of humans (including 
sensitive subpopulations) for the duration of exposure specified. Examples include: MRL, RfC, TC, TCA, 
WHO Air quality guidelines, DNEL). 
SCOEL: EC Scientific Committee on Occupational Exposure Limits 
Secondary emission: The release of volatile compounds formed by a continuous process (sometimes 
only after induction by an external influence) – for example by oxidation, hydrolysis or other chemical 
reaction – after the material is produced. This can result in an unusually prolonged emission phase or 
even an increase in emissions during the 28-day chamber testing period. 
SVOC: Semi-Volatile Organic Compound – An organic compound whose boiling point is in the range 
from (240 °C to 260 °C) to (380 °C to 400 °C).22 
TC (TCA): Tolerable Concentration (or Tolerable Concentration in Air), used by Health Canada and 
RIVM. 
TRV: Toxicological  Reference Value (or "reference dose"); see RfD.  
TVOC: Total Volatile Organic Compounds – TVOC is a simple parameter that summarizes on Tenax TA 
adsorbed VOCs following GC elution between the C6 to C16 chromatographic retention window. TVOC is 
                                                 
22 This classification has been defined by the World Health Organization. Boiling points of some compounds are difficult or 
impossible to determine because they decompose before they boil at atmospheric pressure. Vapour pressure is another 
criterion for classification of compound volatility that may be used for classification of organic chemicals. 
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determined as the total integrated peak area, calibrated with use of toluene as reference compound23. 
Alternatively, the sum of VOCs (TVOCSUM) may be determined by summing the individual 
concentrations of every identified and unidentified component eluting between n-hexane and n-
hexadecane inclusively, at a concentration above 5 μg.m-3, after subtracting non-interfering VOC 
artefacts24. 
UBA: Umweltbundesamt – the German Federal Environment Agency 
VOC: Volatile Organic Compound – An organic compound whose boiling point is in the range from (50 
°C to 100 °C) to (240 °C to 260 °C)1. 
VVOC: Very Volatile Organic Compound – An organic compound whose boiling point is in the range 
from <0 °C to (50 °C to 100 °C)1.  
WHO: World Health Organization  
  
                                                 
23 ISO 16000-6 (2004) Indoor Air – Part 6: Determination of volatile organic compounds in indoor and test chamber air by 
active sampling on Tenax TA sorbent, thermal desorption and gas chromatography using MS/FID, Geneva, Switzerland, 
International Organization for Standardization. 
24 As in the German AgBB scheme. 
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APPENDIX A: Data collection sheets and the summary factsheets of 
the compounds which were treated with priority by the EU-LCI WG  
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A.1 Acetaldehyde 
 
Compound ACETALDEHYDE  Data collection sheet 
N° CAS: 75-07-0 
 
EU classification: 67/548/EEC:  F+; R12 
 Carc. Cat. 3; R40, Xi; R36/37  
 
CLP: Flam. Liqu. 1, Carc. 2, Eye Irrit. 2 STOT SE 3 
 
EU: no risk assessment report 
 
ECHA: no DNEL derived 
 
1 ppm = 1.83 mg/m3 Supporting studies for inhalatory repeated toxicity on website available 
 
Organization Name OEHHA Santé Canada US EPA 
Risk Value Name Inhalation REL TC RfC 
Risk Value (µg/m3) 140 390 9 
Risk Value (ppb) 80 220 5 
Reference period Chronic Chronic Chronic 
Year 2008 2000 1991 
Key Study 
Appleman et al., 1982; 
1986; supported by 
Saldiva et al., 1985; 
Woutersen et al., 1986, 
1984; Woutersen and 
Feron, 1987 
Appleman et al. (1982, 
1986). 
Appleman, L.M., et al., 
1986. Effect of 
variable versus fixed 
exposure levels on the 
toxicity of 
acetaldehyde in rats 
Study type 4-weeks study on rats 4-weeks study on rats 4-weeks study on rats 
Species Wistar rats Wistar rats Wistar rats 
Duration of exposure in 
key study 
Inhalation exposure 6 h/d, 
5 d/w, 4 w 
Inhalation exposure 6 
h/d, 5 d/w, 4 w 
Inhalation exposure 6 
h/d, 5 d/w, 4 w 
Critical effect 
respiratory system: 
degenerative, 
inflammatory ans 
hyperplasic changes of the 
nasal mucosa in animals 
no neoplasic effects in 
respiratory system 
Degeneration of 
olfactory epithelium 
Critical dose value 
NOAEL: 270 mg/m3 (150 
ppm) 
CA (acceptable 
concentration): 218 
mg/m3 (120 ppm) 
NOAEL: 275 mg/m3 
(150 ppm) 
  
LOAEL: 720 mg/m3 (400 
ppm) 
  
LOAEL: 728 mg/m3 
(400 ppm) 
Adjusted critical dose 
BMC05: 178 mg/m3 (99 
ppm) 
Temporal  Temporal + HEC 
  
Human equivalent 
concentration: 242.1 mg/ 
m3 (134.6 ppm) 
218 x 6/24 x 5/7 = 39 
mg/m3 (0.20 ppm) 
NOAEL(ADJ): 48.75 
mg/cu.m (26 ppm) = 
273 mg/m3 x 6/24 x 5 
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d/7 d 
  
Time-adjusted exposure: 
43.2 mg/m3 (24 ppm) = 
(134.6*6/24*5/7) 
  
NOAEL(HEC): 8.7 
mg/m3 * 
Single assessment factors 
(see table R.8.6) 
UFA √10 x UFS √10x UFH 
(10 x √10) = 300  UFA 10 x UFH 10  = 100  
UFS 10 x UFA 10 x UFH 
10  = 100  
Other effects       
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD 
data deficiencies 
 
* The NOAEL(HEC) was calculated for a gas:respiratory effect in the ExtraThoracic region.  
MVa = 0.23 m3/day, MVh = 20 m3/day, Sa(ET) = 11.6 sq. cm, Sh(ET) = 177 sq. cm.  
RGDR(ET) = (MVa/Sa) / (MVh/Sh) = 0.18.                                       
NOAEL(HEC) = NOAEL(ADJ) x RGDR = 8.7 mg/m3 
 
 
 
Compound ACETALDEHYDE Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 1200  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 12 December 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX  605-003-00-6 
EC-Nr. 5  EINECS – ELINCS - NLP    200-836-8  
CAS-Nr. 6 Chemical Abstracts Service number   75-07-0 
Harmonised CLP classification 7 Human health risk related classification  Flam. Liq. 1 
Eye Irrit. 2 
STOT SE 3 
Carc. 2 
Molar mass  8 [g/mol]  44.1 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 Appelman et al., (1982) 
Toxicol.23, 293-307 
Read across compound 10 Where applicable  
Species 11 Rat,… human Rat 
(also hamster inhalation 
studies available which show 
lower sensitivity)   
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Route/type of study 12 Inhalation, oral feed,… Inhalation  
Study length  13 Days, subchronic, chronic  28 days 
Exposure duration 14 Hrs/day, days/week 6 hrs/ day, 5 days a week 
Critical endpoint 15 Effect(s), site of  Nasal irritation  
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 NOAEC 
POD  Value  17 [mg/m³] or [ppm] 275 mg/m3  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
5.6 
AF 
Study Length 
20 sa sc c  
(R8-5) 
2 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d) 2 
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 10 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF) 224  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
       ..……1227.6   µg/m3 
    ……… 676.6   ppb 
 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 1200 
Additional Comments 31   
 
 
 
Rationale Section 32   
Canada (TC: 390 µg/m3) and US-EPA (Inhalation reference concentration: RfC: 800 µg/m3), all evaluations are 
based on the studies by Appleman et al., 1982 and 1986: 
 
POD and assessment factors  
The key study (Appleman et al., 1982) shows the key effect (nasal irritation) and the NOAEC in the course of a 28 
days study. For acetic aldehyde and also for other aldehydes is has been experimentally consistently shown that 
the NOAECs for this local effect don’t change much with exposure time. Hence, the time extrapolation factor for 
length of study could be confined to 2. A factor of 2 is proposed for severity of effects. This has been made with 
regard to the carcinogenic effect (nasal tumors in rats if concentrations were driven into a massive irritating 
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state). Aldehydes react directly without metabolic activation, hence enzyme polymorphism is not considered to 
play a significant role. However, interindividual defense mechanisms may vary and this is considered by an 
intraspecies factor of 10.  
 
References: 
Acetaldehyde: CASRN 75-07-0. IRIS Risk information system. US-EPA: http://www.epa.gov/iris/subst/0290.htm 
OEHHA: Office of Environmental Health Hazard Assessment, California: Acetaldehyde Reference Exposure 
Levels: Acetaldehyde: http://oehha.ca.gov/air/toxic_contaminants/pdf_zip/acetaldehyde_112508.pdf 
Canadian Canadian Environmental Protection Act, 1999 Priority assessment substance list assessment report: 
Acetaldehyde: http://www.hc-sc.gc.ca/ewh-semt/alt_formats/hecs-sesc/pdf/pubs/contaminants/psl2-
lsp2/acetaldehyde/acetaldehyde_fin-eng.pdf  
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A.2 Toluene 
 
Compound TOLUENE  Data collection sheet (1/3) 
N°CAS 108-88-3  
 
 1 ppm (in air, 25 °C) = 3.76 mg/m3 
 
Organization Name OMS US EPA IRIS Santé Canada RIVM OEHHA ATSDR 
Risk Value Name Guide Value RfC CJA TCA REL MRL 
Risk Value (mg/m3) 0.26 5 3.75 0.4 0.3 0.3 
Risk Value (ppm) 0.07 1.3 1 0.1 0.07 0.08 
Reference period Chronic Chronic Chronic Chronic Chronic Chronic 
Year 2005 2005 1992 2001 2003 2000 
Key Study 
Foo et al., 1990, 
Chronic 
neurobehavioural 
effects of toluene 
Abbate et al., 1993, 
Boey et al., 1997, 
Cavalleri et al., 
2000, Eller et al., 
1999, Foo et al., 
1990, Murata et al., 
1993, Nakatsuka et 
al., 1992, Neubert 
et al., 2001, Vrca et 
al., 1995, Zavalic et 
al., 1998a 
Andersen et al., 
1983, Human 
response to 
controlled levels 
of toluene in 6-h 
exposures 
Foo et al., 1990, 
Chronic 
neurobehavioura
l effects of 
toluene 
Hillefors-
Berglund et al., 
1995 
supported by 
Foo et al., 1990, 
Orbaek et Nise 
1989 (human) 
Zavalic et al., 
1998, 
Assessment of 
colour vision 
impairment in 
male workers 
exposed to 
toluene generally 
above 
occupational 
exposure limits 
Study type 
Neurobehavioural 
tests: measuring 
manual dexterity 
(grooved peg board), 
visual 
scanning (trail 
making, visual 
reproduction, 
Benton visual 
retention, and digit 
symbol), and 
verbal memory (digit 
see below 
Human response 
to controlled 
levels of toluene 
in six-hour 
exposures 
Neurobehaviour
al tests: 
measuring 
manual dexterity 
(grooved peg 
board), visual 
scanning (trail 
making, visual 
reproduction, 
Benton visual 
retention, and 
digit symbol), 
Subchronic 
inhalation 
study 
Colour vision 
was evaluated by 
Lanthony-D-15 
desaturated test 
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span) and 
verbal memory 
(digit span) 
Species 
Human (30 
female workers) 
Human 
(occupationally-
exposed workers) 
Human Human Rat 
Human (45 male 
workers 
occupationally 
exposed to 
toluene, 
employed in a 
printing press) 
Duration of exposure 
in key study 
Average of 5.7 years see below 
6-h exposures to 
clean air and to 
10, 40 or 100 ppm 
of toluene 
Average of 5.7 
years 
6 h/d, 5 d/w, 4 
weeks, 
followed by 29-
40 days 
recovery 
Average of 16.8 
years (mean 
value of 
[toluene] in 
ambient air = 
119.96 ppm) 
Critical effect 
Decrease in 
performance at 
neuropsychological 
tests 
Neurological 
effects (impaired 
color vision, 
impaired hearing, 
reduced 
performance in 
neuropsychological 
tests, sensations of 
concentration 
difficulties, 
headaches, 
dizziness) 
Decrease in 
neuroligal 
function as 
measured by 
various tests, 
increased 
neurological 
symptoms ans 
respiratory 
irritation 
Decrease 
performance in 
neuropsychologi
cal tests  
Neurological 
effects 
(decrease the 
weight of the 
subcortical 
limbic area of 
the brain and 
alteration of 
dopamine 
receptors) 
Neurological 
effects 
(dysfunctions of 
color vision) 
Critical dose value   
Average NOAEC =  
128 mg/m3 
(34 ppm) 
NOAEC 
150 mg/m3 (40 
ppm) 
  
NOAEC 
150 mg/m3 
(40 ppm) 
  
 
LOAEC 332 mg/m3 
(88 ppm) 
    
LOAEC 
332 mg/m3 
(88 ppm)  
LOAEC 
306.4 mg/m3 
(80 ppm) 
LOAEC 
134 mg/m3 
(35 ppm)  
Adjusted critical dose Temporal Temporal Temporal Temporal Temporal Temporal 
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80 mg/m3 (21 ppm)= 
332 mg/m3 x 8h/24h 
x 5j/7j 
46 mg/m3 (12 
ppm) = 128 mg/m3 
x10m3/20m3 x 
5j/7j 
38 mg/m3 (10 
ppm)= 
150 mg/m3 x 
6h/24h 
119 mg/m3 (30 
ppm)= 
332 mg/m3 x 
10m3/20m3 x 
5j/7j 
26.8 mg/m3 (7 
ppm)= 
150 mg/m3 x 
6h/24h x 5j/7j 
32 mg/m3 (8.3 
ppm)= 134 
mg/m3 x 5j/7j x 
8h/24h 
Single assessment 
factors (see table 
R.8.6) 
UFL 10 x UFH 10 x 
UF(for potential 
effects on the 
developing CNS) 3 = 
300  
UFH 10 UFH 10 
UFL 10 x UFH 10 
x UFD (on neurotoxicity 
and respiratory irritation 
on animal) 3 = 300  
UFS 10 x UFH 
10 = 100 
UFL 10 x UFH 10  
= 100  
Other effects       
Confidence  High  High   
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
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Compound TOLUENE  Data collection sheet (2/3) 
N°CAS 108-88-3  
 
 1 ppm (in air, 25 °C) = 3.76 mg/m3 
 
Organization Name 
Afsset German IAQ Austrian IAQ EU-RAR- based*  
EU-RAR- 
based* 
ECHA 
Registered 
Substances 
Risk Value Name 
VTR IAG (I) IAG DNEL consumer 
DNEL 
consumer 
DNEL 
Risk Value (mg/m3) 3 0.3 0.075 1.40  2.5 56  
Risk Value (ppm) 0.8  0.07  0.02  0.37 0.66 14.75 
Reference period Chronic Chronic Chronic Chronic Chronic Chronic  
Year 2010 1996 2006 2011 2011 2011 
Key Study Zavalic et al., 1998 
Echeverria et al. 
1989 
supported by 
various studies, 
including long 
term occupational 
exposure  
Campagna et al. 
2001 
Thiel and 
Chahoud In RAR, 
2003 
Pryor et al. in 
RAR, 2003 
  
Study type 
Colour vision was 
evaluated by 
Lanthony-D-15 
desaturated test 
Cognitive tests 
Colour 
Confusion Index,  
Lanthony D-15 
desaturated panel 
Developmental 
toxicity  
Multisensory 
conditioned 
avoidance 
response test 
  
Species 
Human (45 male 
workers 
occupationally 
exposed to toluene, 
employed in a 
printing press) 
Human volunteers 
 72 Human 
workers, 
occupationally 
exposed 
  
 
Male fisher rats  
  
Duration of exposure 
in key study 
Average of 16.8 years 
(mean value of 
[toluene] in ambient 
air = 119.96 ppm) 
3 days, 7 hours, 
281 and  562 mg 
Toluol/m-3 
    
14 weeks 
treatment  
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Critical effect 
Neurological effects 
(disorders of color 
vision) 
CNS effects 
CNS-effects: color 
vision loss 
Effects on 
fertility and 
reproduction 
(dev.): 
reduced foetal 
weights and 
birth weights in r 
in the offspring 
of exposed 
mothers. 
Long-lasting 
developmental 
neurotoxicity, 
manifest as 
impaired 
learning ability. 
Hearing loss 
No information 
about DNEL 
derivation 
Critical dose value 
NOAEC 123 mg.m-3 
(32 ppm) 
    
NOAEC 2250 
mg/m3  
NOAEC 2660 
mg/m3  
Long-term 
inhalation  DNEL 
(systemic 
effects) for the 
general 
population  
derived from 
industry 
   
LOAEL: 281 mg/m3 
(73 ppm) 
LOAEL 35 mg/m3 
 (9 ppm)  
      
Adjusted critical dose Temporal Chronic  Chronic Chronic Subchronic 
No information 
about DNEL 
derivation 
 
29 mg/m3 (7.5 ppm)= 
123 mg/m3 x 5j/7j x 
8h/24h 
  
35 mg/m3 / 4.2 =  
8 mg/m3  
401.8 mg/m3 = 
2250 mg/m3x 
5j/7j x 6h/24h 
    
Single assessment 
factors (see table 
R.8.6) 
UFH 10 
Toxicokin: 5x  
Intrasp. 10x 
UF (sens) 2x 
10x 
= 1000 
  UF LOAEL-
NOAEL 10x 
UF Intrasp. 10 
=100 
UF 2x Intersp. 
2.5x4 
Intrasp. 10x 
UF (sens) 2x 
=600 
 Intersp. 2.5x4 
Intrasp. 10x 
Exp.dur:3x 
UF (sens) 2x 
=600 
Total AF: 1.7  
Other effects             
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Confidence       
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
*DNELs derived based on key studies selected for risk characteriszation in the EU RAR (risk characterization in the RAR is based on the margin of safety 
MOS concept for defined consumer scenarios (e.g. spray painting). 
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Compound TOLUENE  Data collection sheet (3/3) 
 
STUDIES supporting the US EPA RfC 
 
Study number 
and reference 
Number of workers 
and duration of 
exposure  
(average years ± SD) 
NOAEL 
(ppm) 
LOAEL 
(ppm) 
Effect/test 
Response level at the LOAEL 
(statistically significant 
response compared to 
controls)a 
Noted potential 
limitations 
1. Abbate et al., 
1993 
Reference (n=40), 
 
exposed (n=40) 
  
(12-14 years; no SD 
reported) 
None 97 
Brainstem response 
auditory-evoked 
potential 
28% increase of the latency shift 
for wave-I during passage from 
11 to 90 repetitions. 
  
2. Boey et al., 
1997 
Reference (n = 29) 
 
exposed (n = 29) 
  
  
(4.9 ± 3.5 years; 
range of 1-13 years) 
None 91 
Neuropsychological 
examination; digit 
span, visual 
reproduction, 
Benton visual 
retention test, trail 
making test, symbol 
digit modality test, 
grooved pegboard 
test, and finger 
tapping tests 
Increased time to complete the 
grooved pegboard test 7% and 
6% for dominant and non-
dominant hands respectively, 
increase in time to complete trail-
making test parts A&B, 31% & 
28%, respectively; 15% decrease 
in backward digit span test; 12% 
and 10% decrease in symbol digit 
modality test for written and oral 
sections, respectively. 
Control workers 
were exposed to 12 
ppm toluene 
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3. Cavalleri et 
al., 2000 
Reference (n=16), 
 
exposed (n=33) 
  
(9.75 years; no SD 
reported) 
None 42 
Colour vision 
impairment 
(Lanthony D-15) 
29% increase in CCI and 49% 
increase in total confusion index 
(TOCI) (reported as mean of both 
eyes). 
Exposure measured 
from urinary 
excretion of toluene: 
on the basis of 
previous data, air 
concentrations 
estimated to be 42 
ppm. 
4. Eller et al., 
1999 
Reference (n=19), 
 
low exposure (n=30), 
 
high exposure (n=49) 
  
low exposure (1-12 
years; no SD 
reported) 
 
high exposure (>12 
years) 
20 >100 
Neuropsychological 
examination 
(Cognitive Function 
Scanner); verbal and 
nonverbal learning 
and memory, 
visuomotor 
function, 
computerized 
neurological 
examination 
(CATSYS, TREMOR, 
and SWAY), 
subjective 
assessment 
13% increase in performance 
time on Bourdon Wiersma Test 
but no increase in the number of 
missed or incorrect detections; 
33% of exposed population 
reported concentration 
difficulties. 
The high exposure 
classification was 
based on historical 
exposures which 
may have exceeded 
100 ppm for up to 27 
years. 
5. Foo et al., 
1990 
Reference (n=30), 
 
exposed (n=30) 
  
(5.7 ± 3.2 years) 
None 88 
Neurobehavioral 
tests: Benton visual 
retention test, visual 
reproduction, trail 
making, grooved 
pegboard, digit 
span, digit symbol, 
finger tapping, and 
simple reaction time 
Increased time to complete the 
trail-making test parts A&B, 51% 
& 63%, respectively; 25% 
decrease in digit symbol test 
performance; 16% decrease in 
total digit span test scores (both 
forward and backward). 
Control workers 
were exposed to 13 
ppm toluene for 2.5 ± 
3.2 years. The 
education level was 
lower in the exposed 
group. As a result, 
data from the 
neurobehavioral 
tests were adjusted 
for years of 
education using a 
generalized linear 
model. 
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6. Murata et al., 
1993 
 
Reference (n=10), 
 
exposed (n=10) 
  
(11 years; range of 1-
36 years; no SD 
reported) 
None 83 
Electrophysiological 
analysis of maximial 
motor and sensory 
nerve conduction 
velocity 
(MCV & SCV) 
  
  
9% reduction in the MCV in the 
forearm and 6% reduction in the 
SCV in the palm. 
Exposed workers 
were matched for 
age but not alcohol 
consumption. 
7. Nakatsuka et 
al., 1992 
Reference (n=120), 
 
exposed (n=174) 
44-48 None 
Color vision 
impairment 
(Lanthony's new 
colour test and 
Ishihara's color 
vision test) 
No measured effect on colour 
vision. 
In lieu of 
determining 
exposure duration, 
groups were age-
matched to control 
for effects of aging on 
colour vision. 
8. Neubert et 
al., 2001 
Ref-ex (n=109), ref-
int (n=48), 
 
exp gp I (n=316), 
 
exp gp II (n=535), 
 
exp gp III (n=308), 
 
exp gp IV (n=65) 
39 
 
(exp gp 1) 
  
  
  
81 
 
(ex gp IV) 
  
  
  
Psychophysiological 
and psychomotor 
testing: verbal 
memory span, 
visuomotor 
performance, 
immediate visual 
memory, self-rating 
of feeling, 
biosensory 
vigilance, critical 
flicker fusion 
frequency test, 
personality 
dispositions 
5% reduction in ascending flicker 
fusion frequency. 
Exposure was 
identified as chronic 
but the duration was 
not reported. 
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9. Vrca et al., 
1995 
Reference (n=59), 
 
exposed (n=49) 
  
(21.4 ± 7.4 years) 
None 40-60 
Visual evoked 
potentials 
The amplitudes of visual evoked 
brain potentials were 24, 43, and 
55% higher for N75, P100, and 
N145, respectively. 
Exposure levels were 
estimated based on 
urinary levels of 
metabolites and 
toluene levels in 
blood. 
10. Zavalic et 
al., 1998a 
Reference (n=90), 
 
low exposure (n=46), 
 
 high exposure (n=37) 
  
low exposure (16.21 ± 
6.1 years) 
 
high exposure (18.34 
± 6.03 years) 
32 132 
Color vision 
impairment 
(Lanthony D-15) 
10-14% increase in CCI (both 
eyes). 
The results from this 
investigation were 
reported in several 
publications (Zavalic 
et al., 1998 a, b ,c); 
some reporting 
discrepancies exist 
regarding the 
number of workers 
in the exposed and 
control groups and 
the statistical 
analyses. 
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Compound TOLUENE Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³]  2900   
EU-LCI status 2 Interim / Confirmed Interim  
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
29 August 2012  
General Information    
CLP-INDEX-Nr.  4  INDEX  R2B 
EC-Nr. 5  EINECS – ELINCS - NLP 203-625-9  
CAS-Nr. 6 Chemical Abstracts Service number  108-88-3 
Harmonised CLP classification 7 Human health risk related classification   Flam. Liq. 2 
Asp. Tox. 1 
Skin. Irrit. 2 
STOT SE 3 
Rep. 2 
STOT RE 2 
Molar mass  8 [g/mol] 92.14  
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
Zavalic et al., 1998  
Read across compound 10 Where applicable  
Species 11 Rat,… human Human  
Route/type of study 12 Inhalation, oral feed,… Inhalation, occupational  
Study length  13 Days, subchronic, chronic 17 years  
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of  Neurological effects 
(colour vision impairment)  
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose,…. 
LOAEC  
POD  Value  17 [mg/m³] or [ppm]  123 mg/m3 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
4.2 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 2 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
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 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 5 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF) 42  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
        ……2928.57   µg/m3 
      ….. 772.58   ppb 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 2900 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Rationale for critical effects 
Neurological effects have been demonstrated in rodents and in humans exposed by the respiratory route 
during chronic exposure. Toluene like many other organic solvents can impair colour vision, even at 
concentrations below 50 ppm. Reprotoxic and developmental effects have also been shown, particularly in 
animals. However, the neurological effects were reported at lower concentrations than those for effects on 
fertility or development. 
WHO, RIVM, ATSDR, US-EPA, ANSES, German IAQ, Austria IAQ, based their values on human studies showing 
neurologic effects (could be neurobehavioural, vision impairment, …). 
 
Rationale for key study  
The reference value is based on the Zavalic´et al. (1998) study. In this study, colour vision was examined in 
two groups of workers occupationally exposed to toluene and in a control group. The authors referenced 
standard methods for measuring both ambient air concentrations and individual blood toluene levels. 
Significantly higher values of colour confusion index and alcohol intake-adjusted colour confusion index in 
exposed groups in comparison to the non-exposed group were reported. The colour confusion index scores 
were adjusted for alcohol consumption.  A LOAEC of 134 mg/m3 (35 ppm) could be derived from this study.  
ATSDR (2000) and Anses (2010) also based their toxicological reference value on this study. US-EPA (2005) 
considered several human studies as key studies, including the Zavalic´et al. (1998). An average NOAEC from 
these studies was used.   
The study from Zavalic´was selected as the key study as it is an epidemiological study on workers exposed for 
many years and a dose-response relationship for neurological effects was observed in this study. 
 
Rationale for starting point 
 
In the study of Zavalic´ et al. (1998), two groups of exposed workers to toluene and a control group have been 
evaluated:  
- the first exposed group, Group E1, comprised 41 workers (toluene exposure ranged from 11.3 to 
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49.3 ppm; median 32.0 ppm) 
- the second exposed group, Group E2, comprised 32 workers (toluene exposure ranged from 
66.00 to 250.00 ppm; median 132.00 ppm).  
- the non-exposed group, Group NE, comprised 83 subjects.  
 
Each group was divided into two subgroups; alcohol consumers and non-consumers. Colour vision loss was 
expressed as a colour confusion index (CCI) and as an age and alcohol intake-adjusted colour confusion index 
(AACCI). 
The AACCI value was significantly higher in Group E2 compared to Group NE (t-test, P <0.0001) and Group 
E1 (t-test; P <0.05), and in Group E1 compared to Group NE (t-test; P < 0.05). Difference was not established 
in CCI value between groups E1 and NE. No statistically significant correlation was established between 
AACCI and any marker of toluene exposure in Group E1, or in the subgroups of alcohol consumers and non-
consumers. Significant correlation was established between the AACCI value and toluene in air, between 
AACCI and orthocresol in urine and between AACCI and hippuric acid in urine in this Group. 
The authors concluded that age and alcohol intake, play a role in colour vision impairment. Alcohol intake 
plays a role as an additive cofactor with toluene. 
Based on the evidence that the AACCI value was significantly higher in Group E1 (median toluene exposure 
32.0 ppm) compared to Group NE, 32 ppm could be considered as a LOAEC. 
 
Rationale for Uncertainty factors 
o AF Dose response: An assessment factor of 2 is applied to account for extrapolating from a LOAEC to 
a NOAEC. This low factor is justified by the fact that numerous human studies have identified 
NOAELs in the range of 25-50 ppm toluene for individual neurological effects  and also by the fact 
that US-EPA considered 34 ppm as a NOAEC (US-EPA, 2005)  .  
o Adjusted study length factor: an assessment factor to account for extrapolating from less than 
chronic results was not necessary. Most of the studies used in the analysis were of chronic 
duration. 
o Adjusted exposure duration factor: The LOAEL (average) of 32 ppm (123 mg/m3) was adjusted from 
an occupational exposure scenario to continuous exposure conditions as follows: 
NOAEL (adj) = NOAEL (average) x 8 hours /24 hours x 5 days/7 days  = 123 mg/m3 x 10m3/20m3 x 5 days/7 
days = 30 mg/m3 
o Interspecies differences: an assessment factor to account for laboratory animal-to-human 
interspecies differences was not necessary because the point of departure is based on human 
exposure data. 
o Intraspecies differences:  a 5-fold assessment factor for was used to account for potentially 
susceptible human subpopulations and life stages. Differences in human susceptibility may also be 
due to life stage (e.g., childhood or advanced age), differences among the adult population, genetic 
polymorphisms, decreased renal clearance in disease states, and unknown pharmacodynamic 
variations in response to toluene exposure.  
References 
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              A.3 Xylenes 
 
Compound XYLENES  Data collection sheet (1/2) 
N°CAS 1330-20-7 
  
EU- Classification: 67/548/EEC:  R10, Xn; 
R20/21, Xi; R38  
 
CLP:  Flam. Liq. 3 
Acute Tox. 4, Acute Tox. 4  
*Skin Irrit. 2 
 
 
 
Organization Name INDEX Project ATSDR OEHHA U.S. EPA 
Risk Value Name Chronic exposure limit Chronic inhalation MRL REL RfC 
Risk Value (µg/m3) 
200 175 
700 for mixed 
xylenes or for total of 
individual isomers 
100 
Risk Value (ppb) 57 50 200 29 
Reference period Chronic Chronic Chronic Chronic 
Year 2005 2007 2000 2003 
Key Study Uchida et al., 1993 Uchida et al., 1993 Uchida et al., 1993 Korsak et al., 1994 
Study type 
Epidemiologic study on 
workers (175 
exposed/241 control) 
Epidemiologic study on 
workers (175 
exposed/241 control) 
Epidemiologic study 
on workers (175 
exposed/241 control) 
3 months animal study 
Species Human  Human Human Male Rats  
Duration of exposure 
in key study 
Occupational exposure 
for an average of 7 years 
Occupational exposure 
for an average of 7 years 
Occupational 
exposure for an 
average of 7 years 
6h/d, 5d/w at 0 or 100 
ppm for 6 months or 
1000 ppm for 3 months 
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Critical effect 
Dose related increase in 
the prevalence of eye 
irritation, sore throat, 
floating sensation, and 
poor appetite. 
neurotoxicity (anxiety, 
forgetfulness, floating 
sensation) and 
respiratory toxicity 
(nasal irritation and sore 
throat) and eye irritation. 
 Dose related increase 
in the prevalence of 
eye irritation, sore 
throat, floating  
sensation, and poor 
appetite. 
CNS: impaired motor 
coordination (decreased 
rotarod performance) 
Subchronic inhalation 
study in male rats 
Critical dose value       
NOAEL: 50 ppm (217 
mg.m-3) 
 
LOAEL: 62 mg/m3 (14.2 
ppm) 
LOAEL: 62 mg/m3 (14.2 
ppm) 
LOAEL: 62 mg/m3 
(14.2 ppm) 
LOAEL: 100 ppm  
LOAEL(HEC): 78 mg/m3 
Adjusted critical dose Subchronic -> chronic No duration adjustment Temporal Temporal 
 22 mg/m3 (5.03 ppm)   
14.2 x 10/20 x 5/7 = 
5.1 ppm (22.3 
mg/m3) 
NOAEL = 217 x 6/24 x 
5/7 = 39 mg/m3 (9 ppm) 
Single assessment 
factors (see table 
R.8.6) 
UFL  10 x UFH 10 = 100 
UFL  10 x UFH 10 x UFS 3 = 
300 
UFL  3 x UFH 10 = 30 
UFD  3 x UFS  3 x UFA 3* x 
UFH 10 = 300 
Other effects         
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
* A factor of 3 was applied because default NOAEL [HEC] dosimetric adjustments were used to calculate a human equivalent 
concentration (HEC), reducing the uncertainty involved with the extrapolation from the results of an animal study to a human 
exposure scenario (i.e., the toxicokinetic portion of the UF is 1; the toxicodynamic portion of the UF is 3).    
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Compound XYLENES  Data collection sheet (2/2) 
N°CAS 1330-20-7 
  
EU- Classification: 67/548/EEC:  R10, Xn; 
R20/21, Xi; R38  
 
CLP:  Flam. Liq. 3 
Acute Tox. 4, Acute Tox. 4  
*Skin Irrit. 2 
 
 
 
 Reprotoxic effects Provisional  
Organization Name 
RIVM Health Canada 
ECHA Registered 
substance 
ICPS, 1997 
Risk Value Name TCA TC DNEL Guidance value 
Risk Value (µg/m3) 870 180 (provisional) 14800 870 
Risk Value (ppb) 250     200 
Reference period Chronic     Chronic 
Year 1999 1991 2011 1997 
Key Study 
Hass and Jakobsen, 1993, 
Prenatal toxicity of 
xylene inhalation in the 
rat: A teratogenicity and 
postnatal study 
Ungvary and Tatrai, 1985   Hass and Jakobsen, 1993 
Study type 
Teratology and postnatal 
study 
    
Teratology and postnatal 
study 
Species Rats Rats   Rats 
Duration of exposure 
in key study 
6 h/d on days 4 to 20 of 
gestation 
    
6 h/d on days 4 to 20 of 
gestation 
Critical effect 
Developmental (the 
postnatal study, the 
xylene-exposed pups had 
a higher body weight and 
an impaired performance 
on a motor ability test 
(Rotarod)) 
Developmental 
No information 
available* 
Developmental (the 
postnatal study, the 
xylene-exposed pups had 
a higher body weight and 
an impaired performance 
on a motor ability test 
(Rotarod)) 
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Critical dose value     
Long-term inhalation 
DNEL for consumers 
(systemic effects) 
derived by industry 
(ECHA-website: 
registered 
substances), no 
information about 
derivation of DNEL 
  
 
LOAEL: 870 mg/m3 (250 
ppm) 
    
LOAEL: 870 mg/m3 (250 
ppm) 
Adjusted critical dose No duration adjustment     No duration adjustment 
         
Single assessment 
factors (see table 
R.8.6) 
UFL  10 x UFH 10 x UFA 10 
= 1000 
    
UFL  10 x UFH 10 x UFA 10 
= 1000 
Other effects         
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
* A factor of 3 was applied because default NOAEL [HEC] dosimetric adjustments were used to calculate a human equivalent 
concentration (HEC), reducing the uncertainty involved with the extrapolation from the results of an animal study to a human 
exposure scenario (i.e., the toxicokinetic portion of the UF is 1; the toxicodynamic portion of the UF is 3).    
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Compound XYLENES Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 500  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 30 November 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX 601-022-00-9 
EC-Nr. 5  EINECS – ELINCS - NLP  215-535-7 
CAS-Nr. 6 Chemical Abstracts Service number 1330-20-7  
Harmonised CLP classification 7 Human health risk related classification  Flam. Liq. 3 
Acute Tox. 4 (skin) 
Skin Irrit. 2 
Acute Tox. 4 (inhalation)  
Molar mass  8 [g/mol] 106.16  
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 Uchida et al., 1993 
Read across compound 10 Where applicable  
Species 11 Rat,… human  Human 
Route/type of study 12 Inhalation, oral feed, …  Inhalation/occupational 
exposure 
Study length  13 Days, subchronic, chronic  7 years 
Exposure duration 14 Hrs/day, days/week Average 7 y, 8 h/d, 5 d/wk 
Critical endpoint 15 Effect(s), site of  Sensory irritation* (eye 
irritation, sore throat) and 
CNS effects ( floating 
sensation and poor 
appetite in humans); 
supported by neurological 
and developmental toxicity 
in rats  
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 LOAEC 
POD  Value  17 [mg/m³] or [ppm]  14.2 ppm 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
4.2 
AF 
Study Length 
20 sa sc c  
(R8-5) 
2 
Route-to-route extrapolation 
factor 
21   
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AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 3 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 5 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  126 
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
    ……  492.2    µg/m3 
    ……112.7    ppb 
 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 500 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Xylene (CAS 1330-20-7) has three isomers: 
 o-xylene (CAS: 95-47-6) 
 m-xylene (CAS: 108-38-3) 
 p-xylene (CAS: 106-42-3) 
 
A risk value for xylenes was derived by US-EPA (RfC: 100 µg/m²), RIVM (TCA: 870 µg/m³), Health Canada 
(provisional TC: 180 µg/m³), ICPS (guidance value: 870 µg/m³), INDEX (chronic exposure limit: 200 µg/m³), 
ATSDR (chronic inhalation MRL: 175 µg/m³)  and OEHHA (REL: 700 µg/m³).  
 
POD 
The LCI derivation is based mainly on the key study of Uchida et al. (1993). The occupational study of Uchida 
et al. (1993), involved 175 xylene exposed workers and 241 non-exposed workers. The LOAEL of 14 ppm 
derived from the Uchida et al. (1993) study is based on the average exposure levels to the sum of the three 
isomers in the group of exposed workers. Health effects observed in this exposed group were an increased 
prevalence of subjective symptoms in the exposed workers which were apparently related to the effects on 
the central nervous system and to the local effects on the eyes, the nose, and the throat. Evidence of health 
effects of xylenes on the central nervous system is also supported by developmental neurotoxicity effects 
observed in rats exposed to xylenes (Hass & Jakobsen, 1993 and Korsak et al., 1994).  
Evidence for local irritation effects caused by xylenes exposure is contradicted by additional data: In the 
Uchida et al. (1993) study, a LOAEL value of 14 ppm xylenes had been derived based on CNS effects and local 
irritation effects seen for a mixture of solvents, composed from 70 % xylenes and 30 % remaining, 
unidentified compounds. However, it is doubtful whether the observed irritating effect observed in the 
Uchida et al. (1993) have been caused by xylenes exposure, or rather by the 30 % remaining unidentified 
fraction. Based on the RD50 values (mice) for m- and p-xylene, respectively, and the Alarie algorithm  
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(Schaper et al. 1993) the threshold for sensory irritation is calculated to be about 40 ppm for workers. A 
human exposure study (4 hours) with toluene shows a LOAEL value of 100 ppm for sensory irritation 
(Bælum et al., 1990). In addition, based on RD50 values from mice exposed to xylenes, and applying the 
Kuwabara et al. algorithm (2007), which extrapolates animal test RD50 values to LOAEL a LOAEL of 88 ppm 
xylene for sensory irritation for the general population, was predicted (Wolkoff, 2012).  Summing up this 
information, there are strong indications that there is no causal relationship between sensory irritating 
effects observed in the Uchida et al. (1993) study and exposure to 14 ppm xylenes.  
 
Assessment Factors 
Standard default assessment factors for:  
1) reliability of dose-response (extrapolation from LOAEL to NOAEL; note 21a): a factor of 3 is applied.  
2) adjustment of study length (note 22),  a factor of 2 is applied considering that in the key study, the workers 
are exposed during 7 years (subchronic exposure). 
3) exposure duration (note 19, a time adjustment factor of 4.2 is applied considering the exposure duration in 
the key study compared to the exposure in the general population.  
4) intraspecies AF (note 24) were applied: a factor of 5 is applied  to take into account the variability among 
the general population.   
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 A.4 Trimethylbenzenes 
 
Compound Trimethylbenzenes  Data collection sheet  
N°CAS 95-63-6 
25551-13-7 
 
EU- Classification: R 10; Xn; R20, Xi; 
R36/37/38 
67/548/EEC annex 1 
CLP:  Flam.  Liq. 3 
Acute Tox. 4,  
Skin Irrit. 2 
Eye Irrit. 2 
Asp. Tox. 1 
 
 
 Alkylbenzenes Trimethylbenzenes 1,2,4-Trimethylbenzene 
Organization Name 
RIVM 
Ontario Ministry of 
Environment 
ECHA: Registered 
substances 
Risk Value Name TCA AAQC DNEL 
Risk Value (µg/m3) 870 220 29400 
Risk Value (ppb)      
Reference period Chronic  Chronic Chronic  
Year 2007 2007 2013 
Key Study 
based on 
Isopropylbenzene 
EU (2001) Risk 
Assessement Report – 
Cumene. European 
Chemicals Bureau, 
Existing Substances. 
Korsak and Rydzynski, 
1996; Gralewicz and 
Wiaderna, 2001; 
Wiaderna et al., 2002 
Clark DG, et al. 1989  
Study type Chronic Subchronic inhalation  Chronic inhalation 
Species Rats Rats Rats  
Duration of exposure 
in key study 
 6h/day, 5 days/week 
chronic 
 6h/day, 5 days/week 
 
6h/day, 5 days/week, 
1 yr 
  
Critical effect Neurotoxicity Neurotoxicity 
Irritation (respiratory 
tract) 
Critical dose value     
Long-term inhalation 
DNEL for consumers 
(systemic effects) 
derived by industry 
(ECHA-website: 
registered substances), 
no transparent 
information about 
derivation of DNEL 
 NOAEL 490 mg/m3 
NOAEL 
123 mg/m³ 
NOAEC  1800 mg/m3 
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Adjusted critical dose 5.6 5.6    
       
Single assessment 
factors (see table 
R.8.6) 
UFH 10 x UFA 10 = 100 
UFs  3 x UFH 3 x UFA 10 = 
100 
1.7 (Overall assessment 
factor) 
Other effects       
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Compound TRIMETHYLBENZENES Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 450  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 22 November 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX 601-025-00-5 
601-043-00-3 
601-025-00-5 
EC-Nr. 5  EINECS – ELINCS - NLP 247-099-9 
202-436-9 
203-604-4 
208-394-8 
CAS-Nr. 6 Chemical Abstracts Service number 25551-13-7 
95-63-6 
108-67-8 
526-73-8 
Harmonised CLP classification 7 Human health risk related classification   Not harmonised 
Molar mass  8 [g/mol]  120.19 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 Korsak and Rydzynski, 
1996,  1997, 2000a, 2000b 
Read across compound 10 Where applicable  
Species 11 Rat,… human  Rat 
Route/type of study 12 Inhalation, oral feed, …  Inhalation 
Study length  13 Days, subchronic, chronic  Subchronic 
Exposure duration 14 Hrs/day, days/week 6h/24h / 5d/7d 
Critical endpoint 15 Effect(s), site of   Neurotoxicity and local 
effects on lungs 
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 NOAEC 
POD  Value  17 [mg/m³] or [ppm]  123 mg/m3 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
5.6 
AF 
Study Length 
20 sa sc c  
(R8-5) 
2 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d)  
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Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic 2.5 
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 10 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  280 
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
     
    ……439.29   µg/m3 
    …..   88.84    ppb 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 450 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Trimethylbenzene (CAS 25551-13-7) has three isomers: 
 1,3,5-trimethylbenzene (synonym: mesitylene; CAS 108-67-8) 
 1,2,4-trimethylbenzene (synonym: pseudocumene; CAS 95-63-6) 
 1,2,3-trimethylbenzene (synonym: hemimellitene; CAS 526-73-8) 
None of the agencies (WHO, EPA, ATDSR, EU RAR, INDEX) provide a human health risk assessment for TMB 
exposure in indoor environments, but the Ontario Ministry of Environment [2007] and RIVM [Dusseldorp et 
al. 2007] reviewed the compound and derived a 24-hour Ambient Air Quality Criterion (AAQC) of 220 μg/m3 
for trimethylbenzenes  and a chronic air limit value (TCA) of 870 µg/m3 respectively. An industry sponsored 
study (Firt 2007) derived an RfD of 3 mg/m³ using standard USEPA methods. 
 
POD 
 
The LCI derivation is based mainly on the key studies by Korsak et al.  [1996, 2000a, b] and Wiaderma et al. 
(2002). In accordance with Ontarion Ministry of Environment (2007) CNS effects were chosen as the critical 
effect observed in 5 subchronic inhalation studies on rats.  In subchronic inhalation studies of 1,2,3 and 1,2,4-
trimethylbenzene (Korsak et al., 2000a and 2000b; Korsak and Rydzynski, 1996) rats were exposed to  123 
mg/m3, 492 mg/m3 and 1230 mg/m3, 6 h/day, 5 days/week for 3 months. The same neurotoxic effects were 
observed as in the subacute studies. A NOAEC of 123 mg/m3 and a LOAEC of 492 mg/m3 was identified for 
TMB which includes also local effects in the lung and is below the exposure concentration (1476 mg/m3) at 
which reprotoxic effects were observed (Sallenfait et al. 2005). A comparison of the available toxicity data for 
1,2,4-TMB and 1,3,5-TMB suggests similar toxicity.  
 
Assessment factors 
Standard default assessment factors for adjustment for exposure duration (note 19), study length (note 22),  
interspecies AF (note 23b) and intraspecies AF (note 24) were applied.  
No additional factor for combined effects was introduced, because according to Clark et al. (1989), the NOAEL 
  Page 
112 
 
  
for a mixture of high aromatic naphtha was without systemic toxicity with a NOAEC of 1800 mg/m³ in a 12 
month rat study. 
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 A.5 Dichloro-(1,4)-benzene 
 
Compound DICHLORO-(1,4)-BENZENE  Data collection sheet  
N°CAS 106-46-7 
Classification:  Carc. Cat. 3; R40,  Xi; R36, N; R50-53 
 
CLP: Carc. 2, Eye Irrit. 2, Aquatic Acute 1, Aquatic Chronic 1 
 
EU Registered Substances: No DNEL published 
 
 
 
1 ppm (in air, 25 °C) = 6.0 mg/m3 
 
Organization Name ATSDR OEHHA US EPA RIVM EU-RAR based*  
Risk Value Name MRL REL Inhalation RfC TCA DNEL 
Risk Value (mg/m3) 0.08 0.8 0.8 0.67 0.8 
Risk Value (ppm) 0.013 0.1 0.1 0.11 0.13 
Reference period Chronic Chronic Chronic Chronic Chronic 
Year 2006 1999 1996 1999 2011 
Key Study 
Aiso S, Takeuchi T, 
Arito H, et al. 2005b. 
Carcinogenicity and 
chronic toxicity in mice 
and rats exposed by 
inhalation to para-
dichlorobenzene for 
two years. 
Chlorobenzene 
Producers 
Association, 1986. 
Parachlorobenzene: 
Two-generation 
reproduction study 
in Sprague-Dawley 
rats. 
Chlorobenzene 
Producers 
Association, 1986. 
Parachlorobenzene: 
Two-generation 
reproduction study 
in Sprague-Dawley 
rats. 
Riley et al., 1980. 
Para-
dichlorobenzene: 
Long-term 
inhalation study 
in the rat. 
JBRC (1995). Toxicology and 
carcinogenesis studies of 1,4-
dichlorobenzene in F344/DuCrj 
rats and Crj:BDF1 mice (two 
years inhalation studies). Japan 
Bioassay Center Research (JBRC), 
November 1995. 
Study type 
2-years inhalation 
study 
10-weeks 
multigeneration 
reproductive study:  
whole-body 
inhalation 
exposures (0, 50, 
150 or 450 ppm) 
10-weeks 
multigeneration 
reproductive study:  
whole-body 
inhalation 
exposures (0, 50, 
150 or 450 ppm) 
76-weeks 
inhalation study 
Inhalation study 
Species 
Male and female 
F344/DuCrj rats + 50 
male and female 
Crj:BDF1 mice 
Sprague-Dawley 
rats (28 
rats/sex/group) 
Sprague-Dawley 
rats (28 
rats/sex/group) 
Rats Mice and rats 
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Duration of exposure 
in key study 
6 h/d, 5 d/w for 104 
weeks 
6 h/d, 7 d/w for 10 
weeks 
6 h/d for 7 d/w for 
10 weeks 
5h/d, 5d/w for 
76 weeks 5h/d, 5d/w for 104 weeks 
Critical effect 
Moderate or severe 
eosinophilic changes in 
the nasal olfactory 
epithelium in female 
rats 
General effects 
(reduced body 
weights and food 
consumption), CNS 
effects (tremors), 
Respiratory/dermal 
effects (nasal and 
ocular discharge), 
Liver effects 
(increased liver 
weight), and Kidney 
effects (increased 
kidney weight) 
Increased liver 
weights in P1 males 
Increased kidney 
and liver weights 
in the high dose 
group. (500 
ppm) 
Liver toxicity (increased liver 
enzyme: AST, ALT, LDH, 
alkalinephosphatases; increased 
liver weight in both sexes and 
histological findings: slight local 
necrosisin both sexes, central 
hepatocellular hypertrophy in 
males) 
Critical dose value 
NOAEL: 158.4 mg/m3 
(19.8 ppm) 
NOAEL: 300 mg/m3 
(50 ppm) 
NOAEL: 301 mg/m3 
(50 ppm) 
NOAEL: 450 
mg/m3 (75 ppm) 
NOEL: 450 mg/m3 (75 ppm) 
 
LOAEL: 598 mg/m3 
(74.8 ppm) 
LOAEL: 900 mg/m3 
(150 ppm) 
LOAEL: 902 mg/m3 
(150 ppm) 
LOAEL: 3000 
mg/m3 (500 
ppm) 
 
Adjusted critical dose 
BMCL10: 57 mg/m3 
(9.51 ppm) 
Temporal 
NOAELHEC: 75 
mg/m3 ( 12.5 ppm) 
NOAELADJ: 67 
mg/m3 (11 ppm) 
NOAELADJ:   80 mg/m3(13 ppm) 
 
BMCLADJ: 9.51 x 6/24 x 
5/7 = 1.70 ppm (10 
mg/m3) 
NOAELHEC: 78 
mg/m3 (50 x 6/24 = 
13 ppm) 
LOAELHEC: 225 
mg/m3 (37 ppm) 
  
Single assessment 
factors (see table 
R.8.6) 
UFA 3 x UFH 10 = 30 
UFS 3 x UFA 3 x UFH 
10 = 100 
UFS 3 x UFA 3 x UFH 
10 = 100 
UFA 10 x UFH 10 
= 100 
UFA2.5x4xUFH10 =25 
Other effects           
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data 
deficiencies 
 
*DNEL derived based on key studies selected for risk characteriszation in the EU RAR (risk characterization in the 
RAR is based on the margin of safety MOS concept.  
 
EU Risk Assessment Report 
(RAR). 2004France.  
http://ecb.jrc.ec.europa.eu/risk-
assessment/REPORT/14dichloro
benzenereport001.pdf   
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Compound 1,4-DICHLOROBENZENE Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³]  150 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 27 November 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX  602-035-00-2 
EC-Nr. 5  EINECS – ELINCS - NLP  203-400-5 
CAS-Nr. 6 Chemical Abstracts Service number  106-46-7 
Harmonised CLP classification 7 Human health risk related classification   Carc. 2 
Eye Irrit. 2 
Aquatic Acute 1 
Aquatic Chronic 1 
Molar mass  8 [g/mol]  147.0 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
Aiso S, Takeuchi T, Arito H, 
et al. 2005 
Carcinogenicity and 
chronic toxicity in mice and 
rats exposed by inhalation 
to para-dichlorobenzene 
for two years. The Journal 
of Veterinary Medical 
ScienceVol. 67, p1019–
1029  
Read across compound 10 Where applicable  
Species 11 Rat,… human  Rodent 
male and female 
F344/DuCrj rats  
+ 50 male and female 
Crj:BDF1 mice 
Route/type of study 12 Inhalation, oral feed, …  Inhalation 
Study length  13 Days, subchronic, chronic  Chronic 
104 weeks 
Exposure duration 14 Hrs/day, days/week 6 hrs/day, 5 days/week 
Critical endpoint 15 Effect(s), site of   The nasal olfactory 
epithelium 
moderate or severe 
eosinophilic changes in the 
nasal olfactory epithelium 
in female rats, 
respiratory metaplasia 
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 NOAEC 
POD  Value  17 [mg/m³] or [ppm] 20 ppm  
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Assessment Factors (AF) 18   
Adjustment for exposure duration 19 Study exposure 
hrs/day, days/week 
5.6 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d) 5 
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic 2.5 
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 10 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment factors 27 Total Assessment Factor (TAF)  700 
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
    ……..172.78    µg/m3 
   ………28.57    ppb 
 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 150 
Additional Comments 31   
 
 
 
Rationale Section 32   
The most recent reliable chronic inhalation study was conducted by the Japan Bioassay Research Center (Aiso et 
al. 2005) and was selected as key study of the ATSDR risk assessment as well as of this assessment.  
50 BDF1 mice and 50 F344 rats of both sexes were exposed to p-DCB by vapour with 0, 20, 75 and 300 ppm for 6 
hours/day, 5 days/week and 2 years. Clear evidence of carcinogenicity for male and female mice as shown in 
increased incidences of hepatocellular carcinomas and hepatoblastomas and histiocytic sarcomas in the 300 
ppm exposed male mice and in the increased incidences of hepatocellular adenomas and carcinomas and 
hepatoblastomas in the 300 ppm exposed female mice was found. In rats no tumor induction was reported. The 
most sensitive endpoint of the chronic inhalation toxicity was the nasal lesion characterized by treatment- and 
age-related increases in the incidences of the eosinophilic globules of the respiratory and olfactory epithelia in 
female rats and the incidence of the respiratory metaplasia of the nasal gland epithelium of female rats and in the 
olfactory epithelium of mice. The lesions were increased in the female rats exposed to 75 – 300 ppm, therefore 
the NOAEL 20 ppm was taken forward as the POD.  
 
POD 
Due to the carcinogenicity of the compound, which is also observed when laboratory rodents were exposed to p-
DCB via the oral route a factor of 5 for severity of effect was applied. At present there is no evidence for 
carcinogenicity of p-DCB in humans. IARC classified p-DCB as possibly carcinogenic to humans, Group 2B. 
The Federal Institute for Occupational Safety and Health (BAuA) derived an occupational exposure limit and 
calculated a theoretical cancer risk of 4 in 100,000 at 0.1 ppm. The EU-LCI value of 150 µg/m³ (0.025 ppm) 
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would account for an almost similar risk for the general population. Morbt et al. (2011) found that exposition of 
human lung-cells to chlorinated benzenes (CB, o-DCB) yield to altered protein expression and oxidative stress 
response at very low concentrations (CB 2.2 ppm, o-DCB 0.17 ppm). Therefore an interspecies factor for local 
effects seemed to be justified. 
References 
Aiso S, Takeuchi T, Arito H, et al. 2005b. Carcinogenicity and chronic toxicity in mice and rats exposed by 
inhalation to para-dichlorobenzene for two years. The Journal of Veterinary Medical Science Vol. 67, p1019–
1029(2005). 
ATSDR (2006) Toxicological profile for dichlorobenzenes. U.S. Department of human health and services.  Public 
Health Service. Agency for Toxic Substances and Disease Registry. 
http://www.atsdr.cdc.gov/toxprofiles/tp10.pdf  
IARC Monograph 1999, Vol. 73: Some Chemicals that Cause Tumours of the Kidney or Urinary Bladder in 
Rodents and Some Other Substances. Dichlorobenzenes p. 223–76). 
JBRC (1995). Toxicology and carcinogenesis studies of 1,4-dichlorobenzene in F344/DuCrj rats and Crj:BDF1 
mice (two years inhalation studies). Japan Bioassay Center Research (JBRC), November 1995. 
Federal Institute for Occupational Safety and Health: Bundesanstalt für Arbeitsschutz und Arbeitsmedizin 
(BAuA) Ausschuß zur Bewertung von Gefahrstoffen: Begründung zu 1,4-Dichlorbenzol in TRGS 900. 
Morbt N, Tomm J, Feltens R,  Mögel I, Kalkhof S, i Murugesan K, Wirth H, Vogt C, Binder H, Lehmann I, Bergen M, 
Chlorinated Benzenes Cause Concomitantly Oxidative Stress and Induction of Apoptotic Markers in Lung 
Epithelial Cells (A549) at Nonacute Toxic Concentrations. Journal of Proteome Research 2011, 10, 363–378. 
RAR (2004) European Union Risk Assessment Report. 1,4-Dichlorobenzene, CAS No: 106-46-7, Final Report, 
2004, France. http://ecb.jrc.ec.europa.eu/risk-assessment/REPORT/14dichlorobenzenereport001.pdf  
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            A.6 2-Butoxyethanol 
 
Compound 2-BUTOXYETHANOL  Data collection sheet 
N° CAS: 111-76-2  
 
  1 ppm = 4.91 mg/m
3 
  
Organization Name 
ATSDR US EPA Santé Canada 
ECHA: registered 
substances  
Risk Value Name Chronic Inhalation MRL Inhalation RfC CA DNEL 
Risk Value (mg/m3) 1 1.6 11 49 
Risk Value (ppm) 0.2 0.3 2.2  
Reference period Chronic   Chronic   Chronic    
Year 1998 2010 1999  
Key Study 
Haufroid et al., 1997 
NTP (2000), NTP 
technical report on the 
toxicology and 
carcinogenesis studies of 
2 butoxyethanol 
NTP 1998 
 
Study type 
chronic study in workers 
Chronic (rat and mouse) 
inhalation study 
Chronic inhalation 
study 
 
Species 
Human (31 male workers) 
F344/N rats and 
B6C3F1 mice 
F344 Rats 
 
Duration of exposure in 
key study 
1 to 6 years 6 h/d, 5 d/w for 2 years 
6 h/d, 5 d/w for 2 
years 
 
Critical effect 
Decrease in haematocrit 
values and increase in 
mean corpuscular 
haemoglobin 
concentration 
Hemosiderin deposition 
in the liver 
Haemolytic anemia 
(macrocytic and 
normochromic) 
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Critical dose value 
NOAEL: 0.6 ppm NOAEL: 31 ppm   
Long-term inhalation 
DNEL for consumers 
(systemic effects) 
derived by industry 
(ECHA-website: 
registered substances), 
no transparent 
information about 
derivation of DNEL 
  
  LOAEL: 62.5 ppm 
LOAEL: 150 mg/m3 
(31 ppm) 
 
Adjusted critical dose 
  PBPK and BMCL10   
 
  
  BMCLHEC: 16 mg/m3   
 
Single assessment 
factors (see table R.8.6) 
UFH 3 = 3 UFH 10 = 10 
0.5 x 0.1 x 3.2 x 3.2 = 
0.5 
No information on DNEL 
derivation  
Other effects        
Confidence  Medium/High Medium  
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD 
data deficiencies 
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Compound 2-BUTOXYETHANOL Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 1100  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 27 November 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX  603-014-00-0 
EC-Nr. 5  EINECS – ELINCS - NLP 203-905-0  
CAS-Nr. 6 Chemical Abstracts Service number  111-76-2 
Harmonised CLP classification 7 Human health risk related classification   Acute Tox 4 (H302) 
Acute Tox 4 (H312) 
Skin Irrit. 2 
Eye Irrit. 2 
Acute Tox 4 (H332) 
Molar mass  8 [g/mol]  118.2 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 Dodd et al. 1983 
Read across compound 10 Where applicable  
Species 11 Rat,… human  F344-Rat 
Route/type of study 12 Inhalation, oral feed, …  Inhalation 
Study length  13 Days, subchronic, chronic 90d  
Exposure duration 14 Hrs/day, days/week 6h/d, 5d/w 
Critical endpoint 15 Effect(s), site of   Haematology,  haemolysis, 
Liver hemosiderin deposition 
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L,  NOAEC 
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Benchmark dose, …. 
POD  Value  17 [mg/m³] or [ppm]  122.8 mg/m3 
Assessment Factors (AF) 18   
Adjustment for exposure duration 19 Study exposure 
hrs/day, days/week 
5.6 
AF 
Study Length 
20 sa sc c  
(R8-5) 
2 
Route-to-route extrapolation factor 21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 10 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment factors 27 Total Assessment Factor (TAF)  112 
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
     ……1096.43   µg/m3 
    ……. 225.48   ppb 
 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 1100 
Additional Comments 31   
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Rationale Section 32   
 
Existing risk assessments for EGBE: EPA has derived a chronic reference concentration (RfC) of  1.6 mg/m3 ( 0.3 ppm), Health Canada 
derived a tolerable concentration (TC) of 11 mg/m3 and ATSDR derived a chronic minimal risk level (MRL) of 0.96 mg/m3 (0.2 ppm),  and 
there exists a MOS evaluation in the EU-RAR (2006). 
Dodd et al. (1983) performed a 90-day subchronic inhalation study on F344 rats. Male and female rats were exposed to EGBE for 6 
hours/day, 5 days/week at concentrations of 0, 5, 25, and 77 ppm. After 6 weeks, the 77 ppm exposed female rats had slight but 
statistically significant decreases in RBC counts (13% below control value) and Hb concentrations, accompanied by an 11% increase above 
the control value in MCH. At the end of the 90-day study (66 exposures), the haematologic effects seen in the 77 ppm exposed animals had 
either lessened or returned to the ranges of control values and were no longer statistically significant. The NOAEL was determined to be 25 
ppm, and the LOAEL was 77 ppm. 
NTP (2000) did a two-species, 2-year inhalation study on EGBE in both genders of rats and mice. Animals were exposed to EGBE 6 
hours/day, 5 days/week at concentrations of 0, 31, 62.5, and 125 ppm (0, 150, 302, and 604 mg/m3) for groups of 50 F344/N rats and 0, 
62.5, 125, and 250 ppm (0, 302, 604, and 1,208 mg/m3) for groups of 50 B6C3F1 mice. 
Non-neoplastic effects in rats (males and females) included hyaline degeneration of the olfactory epithelium and Kupffer cell pigmentation 
in the livers, the latter a secondary effect of the EGBE related hemolysis. In rats, a NOAEL could not be determined, and a LOAEL of 31 ppm 
was determined for hemosiderin deposition. 
Incidences of hyaline degeneration of the olfactory epithelium were significantly increased in all exposed groups of males and in females 
exposed to 62.5 or 125 ppm. The severity of this lesion was not affected by exposure. In exposure-related cases, this change has been 
proposed to have an adaptive/protective role (St Clair and Morgan 1992).  
 
POD 
Available data indicate haemolysis as the primary and critical response. The increased incidence of hyaline degeneration of the olfactory 
epithelium observed in rodents  appears to be an adaptive response  typical for the species and was unaffected by increasing exposure 
concentrations. The subchronic inhalation study with the NOAEC of 25 ppm for haematologic effects  that described by Dodd et al. (1983) 
provides an appropriate POD for derivation of the LCI, which is supported by the chronic NTP study LOAEC of 31 ppm for haemosiderin 
deposition.  
 
AF Study length 
The study length is appropriately considered by a factor of 2 for subchronic  to chronic exposure. 
 
AF Interspecies 
It can be assumed that humans are  less sensitive to nasal effects and haemolysis by butoxyacetic acid (BAA, the active metabolite causing 
haemolysis), also sensitive human sub-populations, including the children, the elderly and those with sickle cell anaemia are also equally 
resistant (Ghanayem  et al. 1993, Udden 1994).  An AF interspecies between 0.1 - 1 could thus be considered as defensible, a factor of 1 was 
selected. 
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AF intraspecies 
A value of 10 was selected to account for variation in sensitivity within the human population.  
 
AF sensitive individuals and other adjustment factors 
It can be assumed that developmental toxicity due to EGBE in humans could not be expected without maternal toxicity. Consequently, there 
is no concern for this endpoint and no need for an additional AF.  
 
References 
 
Ghanayem BI and Sullivan CA, 1993. Assessment of the haemolitic activity of 2-butoxyethanol and its major metabolite, butoxyacetic acid, 
in various mammals including humans. Human & Exp. Toxicol., 12, 305-311. 
Udden MM, 1994. Hemolysis and deformability of erythrocytes exposed to butoxyacetic acid, a metabolite of 2-butoxyethanol. Resistance in 
red blood cells from humans with potential susceptibility. J. Appl. Toxicol., 14(2), 97-102. 
St. Clair, M.B.G. & Morgan, K.T., 1992. Changes in the upper respiratory tract. In Pathobiology of the Aging Rat (U.Mohr, D.L. Dungworth & 
C.C. Capen, Eds.) Vol.1, pp. 111-127. ILSI Press, Washington, DC. 
EU-RAR, RAR (2006). European Union Risk Assessment Report. 2-Butoxyethanol. CAS No: 111-76-2 .INERIS, FranceIneris France: 
http://esis.jrc.ec.europa.eu/doc/risk_assessment/REPORT/egbereport408.pdf 
Dodd DE; Snellings WM; Maronpot RR; Ballantyne B. 1983. Ethylene glycol monobutyl ether: acute 9-day, and 90-day vapor inhalation 
studies in Fischer 344 rats. Toxicol Appl Pharmacol 68:405–414 (1983) and supported by NTP (2000) Toxicology and carcinogenesis 
studies of 2-butoxyethanol (Cas No. 111-76-2) in F344/N rats and B6C3F1 mice (inhalation studies). National Toxicology Program 
Technical Report Series No. 484. National Toxicology Program, Research Triangle Park NC, USA. 
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       A.7 Styrene 
 
Compound STYRENE  Data collection sheet (1/3) 
 
N°CAS 100-42-5 
 
 
 
 
Organization Name EU-INDEX Project OEHHA U.S. EPA ATSDR 
Risk Value Name long-term exposure limit REL RfC MRL 
Risk Value (µg/m3) 250 900 1000 900 
Risk Value (ppb) 55 200 222 200 
Reference period chronic Chronic Chronic Chronic 
Year 2005 2000 1993 2010 
Key Study 
Mutti et al. 1984, 
Neuroendocrine effects of 
styrene on occupationally 
exposed workers 
Mutti et al. (1984)., 
Exposure-effect and 
exposure-response 
relationships between 
occupational exposure 
to styrene and 
neurophychological 
functions 
Mutti et al. (1984). 
Exposure-effect and 
exposure-response 
relationships between 
occupational exposure to 
styrene and 
neuropsychological 
functions 
Benignus VA, Geller AM, Boyes 
WK, et al. 2005. Human 
neurobehavioral effects of long-
term exposure to styrene: a 
meta-analysis 
Study type 
chronic study in workers 
(study for levels of 
substances associated with 
neuroendocrine function), 
inhalation exposure 
Inhalation 
Cross-sectional study in 
workers (Occupational) 
Benignus et al. used data from 
occupational exposure studies 
examining color vision 
impairment (Campagna et al. 
1996; Eguchi et al. 1995; Gobba 
et al. 1991; Gong et al. 2002; 
Kishi et al. 2001) and delays in 
choice reaction time (Jegaden et 
al. 1993; Mutti et al. 1984a; 
Triebig et al. 1989; Tsai and 
Chen 1996). 
Species Human (30 females) 
Human (occupational, 
50 workers) 
Human (occupational, 50 
workers) 
Human 
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Duration of exposure 
in key study 
8 hours/day, 5 days/week 
8.6 years (average 
years at work) 
8.6 years (average years 
at work) 
20 ppm for 8 work-years would 
result in a 6.5% increase in 
choice reaction time and a 
2.23% increase in CCI score. 
Critical effect 
CNS; neuropsychological 
tests: reaction time, s/l 
term logic memory, s/l 
term verbal memory, digit-
symbol association, block 
design and figure 
identification 
Neuropsychological 
deficits in humans as 
measured by memory 
and sensory/motor 
function tests 
CNS effects 
Colour vision impairment and 
delays in choice reaction time 
Critical dose value     
NOAEL: 94 mg/m3 (25 
ppm) 
  
 
LOAEL: 107 mg/m3 (25 
ppm) 
LOAEL: 15 ppm 
LOAEL: >94 mg/m3 (>22 
ppm) 
LOAEL = 20 ppm based on the 
findings of Triebig et al. (2001) 
Adjusted critical dose 
Occupationnal -> 
continuous pattern of 
exposure (factor of 4.2) 
BMC05 = 1.7 ppm     
 
LOAELADJ: 107/4.2 = 25 
mg/m3 
HEC = 1.7 x 10/20 x 
5/7 =  0.61 ppm 
NOAEL(HEC): 34 mg/m3 
LOAELADJ = 20 ppm x 8h/24h x 
5 d/7 d = 4.8 ppm 
Single assessment 
factors (see table 
R.8.6) 
UFL 10 x UFH 10 = 100 UFH 3 = 3 UFS 3 x UFD 3 x UFH 3 ≈ 30 UFL 3 x UFH 10 = 30 
Other effects         
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
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Compound STYRENE  Data collection sheet (2/3) 
 
N°CAS 100-42-5 
 
 
 
 
Organization Name WHO RIVM Sw Criteria Group 
Risk Value Name Guideline value TCA n.a. 
Risk Value (µg/m3) 260 900 n.a. 
Risk Value (ppb) 58 200 n.a. 
Reference period Chronic Chronic Chronic 
Year 2001 2000 2010 
Key Study 
Eguchi, T. et al., 1995, 
Impaired colour 
discrimination among 
workers exposed to 
styrene: relevance to a 
urinary metabolite 
  
Several: Hanova 2011, Laffon 2001, Migliore 2006, Teixeira 
2010, Wongvijitsuk 2011, Benignus 2005, Gong 2002, Kishi 
2001, Mascagni 2007, Morata 2002, Sliwinska-Kowalska 
2003, 2005 
Study type   
Intermittent 
occupational exposure 
of humans 
Intermittent occupational exposure of humans 
Species Human Human Human 
Duration of exposure 
in key study 
  
8.6 years (average 
years at work) 
8.6 years (average years at work) 
Critical effect 
Reductions in visuomotor 
accuracy, verbal learning 
skills and subclinical 
effects on colour vision, 
sensory effects or 
annoyance reactions 
Minor effects on the 
central neural system: 
verbal learning skills 
Genotoxicity, hearing loss and effects on colour vision 
Critical dose value   NOAEL = 107 mg/m3 LOAEL approx. 10 ppm 
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LOAEL = 107 mg/m3 (25 
ppm) 
    
Adjusted critical dose 
Occupationnal -> 
continuous pattern of 
exposure (factor of 4.2) 
Occupationnal -> 
continuous pattern of 
exposure (factor of 4.2) 
Occupationnal -> continuous pattern of exposure (factor of 
4.2) 
   26 mg/m3 2.4 ppm 
Single assessment 
factors (see table 
R.8.6) 
UFL 10 x UFH 10 = 100 UFS 3 x UFH 10 = 100 n.a. 
Other effects     
  
  
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
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Compound STYRENE  Data collection sheet (3/3) 
 
N°CAS 100-42-5 
 
 
 
 
Organization Name 
German IAQ Austrian IAQ  EU-TDR EU: TRD based* 
ECHA: Registered 
Substances 
Risk Value Name IAG IAG DNEL DNEL DNEL 
Risk Value (µg/m3) 30 40 34640 2300 10200 
Risk Value (ppb) 6.90 10 8000 520 2356 
Reference period 
Chronic chronic 
exp. Scen. (DIY 
tasks*) 
chronic chronic 
Year 2004 2004 2008 2011 2011 
Key Study 
Chia et al. Impairment of 
colour vision among 
workers exposed to low 
concentrations of styrene 
.AmJ.Ind. Med. 
26 (1994)  supported by 
various other studies   
 Mutti A, Mazzucchi A, 
Rustichelli P, Friger G, 
Arfini G, Franchini I 
(1984a): 
Exposureeffect 
and exposure-response 
relationships between 
occupational exposure 
to 
styrene and 
neuropsychological 
functions. Am J Ind Med 
5, pp 275-286 
 In EU-RAR, 2008- 
UK 
EU-TRD, UK, 
RCruzan G, Faber 
WD, Johnson KA, 
Roberts LS, 
Hellwig J, Carney 
E, Yarrington JT 
and 
Stump DG (2005a) 
Two generation 
reproduction 
study of styrene 
by inhalation in 
Crl-CD rats. 
Birth Defects 
Research (Part B) 
74: 211-220. 
 In EU-RAR, 2008- 
UK 
EU-TRD, UK, 
RCruzan G, Faber 
WD, Johnson KA, 
Roberts LS, 
Hellwig J, Carney 
E, Yarrington JT 
and 
Stump DG (2005a) 
Two generation 
reproduction 
study of styrene 
by inhalation in 
Crl-CD rats. 
Birth Defects 
Research (Part B) 
74: 211-220. 
No information on 
DNEL derivation; 
DNEL derived by 
industry  
Study type Occupationnal  exposure  Occupational exposure  
2-generation 
study 
2-generation 
study 
 
Species Human Human Rat Rat  
Duration of exposure 
in key study 
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Critical effect 
Effects on CNS, colour 
vision  
Effects on CNS, colour 
vision  
Developmental 
effects 
Developmental 
toxicity 
 
Critical dose value LOAEL: 34 mg/m3 NOAEL: 1.3 mg/m3 NOAEC: 150 ppm  
 
 
 
 
 
 
NOEC= 150 ppm 
(649.5) 
Long-term 
inhalation DNEL 
for consumers 
(systemic effects) 
derived by 
industry (ECHA-
website: 
registered 
substances), no 
transparent 
information about 
derivation of 
DNEL 
       
   
Adjusted critical dose 
Occupationnal -> 
continuous pattern of 
exposure (factor of 5) 
Occupationnal -> 
continuous pattern of 
exposure (factor of 5) 
x 0.75 x 3.5 = 394 
ppm (8-hour) 
Animal exp. - 
human consumer 
649.5*0.25*0.71 
115.29 
 
         
Single assessment 
factors (see table 
R.8.6) 
5 (exp. Time)x 
Intrasp. 10x 
UF (sens.) 2x 
x10 
=100 
5 (exp. Time)x 
Intrasp. 3x 
UF (sens.) 2x 
=30 
UF2x Intersp2.5 
Intrasp10= 50 
UF2x Intersp2.5 
Intrasp5xUF2 = 50 
Overall 
assessment factor: 
1 
Other effects           
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
              * DNEL derived based on key studies selected for risk characteriszation in the EU RAR. 
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Compound STYRENE Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 250  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 27 November 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX  601-026-00-0 
EC-Nr. 5  EINECS – ELINCS - NLP  202-851-5 
CAS-Nr. 6 Chemical Abstracts Service number  100-42-5 
Harmonised CLP classification 7 Human health risk related classification   Flam. Liq. 3 
Skin Irrit. 2 
Eye Irrit. 2 
Acute Tox. 4 (inhalation) 
Molar mass  8 [g/mol] 104.15  
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
Several critical studies 
with effects at similar 
exposure levels. Single 
study cannot be identified 
since exposure 
measurements are 
uncertain in occupational 
studies  
Read across compound 10 Where applicable  
Species 11 Rat,… human Human  
Route/type of study 12 Inhalation, oral feed, … Inhalation/occupational 
exposure  
Study length  13 Days, subchronic, chronic  Chronic 
Exposure duration 14 Hrs/day, days/week Several years, 8 h/d,  
5 d/wk 
Critical endpoint 15 Effect(s), site of   Genotoxicity, neurotoxicity 
and hearing loss 
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 LOAEC 
POD  Value  17 [mg/m³] or [ppm]  10 ppm 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
4.2 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  22 a Reliability of dose-response,   3 
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Dose-response  LOAEL  NOAEL  
 22 b Severity of effect (R 8-6d) 3 
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 5 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF) 189  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
   ……226.66  µg/m3 
       …… 52.9    ppb 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 250 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
The following risk assessments were considered for styrene: EU-INDEX project (2005), OEHHA (2000), US 
EPA (1993), ATSDR (2010), WHO (2001), RIVM (2000), German IAQ (2004) and the Swedish Criteria Group 
(Montelius 2010). The latter report was chosen as it represents the most recent evaluation and also 
identified the lowest effect level. A Pubmed search (December 2011) was carried out to include more recent 
studies not cited in Montelius (2010). 
According to the Swedish concensus report (Montelius 2010), the critical effects of styrene are genotoxicity, 
hearing loss and effects on colour vision. Styrene is probably genotoxic to humans and possibly also 
carcinogenic. Genotoxic effects (chromosomal aberrations, micronuclei, strand breaks, DNA repair) have 
been observed at occupational exposures down to about 10 ppm (Hanova 2011; Laffon 2001; Migliore 2006; 
Teixeira 2010; Wongvijitsuk 2011). Effects on colour perception and choice reaction time have also been 
documented at occupational exposures around 10 ppm (Benignus 2005; Gong 2002; Kishi 2001). Hearing 
loss (Mascagni 2007; Morata 2002; Sliwinska-Kowalska 2003, 2005) is presumed to occur at approximately 
the same level. 
 
POD and assessment factors 
An assessment of 3 was applied as the point of departure (POD) is a LOAEL and not a NOAEL. Another factor 
of 3 was applied to account for the severity of the genotoxic effect. As the data stem from several years of 
occupational exposure, a factor of 2 was applied to account for life-long exposure. No route extrapolation or 
interspecies extrapolation factors were needed. The adjustment for duration of exposure was set to 4.2, 
assuming 40 hours per week in the study group and continuous exposure in the target population. A factor of 
5 was applied to account for the heterogeneity of the general population (including children), as compared to 
the small group of workers studied. 
The resulting LCI value of 250 µg/m3 is similar to the lower odour threshold for styrene of 202 µg/m3 
reported by Ruth (1986). 
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A.8 Ethylbenzene 
 
Compound ETHYLBENZENE  Data collection sheet (1/2) 
N°CAS 100-41-4  
 
 1 ppm (in air, 25 °C) = 4.35 mg/m3 
 
Organization Name WHO ATSDR US EPA (IRIS) OEHHA RIVM AFSSET  
Risk Value Name 
on-going                       
re-evaluation                             
Guideline Value 
MRL RfC inhalation REL TCA CLI (VTR RIVM) 
Risk Value (mg/m3) 22 0.261 1  2 0.77  0.75  
Risk Value (ppm) 5  0.06  0.23  0.4  0.177  0.172 
Reference period Chronic Chronic Chronic Chronic Chronic Chronic 
Year 1996 2010 1991 2000 2001 2009 
Key Study 
NTP semi chronic study 
(13-week), 1992 
NTP, 1999 
Andrew et al., 
1981, teratologic 
assessment of 
ethylbenzene and 
2-ethoxyethanol                                              
Hardin et al., 1981, 
Testing of selected 
workplace 
chemicals for 
teratogenic 
potential  (rats, 
rabbits) 
NTP, 1999 and 
Chan et al., 1998 
(lifetime 
toxicity/carcinoge
nesis study - 
discontinuous 
inhalation) 
NTP semi chronic 
study, 1992 
NTP semi chronic 
study, 1992 
Study type Inhalation studies Inhalation studies 
Teratologic 
assessment 
Discontinuous 
inhalation 
Inhalation studies Inhalation studies 
Species Rats Rats, mice Rats, rabbits Rats, mice Rats, mice Rats, mice 
Duration of 
exposure in key 
study 
6 h/d, 5 d/w for 13 
weeks. 
6 hours per day, 5 
days per week, for 
104 weeks. 
6 (7)h/d, 7 d/w 
during days 1-19 
(1-24) of gestation 
- rats (rabbits) 
6 hours/day, 5 
days/week, 103 
weeks. 
6 h/d, 5 d/w for 
13 weeks. 
6 h/d, 5 d/w for 13 
weeks. 
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Critical effect 
Increase in liver weight 
unassociated with any 
histopathological 
findings 
Kidney effect: 
chronic 
progressive 
nephropathy in 
female rats 
increased 
Increase in 
maternal liver, 
kidney, and spleen 
weights 
Nephrotoxicity, 
body weight 
reduction (rats); 
hyperplasia of the 
puituiray gland; 
liver cellular 
alterations and 
necrosis (mice) 
Liver and kidney 
effects 
Liver and kidney 
effects 
Critical dose value 
NOEL 2150 mg/m3 
(500 ppm) 
 
NOAEL 435 
mg/m3 (100 ppm) 
NOAEL 325 mg/-3 
(75 ppm) 
NOAEL 430 
mg/m3 
NOAEL 430 mg/m3 
 
NOAEL 4300 mg/m3 
(1000 ppm) 
LOAEL 326 mg/m3 
(75 ppm) 
LOAEL 4350 
mg/m3 (1000 
ppm) 
LOAEL 1087 
mg/m3 (250 ppm) 
  
Adjusted critical 
dose 
No duration adjustment PBPK model 
No duration 
adjustment 
Temporal Temporal Temporal 
  
75.7 mg/m3 (17.45 
ppm) 
 
NOAEL 56.5 
mg/m3 (75 ppm x 
6/24 x 5/7 = 13 
ppm) 
NOAEL 77 mg/m3 
(17.70 ppm) 
NOAEL 77 mg/m3 
(17.70 ppm) 
Single assessment 
factors (see table 
R.8.6) 
UFA 10 x UFH 5 x UFD 2 
= 100 
UFA 3 x UFH 10 x 
UFL 10 = 300 
UFA 3 x UFH 10 x 
UFD 10 = 300 
(D=absence of 
multigenerational 
reproductive and 
chronic studies) 
UFA 3 x UFH 10 = 
30 
UFA 10 x UFH 10 = 
100 
UFA 10 x UFH 10 = 100 
Other effects             
Confidence   Low    
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
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COMPOUND  
 
ETHYLBENZENE Data collection 
sheet (2/2) 
N°CAS 100-41-4  
 1 ppm (in air, 25 °C) = 4.35 mg/m3 
 
Organization Name EU TRD-RRS 
EU TRD-RRS 
based* 
ECHA Registered Substances 
Risk Value Name Refv. workplace DNEL consumer DNEL 
Risk Value (mg/m3) 16.4 1.08 15 
Risk Value (ppm) 3.7 0.25 3.4 
Reference period Work exp. Chronic Chronic 
Year 2008 2011 2011 
Key Study 
 
Faber In RAR,  
TRD-RRS,  2008 
 
Faber In RAR, 
 TRD-RRS, 2008  
Study type Inhalation Inhalation  
Species Rats Rats  
Duration of 
exposure in key 
study 
6 h/d, 5 d/w 6 h/d, 5 d/w  
Critical effect 
Dev. Tox.: ↓ pup 
survival un-til PND 4, 
dose-related mortality 
and signs of CNS 
depression in PND 22 
exposed off-spring, ↓ 
weanling body weight 
on PND 34 in the PND 
22 and in the PND 33 
exposed off-spring at 
500 (LOAEC) and 1000 
ppm 
Dev. Tox.: ↓ pup 
survival un-til 
PND 4, dose-
related mortality 
and signs of CNS 
depression in PND 
22 exposed off-
spring, ↓ weanling 
body weight on 
PND 34 in the PND 
22 and in the PND 
33 exposed off-
spring at 500 
(LOAEC) and 1000 
ECHA- homepage: 
long-term inhalation  DNEL 
(systemic effects) for the general 
population  derived from 
industry: 
limited  information about DNEL 
derivation 
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ppm 
Critical dose value NOEC 441 mg.m-3 NOEC 441 mg.m-3 NOEC 
 
    
  
Adjusted critical 
dose     
  
 
441 (NOEC)  
• 0.45 / 0.65 • 6.7/10 
441 (NOEC)            
• 0.45 / 0.65 * 
0.25*0.71= 
54.2mg/m3 
 
Single assessment 
factors (see table 
R.8.6) 
Intersp. 2.5x 
Intrasp. 5 
=12.5 
Intersp. 2.5x 
Intrasp. 10x 
UF (sens 2x) 
=50 
Total AF: 5 
Other effects       
Confidence       
                                                 * DNEL derived based on key studies selected for risk characteriszation in the EU RAR   
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Compound ETHYLBENZENE Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 850  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 4 December 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX   
EC-Nr. 5  EINECS – ELINCS - NLP   
CAS-Nr. 6 Chemical Abstracts Service number  100-41-4 
Harmonised CLP classification 7 Human health risk related classification  Flam. Liq. 2 
Acute Tox. 4 (inhalation)  
Molar mass  8 [g/mol]  106.17 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 
Critical study with lowest relevant effect 
level 
 Gagnaire F, Langlais C, 
Grossmann S, Wild P 
(2007). Ototoxicity in rats 
exposed to ethylbenzene 
and to two technical xylene 
vapours for 13 weeks. 
Arch. Toxicol. 81: 127-143 
Read across compound 10 Where applicable  
Species 11 Rat,… human Rat  
Route/type of study 12 Inhalation, oral feed, …  Inhalation 
Study length  13 Days, subchronic, chronic  13 weeks 
Exposure duration 14 Hrs/day, days/week 6h/24 h, 5 d/7 
Critical endpoint 15 Effect(s), site of   Ototoxicity 
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 LOEAC 
POD  Value  17 [mg/m³] or [ppm] 200 ppm 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
4.7 
AF 
Study Length 
20 sa sc c  
(R8-5) 
2 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 3 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
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 23 b Kinetic + dynamic 1.44 x 2.5 
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
10  
AF (sensitive population) 25 Children or other sensitive groups  
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  1015 
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
    ……..860.63    µg/m3 
    .……197.04   ppb 
 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 850 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
ATSDR, RIVM, and US EPA have evaluated the non-cancer inhalation toxicity data for ethylbenzene. ATSDR  
derived a chronic-duration inhalation minimal risk level (MRL) of 0.26 mg/m3 using a human PBPK model.  
RIVM derived a tolerable concentration in air (TCA) of 0.77 mg/m3 based on liver and kidney effects 
observed in rats and mice. EPA derived a reference concentration (RfC) of 1 mg/m3 based on developmental 
effects observed in rats and rabbits.  Using the 13-week study by NTP (1996), RIVM derived a tolerable 
concentration in air (TCA) of 0.77 mg/m3. 
 
POD 
According to several case reports, where hearing deficits were observed in humans occupationally exposed 
to organic solvents or from people after solvent abuse. The data from a subchronic rat study (Gagnaire et al., 
2007) are considered most relevant for humans. In the key study selected (Gagnaire et al., 2007) male 
Sprague-Dawley rats were exposed to ethylbenzene (200, 400, 600 and 800 ppm) by inhalation, 6 h/day, 6 
days/week for 13 weeks. Ethylbenzene produced moderate to severe ototoxicity in rats exposed to 200 ppm, 
which is close to the NOAEL from the RIVM risk assessment and taken as a LOAEL for ototoxicity. A NOAEL 
was not determined in that study. 
 
Assessment factors 
To derive a NOAEL from the LOAEL for ototoxicty a factor of 3 (2x1.5) for dose response and severity of effect 
is selected. 
Standard AFs for study length and intraspecies extrapolation are used. For interspecies assessment factors, 
values as given in the EU risk assessment report are applied (2). 
The difference in pulmonary absorption between rats and humans for ethylbenzene is considered by the 
ratio of the rat absorption percentage of 45%, divided by human absorption percentage after inhalation of 
65%. 
In the absence of clear carcinogenic evidence and ethylbenzene’s carcinogenic mechanism being  most likely 
not relevant for humans, and a NOAEL (500 ppm) for maternal reproductive toxicity, developmental toxicity, 
and developmental neurotoxicity, no further assessment factors  are introduced. 
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A.9 ε-Caprolactam 
 
Compound ε-CAPROLACTAM Data collection sheet  
N°CAS 105-60-2  
 
 1 ppm (in air, 25 °C) = 4.7 mg/m3 
 
Organization Name 
US EPA IRIS OEHHA 
ECHA Registered 
Substances 
DFG ACGIH NIOSH 
Risk Value Name RfC REL DNEL MAK TLV-TWA REL-TWA 
Risk Value n.a. 2.2 µg/m3 2.5 mg/m3 5 mg/m3 5 mg/m3 1 mg/m3 
Risk Value  n.a. 0.5 ppb 0.5 ppm 1.06 ppm 1.06 ppm 0.2 ppm 
Reference period Chronic Chronic chronic  Chronic (worker) Chronic (worker) Chronic (worker) 
Year 1994 2011 (draft) 2010 2002 2003 1995 
Key Study 
Health effect data 
was determined to 
be inadequate for 
the derivation of an 
inhalation RfC 
Reinhold et al., 
Toxicol.Sci. 44, 
197-205; 1998 
Ziegler et al., Int. 
Arch. Occup. 
Environ. Health 
81:743–753; 2008 
Ferguson & 
Wheeler, Am. Ind. 
Hyg. Ass. J. 34, 384-
389; 1973 
Ferguson & 
Wheeler, Am. Ind. 
Hyg. Ass. J. 34, 384-
389; 1973 
Ferguson & 
Wheeler, Am. Ind. 
Hyg. Ass. J. 34, 384-
389; 1973 
Study type   
Subchronic 
inhalation study 
Exposure chamber 
study, 
chemosensory 
effects in low 
concentration range. 
Health surveillance Health surveillance Health surveillance 
Species   Rat Human Human Human Human 
Duration of 
exposure in key 
study 
  
6 h/d, 5 d/w, 13 
weeks, followed by 
4 week recovery 
6 h / 4d Not specified Not specified Not specified 
Critical effect   
Respiratory tract 
irritation 
Respiratory tract 
irritation 
Respiratory tract 
irritation 
Respiratory tract 
irritation 
Respiratory tract 
irritation 
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Critical dose value   
LOAEL 24 mg/m3 
(14 ppm) 
NOAEC > 5 mg/m3  
NOAEC >32 mg/m3 
(7 ppm) 
NOAEC >32 mg/m3 
(7 ppm) 
NOAEC >32 mg/m3 
(7 ppm) 
   
BMCL05 3 mg/m3 
(1.13 ppm) 
        
Adjusted critical 
dose 
  Chronic Chronic  Chronic Chronic   
   
Human equivalent 
concentration: 
0.134 mg/m3 (3 
mg/m3 x 6/24 x 
5/7 x 0.25) 
(0.25 = "regional 
gas dose ratio") 
No dose adjustment  
(conc. dependent 
local effect)  
      
Single assessment 
factors (see table 
R.8.6) 
  
UFA √10 x UFH 10 
x UFS 2  = 60 
Reliable human data 
Intrasp. 2x 
(worker - general) 
Not indicated Not indicated   
Other effects             
Confidence        
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
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Compound ε-CAPROLACTAM  Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 300  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 18 June 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX   
EC-Nr. 5  EINECS – ELINCS - NLP   
CAS-Nr. 6 Chemical Abstracts Service number 105-60-2  
Harmonised CLP classification 7 Human health risk related classification  Acute Tox.4 (Swallow) 
Skin Irrit.2 
Eye Irrit.2 
Ecute Tox.4 (Inhalation) 
STOT SE 3 
Molar mass  8 [g/mol]  113.6 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 Critical study with lowest 
relevant effect subchronic 
study (Reinhold et al., Tox. 
Sci. 44, 197-205; 1998) 
Read across compound 10 Where applicable  
Species 11 Rat,… human  Rat 
Route/type of study 12 Inhalation, oral feed, …  Inhalation 
Study length  13 Days, subchronic, chronic 90 days 
(subchronic)  
Exposure duration 14 Hrs/day, days/week 6 hrs/day, 5 days a week 
Critical endpoint 15 Effect(s), site of  Irritation of respiratory 
tissues    
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 NOAEC 
POD  Value  17 [mg/m³] or [ppm]  24 mg/m3 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
5.6 
AF 
Study Length 
20 sa sc c  
(R8-5) 
3 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
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 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
5  
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  84 
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
   ………285.7    µg/m3 
    ……...61.13    ppb 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 300 
Additional Comments 31   
 
 
 
Rationale Section 32   
ε-Caprolactam is a chemical with an unpleasant odor and moderately irritating properties at the port of 
entry, especially in form of particles. The available toxicological studies (which cover all toxicological 
endpoints) do not show a specific target organ of systemic toxicity and no indication of CMR properties or 
neurotoxicity. 
Above air-borne concentrations of 10 mg/m³ the major part of ε-caprolactam appears in the form of particles 
(dust, aerosols). Concentrations higher than 33 – 66 mg/m³ were clearly irritating to the respiratory tract in 
occupationally exposed persons (Ferguson and Wheeler, 1973). 
Ziegler et al. (2008) investigated chemosensory effects among volunteers. No adverse effects were recorded 
at the concentrations employed (50, 150 and 5000 µg/m³; 6 hrs per day, 4 subsequent days). Unpleasant 
odour, however, was noted within a concentration-dependent relationship.  
These two human studies are employed as supporting studies. The selected key study is a subchronic 
inhalation study in rats (Reinhold et al., 1998) which is considered of high validity. No systemic toxicity has 
been noted and local irritation of respiratory tissues was the only effect observed. The authors considered 
the top concentration (240 mg/m³) as clearly adverse and the discrete effect observed at the medium dose 
(70 mg/m³) as only adaptive in nature. The lowest concentration (24 mg/m³) was a NOEC. For the EU-LCI 
derivation, however, the lowest concentration was taken as POD. The reason is that 70 mg/m³ has been 
identified as irritating in humans. So, in order to employ a higher degree of conservatism which takes into 
account also observations in humans, the lowest concentration is taken as POD.   
For the assessment factors it was assumed that the local effects observed were more concentration- related 
than dose- related, therefore the extrapolation factor for length of study was confined to 3. Furthermore, a 
time adjustment factor of 5.6 was employed in order to adjust from the exposure intervals in the 
experimental study to continuous exposure and an intra-species variability factor of 5 proposed. This 
amounts to an overall factor of 84 (rounded to 80) which is taken as a divisor for the POD and results in an 
LCI value of 300 µg/m³.  
It is pointed out that perception of an unpleasant odour may occur at concentrations below this value.  
References 
Ferguson and Wheeler. 1973. Am. Ind. Hyg. Assoc. J. 34, 384 – 389. 
Ziegler et al., 2008. Int. Arch. Occup. Environm. Health 81 743 – 753. 
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A.10 α-Pinene 
 
Compound α-PINENE Data collection sheet (1/2) 
N°CAS 80-56-8 
Classification GHS:  H332: Harmful if inhaled (cat. 4), 
H319: Causes serious eye irritation (cat. 2) 
 
CLP: not included 
 
 
 
 
1 ppm (in air, 23 °C) = 5.61 mg/m3 
 
1 ppm (in air, 20 °C) = 5.66 mg/m3 
 
MW=136.23 
 
 
Organization Name ACGIH BAuA German IAQ AgBB ANSES AFS 
Risk Value Name 
8-h TWA Occup. target value 
RWI (target value) 
RWII (adverse effects 
possible) 
for bicyclic monoterpenes, 
model substance = α-
pinene 
NIK (=LCI) CLI (=LCI) OEL 
Risk Value (mg/m3) 
112.12 
(calculated for 
23°C) 
56.06 (calculated for 
23°C) 
RWI=0.2 
RWII=2.0 
1.5 0.45 150 
Risk Value (ppm) 
20 10 
RWI=0.036 
RWII=0.357 
(calculated for 23°C) 
0.267 
(calculated for 
23°C) 
0.0803 
(calculated for 
23°C) 
25 
Reference period  Subacute Subacute    
Year 2008 2005 2003   1990 
Key Study 
No information 
available 
Järvisalo J, Vainio H: Acta 
Pharmacologica et 
Toxicologica 
1980;46(1):32–36 
Johard U, Larsson K, Löf A, 
Eklund A: Controlled 
short-time terpene 
exposure induces an 
increase of the 
macrophages and the 
mastcells in 
bronchoalveolar lavage 
Value derived 
from 
AFS-OEL: 
× 0.01 
Value taken 
from 
the EU-INDEX 
Project 
No information 
available 
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fluids. Am J Ind Med 
1993;23:793–799 
Study type 
  
Inhalation study 
8 volunteers inhalating  
450 mg/m3 mixture of α-
pinene, beta-pinene, delta-
3-carene (10:1:5). 4×3hrs. 
in 2 weeks. Elevated cell-
concentrations in BAL 
after exposition, 
interpreted as acute 
alveolar cellular reaction / 
inflammation marker. 
   
Species   Rat Man    
Duration of 
exposure in key 
study 
  
6h/d, 5d/w for 8 weeks 4 × 3 hrs. in 2 weeks    
Critical effect 
  Study with turpentine 
(95% α-pinene). 
Enhanced activities of 
drug biotransformation 
enzymes of liver 
microsomes: NADPH 
cytochrome c reductase 
and 7-ethoxycoumarin 
deethylase, and 
microsomal content of 
cytochrome P-450 
(increased 35–60% only 
during first weeks). 
Increase in liver 
microsomal 
epoxide hydratase and 
UDPglucuronosyltransfer
ase tended to adapt less.  
Result describes not an 
adverse effect per se, but 
influence of 
biotransformation of 
20 hrs after exposure 
significant higher 
concentrations of alveolar 
cell concentrations 
(median pre-exposure 76 × 
l06 cells/L -> 126 × l06 
cells/L), predominantly 
due to macrophages (72 × 
l06  cells/L -> 121 × l06 
cells/L). Also mast cells 
increased: 1/10 ->  5/10 
visual fields. 
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drugs is possible. 
Critical dose value 
  
1,710 mg/m3 (300 ppm) LOAEL: 450 mg/m3    
Adjusted critical 
dose 
 
ENAELinhal: 128 mg/m3 
(23 ppm) 
    
  
Derived Exposure Target 
Value 
56 mg/m3 (10 ppm) 
    
Single assessment 
factors (see table 
R.8.6) 
 No information given 
UFS 12 x UFH 10 x UFChildren 
2 = 1.875 mg/m3  
-> RWII = 2 mg/m3 
   
Other effects    
Odour thresholds, different 
values published: 
α-pinene 3.9 mg/m3 
(+)α-pinene 23 mg/m3 
(−)α-pinene 107 mg/m3 
   
Confidence        
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
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Compound α-PINENE Data collection sheet (2/2) 
N°CAS 80-56-8 
Classification GHS:  H332: Harmful if inhaled (cat. 4), 
H319: Causes serious eye irritation (cat. 2) 
 
CLP: not included 
 
 
 
 
1 ppm (in air, 23 °C) = 5.61 mg/m3 
 
1 ppm (in air, 20 °C) = 5.66 mg/m3 
 
MW=136.23 
 
 
Organization Name EU-INDEX Project 
Mersch-Sundermann 
review 
Gminski et al. 
Data from ECHA for 
not specified α-
pinene, CAS 80-56-8 
NTP study with not 
specified α-pinene,   
CAS 80-56-8 
Risk Value Name 
IAQ Proposed LCI Not appointed 
Long-term exposure 
systemic effects 
general population 
inhalation DNEL 
NOAEL 
Risk Value (mg/m3) 0.45 4 Not appointed 1.06  
Risk Value (ppm) 
0.0803 
(calculated for 23°C) 
0.714 
(calculated for 23°C) 
Not appointed 
0.187 
(calculated for 23°C) 
50 
Reference period    Subchronic Subchronic 
Year 
2005 2007 2011 
2012 (status ECHA-
Homepage) 
2006 
Key Study 
Falk Filipsson A: Short 
term inha-lation 
exposure to turpentine: 
toxicokinetics and 
acute effects in men. 
Occup Environ Med 
1996;53:100–105 
 
Falk A, Hagberg M, Löf 
A, Wigaeus-Hjelm E, 
Wang Z: Uptake, 
distribution and 
elimination of a-pinene 
Animal study: 
Kasanen JP, Pasanen 
AL, Pasanen P, 
Liesivuori J, Kosma VM, 
Alarie Y: Stereospecifity 
of the sensory irritation 
receptor for 
nonreactive chemicals 
illustrated by pinene 
enantiomers. Arch 
Toxicol 1998; 72:514–
523 
 
Human inhalation study: 
Gminski R.  Marutzky R.  
Keve-kordes S.  Fuhrmann F.  
Burger W.  Hauschke D.  
Ebner W.  Mersch-
Sundermann V: 
Chemosensory irritations 
and pulmonary effects of 
acute exposure to emissions 
from oriented strand board. 
Human & Experimental 
Toxicology 
2011;30(9):1204–21 
NTP-Study 2005 
NTP-Study 
TDMS Number 2030203 
=TOX-81 Study 
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in man after exposure 
by inhalation. Scand J 
Work Environ Health 
1990;16:372–8 
Human exposure study: 
Falk Filipsson A: Short 
term inhalation 
exposure to turpentine: 
toxicokinetics and 
acute effects in men. 
Occup Environ Med 
1996;53:100–105 
 
Lowest OEL-value: 
Swedish OEL 150 
mg/m3 
 
Odour threshold: 
lowest 4 mg/m3 
Study type 
8 volunteers inhalated 
450 mg/m3 turpentene: 
α-pinene, beta-pinene, 
delta-3-carene, 5:1:3 
(1st study) or α-pinene 
alone (2nd study). 
Irritation by α-pinene 
was reported at 450 
mg/m³ but not at 225 
mg/m³. Dis-comfort 
against turpentene was 
reported, also airway 
resistance was 
increased. Both studies: 
1 Exposition for 2 hrs 
Animal study: 
Short-term (30') 
exposure (inhalation) 
and measurement of 
respiratory parameters. 
Concentrations of α-
pinene 100–3,691 ppm. 
24 volunteers were exposed 
for 2hrs to oriented 
strandboard (OSB) 
emissions in an emission 
chamber at 3 points of time 
(panels fresh, 2 and 8 weeks 
old). Chemosensory 
irritation, exhaled nitric 
oxide (NO) concentration, 
eye blink frequency, lung 
function and subjective 
perception of irritation 
(eyes, nose, throat) and 
olfactory perception were 
investigated. 
Animal Study: 
Subchronic  
inhalation study 
exposition at 25 ppm 
/ 50 ppm / 100 ppm / 
200 ppm / 400 ppm. 
10 Animals per sex 
and concentration 
used. 
Animal Study: 
Subchronic inhalation 
study 
exposition at 25 ppm / 
50 ppm / 100 ppm / 200 
ppm / 400 ppm. 
10 Animals per sex and 
concentration used. 
Species Man Mouse / man  
B6C3F1 Mice and 
F344 Rats 
B6C3F1 Mice and F344 
Rats 
Duration of 
exposure in key 
study 
1 Exposure for 2 hrs 
Animal study: 30 min 
3 × 2 hrs 
(14 weeks according 
to ECHA) 
90-day inhalation 
study 
96 days for mice (14 
weeks) 
=test-type "90 days" 
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Critical effect 
Irritation / discomfort 
(self-reported) and 
airway resistance 
Animal study: 
OF1 and NIH/S male 
mice, 4 of each used per 
experiment, exposure 
time 30', measurement 
of lung functions by 
body plethys-mograph. 
Endpoint RD50 = 50% 
depression of 
respiratory rate 
by sensory irritation of 
upper respiratory tract 
 
Human exposure study: 
8 volunteers exposed to 
450 mg/m3 turpentene: 
α-pinene, beta-pinene, 
delta-3-carene, 5:1:3 
(1st study) or α-pinene 
alone (2nd study). 
Irritation by α-pinene 
was reported at 450 
mg/m³ but not at 225 
mg/m³. Discomfort 
against turpentene was 
reported, also airway 
resistance was 
increased. Both studies: 
1 Exposure for 2 hrs 
No effects found except of 
odour perception. 
From ECHA-
Summary: 
 
Male and female mice 
at 100 ppm: minimal 
to moderate 
hyperplasia observed 
in the transitional 
epithelium of the 
urinary bladder 
 
The NOAEL in male 
and female rats is 50 
ppm based on 
minimal to moderate 
hyperplasia observed 
in the transitional 
epithelium of the 
urinary bladder in 
animals treated at 
100 to 400 ppm 
Significant effects 
(p<=0.05) 
 
Male rats, moderate 
effects: granular casts in 
kidney: accumulation of 
hyaline droplets starting 
at 25 ppm. Note: 9/10 
animals showed 
nephropaty in control 
group (other effects) 
 
Female rats, minimal 
effects: chronic lung 
inflammation. Note: 4/10 
in control group, 5/9 at 
400 ppm 
 
Mice in both sexes, 
minimal to moderate 
effects: hyperplasia of 
transitional epithelium of 
urinary bladder starting 
at 100 ppm (13/20 
mice). The effect is 
concentration-dependent 
(200 ppm: 20/20 mice) 
Critical dose value 
LOAEL: 450 mg/m3  
NOAEL: 225 mg/m3 
Animal study: 
RD50 1080 ppm (9 g 
/m3) 
 
Human exposure study: 
LOAEL: 450 mg/m3  
 
OEL: 150 mg/m3 
 
Odour threshold: 4 
mg/m3 
Concentration of α-pinene in 
the chamber: 1.1–2.2 
mg/m3. 
α-pinene was a leading 
component of the OSB-
emission, TVOC was 4.9–8.9 
mg/m3. The results 
represent a NOAEL for OSB-
emissions, including an α-
pinene TVOC-proportion of 
16–25%. 
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Adjusted critical 
dose 
IAQ exposure limit: 
0.45 mg  × m−3 
Animal study: 
4.5 mg/m3 
 
Human exposure study: 
4.5 mg/m3 
 
OEL: 
3.75 mg/m3 
 
Odour threshold: 
no adjustment, 4 
mg/m3 
   
Single assessment 
factors (see table 
R.8.6) 
UFL 10 x UFS10 x UFH 
10 = 1000 
Animal study: 
RD50 x 0.03 = 
reasonable OEL, 
then 
UFS24/6 x UFH 10 = 40 
 
Human exposure study: 
UFS10 x UFH 10 = 100 
 
OEL: 
UFS24/6 x UFH 10 = 40 
   
Other effects 
Odour thresholds: 
(+)α-pinene 12 mg/m3 
(2.1 ppm) 
(−)α-pinene 18 mg/m3 
(3.3 ppm) 
 
Reaction of (+)α-pinene 
with ozone amplifies 
irritative effect: 
 
Wolkoff P, Clausen PA, 
Wilkins CK, Nielsen GD: 
Formation of strong 
airway irritants in 
terpene/ozone 
mixtures. Indoor Air 
2000;10:82–91 
Odour thresholds, 
different values 
published: 
α-pinene range 4–25 
mg/m3 
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(ASTM mouse bioassay: 
56 ppm at 21°C= 316 
mg/m³ -> 30% lower 
respiration rate for 
mixture) 
Confidence       
UFL Used LOAEL; UFH Intraspecies variability; UFA interspecies variability; UFS Used subchronic study; UFD data deficiencies 
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Compound α-PINENE Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³]  2500 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 10 December 2012 
General Information    
CLP-INDEX-Nr.  4  INDEX   
EC-Nr. 5  EINECS – ELINCS - NLP 201-291-9  
CAS-Nr. 6 Chemical Abstracts Service number  80-56-8 
Harmonised CLP classification 7 Human health risk related classification  Not harmonised 
 
Molar mass  8 [g/mol]  136.23 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant 
effect level 
 NTP 2006 
Read across compound 10 Where applicable  
Species 11 Rat,… human Mouse  
Route/type of study 12 Inhalation, oral feed, …  Inhalation 
Study length  13 Days, subchronic, chronic  SC 
Exposure duration 14 Hrs/day, days/week 6h on 5 days/week 
Critical endpoint 15 Effect(s), site of  Bladder epithelial changes  
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 NOAEC 
POD  Value  17 [mg/m³] or [ppm]  50 ppm 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
5.6 
AF 
Study Length 
20 sa sc c  
(R8-5) 
2 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
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 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 10 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  112 
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
     ……    2502    µg/m3 
    …...  446.42   ppb 
 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 2500 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
α-pinene is a major component of turpentine and therefore typical for coniferous wood emissions, mainly 
scots pine and common spruce. To derive risk values (mainly occupational exposures like sawmills), often 
short-term human inhalation studies were used, sometimes only with turpentine.  
Examples for short-term exposures are the study of Falk Filipsson (1996) and Falk et al. (1990). In both 
studies, 8 volunteers were exposed for 2 hrs. Effects were, increased airway resistance and self- reported 
irritation/discomfort. The study of Falk Filipsson used turpentine. Johard et al. (1993) describe the 
exposure of 8 volunteers to turpentine for 4x3 hrs in two weeks and found elevated cell concentrations in 
bronchoalveolar lavage, interpreted as a cellular reaction showing acute inflammation (this study also 
used turpentine). A short-term animal study was the study of Kasanen et al. (1998), which identified the 
RD50 value due to sensory irritation of the upper respiratory tract after exposure of mice against α-
pinenes (D, L) for 30 minutes. 
As described in the rationale for the establishment of EU-LCI values, these values represent a chronic 
exposure scenario, therefore short-term studies require additional factors and are not preferred. Only one 
chronic animal inhalation study was identified by the data compilation sheet: Järvisalo and Vainio (1980), 
but again turpentine was used (95% α-pinene) and the described enhanced activities of drug bio-
transformation enzymes of liver microsomes are not per se adverse.  
Therefore, the chosen POD was derived from the subchronic NTP-toxicity study (TOX-81) which used not 
enantiomer specified α-pinene (CAS-No 80-56-8). This study was also chosen by ECHA to derive a DNEL 
(without providing explanation about the calculation).  
The NTP study is a subchronic inhalation animal study (B6C3F1 Mice and F344 Rats) with exposures at 25 
ppm / 50 ppm / 100 ppm / 200 ppm / 400 ppm. 10 Animals per sex and per concentration were used. The 
duration was up to 96 days (14 weeks) and therefore represents a subchronic 90 day study. Mice of both 
sexes showed minimal to moderate effects, i.e. hyperplasia of transitional epithelium of urinary bladder 
starting at 100 ppm. So, a NOAEL of 50 ppm was found for mice. The effect was concentration-dependent: 
0/20 at 50 ppm, 13/20 at 100 ppm, 20/20 at 200 ppm and 400 ppm. It was decided not to use an 
additional factor for interspecies kinetic and dynamic differences (line 23b), because it is reasonable to 
assume that mice are more sensitive than humans because of faster metabolism, leading to higher 
exposure of bladder epithelium cells (in the NTP-study the effect was only found in mice, not in rats). 
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Although NTP-data are not published in a scientific journal and some information is missing (e.g. methods, 
purity of chemicals) this study was chosen as the best basis for deriving the EU-LCI value. 
It should be noted, that D and L isomers of α-pinene cannot be separated with the analytical method 
normally applied for the emission chamber test standard method. So, the factsheet is prepared for not 
specified α-pinene and the NTP complies with this. For the critical effect chosen (urinary bladder 
epithelium changes), the composition of inhaled isomers can presumably be neglected because bladder 
epithelium is mainly exposed to metabolites rather to α-pinene itself. Ishida et al. (1981) have shown, that 
in rabbits, metabolism of D and L isomers of α-pinene leads to the excretion of the same compounds. Levin 
et al. (1992) confirmed in a human inhalation experiment, that (+) and (–)α-pinene both are metabolised 
to and excreted as verbenol in the same cis:trans ratio of 1:10. However, beta pinene and other terpenes 
showed a different metabolic pattern and may differently affect bladder epithelium, so simple transfer or 
read-across to other bicyclic monoterpenes seem to be inadequate. It should also be noted, that for 
irritation (not used as endpoint in this data sheet), D and L isomers of α-pinene behave different, only the 
D isomer of α-pinene was found to be irritative by Kasanen et al. (1998). 
 
References 
Falk A, Hagberg M, Löf A, Wigaeus-Hjelm E, Wang Z. 1990. Uptake, distribution and elimination of a-pinene 
in man after exposure by inhalation. Scand J Work Environ Health 1990; 16:372–8. 
Falk Filipsson A. 1996. Short term inha-lation exposure to turpentine: toxicokinetics and acute effects in 
men. Occup Environ Med 1996; 53:100–105. 
Ishida T, Asakawa Y, Takemoto T, Aratani T. 1981. Terpenoids biotransformation in mammals III: 
Biotransformation of alpha-pinene, beta-pinene, pinane, 3-carene, carane, myrcene, and p-cymene in 
rabbits. J Pharm Sci 1981; 70:406–15. 
Järvisalo J, Vainio H. 1980. Acta Pharmacologica et Toxicologica 1980; 46(1):32–36. 
Johard U, Larsson K, Löf A, Eklund A. 1993. Controlled short-time terpene exposure inducesan increase of 
the macrophages and the mastcells in bronchoalveolar lavage fluids. Am J Ind Med 1993;23:793–799. 
Kasanen JP, Pasanen AL, Pasanen P, Liesivuori J, Kosma VM, Alarie Y.1998. Stereospecifity of the sensory 
irritation receptor for nonreactive chemicals illustrated by pinene enantiomers. Arch Toxicol 
1998;72:514–523. 
Levin J-O, Eriksson K, Falk A, Löf A1992. Renal elimination of verbenols in man following experimental a-
pinene inhalation exposure. Int Arch Occup Environ Health (1992) 63:571–573. 
NTP-study 2006: Identification: TDMS Number 2030203, TOX-81 Study. 
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A.11 n-Butanal 
 
Compound n-Butanal, n-Butyraldehyde Data collection 
sheet 
 
N°CAS  123-72-8 
EC 204-646-6 
EU- Classification: Not classified 
CLP:   
Acute Tox.  
Skin Irrit.  
Eye Irrit.  
Asp. Tox. 
 
 n-Butanal n-Butanal n-Butanal 
Organization Name    
Risk Value Name LOAEC NOAEC LOAEC 
Risk Value (mg/m3) 363 145 360 
Risk Value (ppm) 125 50 125 
Reference period Subchronic Subchronic Subchronic 
Year 1979 1980 1979 
Key Study 
Union Carbide 
Corporation, 1979  
OECS-SIDS 2005 
Union Carbide 
Corporation, 1980 
 OECS-SIDS 2005 
Union Carbide 
Corporation, 1979 
OECS-SIDS 2005 
Study type Subchronic Subchronic Subchronic 
Species F 344 rats Rats  
Duration of exposure 
in pivotal study 
 6h/day, 5 days/week, 13 
weeks 
 6h/day, 5 days/12 
weeks 
6h/day, 5 days/week, 
14 weeks 
Critical effect 
Squamous metaplasia of 
the nasal cavity 
 
Goblet cell 
hyperplasia within 
the nasal mucosa 
Critical dose value     
  
  
Adjusted critical dose 
 
  
 
    
Single assessment 
factors (see table 
R.8.6) 
 
  
Other effects       
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Compound n-Butanal 
(n-Butyraldehyde) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 650 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX 605-006-00-2 
EC-Nr. 5  EINECS – ELINCS - NLP 204-646-6 
CAS-Nr. 6 Chemical Abstract Service number 123-72-8 
Harmonised CLP classification 7 Human health risk related classification   Not harmonized 
Molar mass  8 [g/mol] 72.11  
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
Union Carbide 1980, OECD 
SIDS (2005)   
Read across compound 10 Where applicable  
Species 11 Rat,… human Rat  
Route/type of study 12 Inhalation, oral feed, …  Inhalation 
Study length  13 Days, subchronic, chronic  Sc 
Exposure duration 14 Hrs/day, days/week 6/24;5/7d; 13 wks 
Critical endpoint 15 Effect(s), site of  Irritation (squamous 
metaplasia of the nasal 
cavity)  
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
NOAEC 
POD  Value  17 [mg/m³] or [ppm]  145 mg/m³ or 50 ppm  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
5.6 
AF 
Study Length 
20 sa sc c  
(R8-5) 
2 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 10 
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AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
2 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF) 224 
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
           662.1    µg/m3 
               223.2    ppb 
Molar adjustment factor  29 Used in read-across  
Rounded value  30 [µg/m3] 650 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
In a non verifiable repeated-dose inhalation study male and female F344 rats were exposed by inhalation to 
n-butyraldehyde vapour at concentrations of 0, 125, 500, or 2000 ppm (0, 363, 1450, or 5800 mg/m3) for 6 
hr/day, 5 days per week, for 13 weeks (Union Carbide Corporation, 1979). Animals in all treatment groups 
displayed a significant increase in the incidence of squamous metaplasia of the nasal cavity.  This study 
resulted in a LOAEC of 125 ppm.  
A subsequent 12-week inhalation study in male and female rats employing lower doses of 0, 1, 10, and 50 
ppm (145 mg/m3) n-butyraldehyde did not result in any adverse effects on the nasal, olfactory, or respiratory 
epithelial tissues resulting in a NOAEC of 50 ppm (Union Carbide Corporation, 1980).  
In another study, beagle dogs were exposed by inhalation to n-butyraldehyde vapor at concentrations of 0, 
125, 500, and 2000 ppm for 6 hr/day, five days a week, for 14 weeks. Dogs exposed to 125 and 500 ppm 
displayed goblet cell hyperplasia within the nasal mucosa (Union Carbide Corporation, 1979). 
 The NOAEC of 50ppm (145 mg/m³) from the rat-study is used for derivation of a EU-LCI.  The subchronic 
NOAEC is divided by standard factors for study duration (2) and exposure duration (5.6).  Rat and dogs -
compared to humans –are considered equally sensitive. Thus no interspecies factor is used. For interspecies 
variation a factor of 10 is used. With the quality of the data base considered as insufficient a factor of 2 is 
selected.  
The EU-LCI is above the odour detection threshold of ~2 µg/m³ (Cometto-Muniz 2010). 
References 
OECS SIDS (2005). N-Valeraldehyde. UNEP Publications. Washington. 
Ernstgard L, Iregren A, Sjögren B et al. (2006). Acute effects of exposure to hexanal vapors in humans. J Occup 
Environ Med 48: 573-580. 
Cometto-Muniz JE, Abraham MH (2010). Odor detection by humans of lineal aliphatic aldehydes and helional 
as gauged by dose-response functions. Chem Senses 35:289-299.  
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A.12 n-Pentanal (read-across from n-Butanal) 
 
Compound n-Pentanal (Valeraldehyde) 
(read-across from n-Butanal) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 800 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX  
EC-Nr. 5  EINECS – ELINCS - NLP 203-784-4 
CAS-Nr. 6 Chemical Abstract Service number 110-62-3 
Harmonised CLP classification 7 Human health risk related classification  Not harmonized  
Molar mass  8 [g/mol] 86.13 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 
Read across compound 10 Where applicable n-Butanal 
Species 11 Rat,… human  
Route/type of study 12 Inhalation, oral feed, …  
Study length  13 Days, subchronic, chronic  
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of   
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 
POD  Value  17 [mg/m³] or [ppm]  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
 
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
 
Molar adjustment factor  29 Used in read-across (86.13/72.11) 1.194 
Rounded value  30 [µg/m3] 
(662.1 µg/m3 x 1.194 = 790.5 µg/m3) 
800 
Additional Comments 31   
 
Rationale Section 32   
 
Rationale for read-across  
 Data poor compound: no adequate toxicological data for pentanal exist from which an EU-LCI value could 
be derived directly using the de novo procedure. 
 Read-across from EU-LCI value of butanal: within the chemical class ‘saturated aldehydes’, butanal is the 
closest homologue compound with an EU-LCI value: one additional CH2 group in the aliphatic side chain 
of pentanal. 
 Toxicological critical endpoint for butanal: irritation (squamous metaplasia of the nasal cavity). 
 
 The key assumption underlying the read-across of the EU-LCI value from butanal to pentanal is that both 
compounds have the same critical endpoint (irritation) and this is caused by the common functional 
group (and not by the additional CH2 group). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
Pentanal 
 
86.13  ?   
(read-across to be used) 
 
800 µg/m³ 
Butanal 
 
72.11 650 µg/m3 
(de novo protocol)  
Unrounded value:  
662.1 µg/m³ or 223.2 ppb 
 
 Unrounded EU-LCI value butanal: 662.1 µg/m³  to be used for read-across EU-LCI of pentanal. 
      No cut-off rule in place: difference in change length between the two homologue compounds is smaller 
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than two CH2 groups per aliphatic chain. 
 Thus, EU-LCI value for pentanal is 662.1 µg/m3.  After MW conversion at 23 °C and 1.013 atm: EU-LCI 
propanal = 662.1 µg/m3 x 1.194 = 790.5 µg/m3  rounded to 800 µg/m³. 
The EU-LCI is above the odour detection threshold of  ~ 2 µg/m³.  
 
References 
 
Nagata Y. (2003). Measurement of odor threshold by triangle odor bag method. Odor Measurement Rev 118-
127. 
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A.13 n-Hexanal (read-across from n-Butanal) 
 
Compound n-Hexanal 
(read-across from n-Butanal) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 900 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX  
EC-Nr. 5  EINECS – ELINCS - NLP 200-624-5 
CAS-Nr. 6 Chemical Abstract Service number 66-25-1 
Harmonised CLP classification 7 Human health risk related classification  Not harmonized  
Molar mass  8 [g/mol] 100.16 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 
Read across compound 10 Where applicable n-Butanal 
Species 11 Rat,… human  
Route/type of study 12 Inhalation, oral feed,…  
Study length  13 Days, subchronic, chronic  
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of   
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 
POD  Value  17 [mg/m³] or [ppm]  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
 
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
 
Molar adjustment factor  29 Used in read-across (100.16/72) 1.39 
Rounded value  30 [µg/m3] 
(662.1 µg/m3 x 1.39 = 920.3 µg/m3) 
900 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Rationale for read-across  
 Data poor compound: no adequate toxicological data for hexanal exist from which an EU-LCI value could 
be derived directly using the de novo procedure. 
 Read-across from EU-LCI value of butanal: within the chemical class ‘saturated aldehydes’, butanal is the 
closest homologue compound with an EU-LCI value: two additional CH2 group in the aliphatic side chain 
of hexanal. 
 Toxicological critical endpoint for butanal: irritation (squamous metaplasia of the nasal cavity). 
 
 The key assumption underlying the read-across of the EU-LCI value from butanal to hexanal is that both 
compounds have the same critical endpoint (irritation) and this is caused by the common functional 
group (and not by the additional CH2 group). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
Hexanal 
 
100.16  ?   
(read-across to be used) 
 
900 µg/m³ 
Butanal 
 
72.11 650 µg/m3 
(de novo protocol)  
Unrounded value:  
662.1 µg/m³ or 223.2 ppb 
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 Unrounded EU-LCI value butanal: 662.1 µg/m³  to be used for read-across EU-LCI of hexanal. 
         No cut-off rule in place: difference in change length between the two homologue compounds is smaller  
than two CH2 groups per aliphatic chain. 
 Thus, EU-LCI value for hexanal is 662.1 µg/m3.  After MW conversion at 23 °C and 1.013 atm: EU-LCI 
hexanal = 662.1 µg/m3 x 1.39 = 920.3 µg/m³  rounded to 900 µg/m³. 
 The EU-LCI is consistent with the results of the acute exposure study in human volunteers and protects 
from acute sensory irritation: In an acute exposure study (Ernstgard et al., 2006) twelve healthy 
volunteers were exposed to 0, 2, and 10 ppm n-hexanal for 2 hours at rest in a balanced order. Two hours 
of exposure to n-hexanal resulted in mild irritation at 10 ppm, with no apparent adversity at 2 ppm (6 
mg/m3).  
The EU-LCI is above the odour detection threshold of ~ 2 µg/m³ (Cometto-Muniz 2010). 
 
 
References  
 
OECS SIDS (2005). N-Valeraldehyde. UNEP Publications. Washington. 
Ernstgard L, Iregren A, Sjögren B et al. (2006). Acute effects of exposure to hexanal vapors in humans. J Occup 
Environ Med 48: 573-580.  
Cometto-Muniz JE, Abraham MH (2010). Odor detection by humans of lineal aliphatic aldehydes and helional 
as gauged by dose-response functions. Chem Senses 35:289-299.  
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A.14 n-Heptanal (read-across from n-Butanal) 
 
Compound n-Heptanal 
(read-across from n-Butanal) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 900 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX  
EC-Nr. 5  EINECS – ELINCS – NLP 203-898-4 
CAS-Nr. 6 Chemical Abstract Service number 111-71-7 
Harmonised CLP classification 7 Human health risk related classification  Not harmonized  
Molar mass  8 [g/mol] 114.18 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 
Read across compound 10 Where applicable n-Butanal 
Species 11 Rat,… human  
Route/type of study 12 Inhalation, oral feed, …  
Study length  13 Days, subchronic, chronic  
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of   
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 
POD  Value  17 [mg/m³] or [ppm]  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
 
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
 
Molar adjustment factor  29 Used in read-across (100.16/72) 1.39 
Rounded value  30 [µg/m3] 
(662.1 µg/m3 x 1.39 = 920.3 µg/m3) 
900 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Rationale for read-across  
 Data poor compound: no adequate toxicological data for heptanal exist from which an EU-LCI value could 
be derived directly using the de novo procedure. 
 Read-across from EU-LCI value of butanal: within the chemical class ‘saturated aldehydes’, butanal is the 
closest homologue compound with an EU-LCI value: three additional CH2 group in the aliphatic side 
chain of heptanal. 
 Toxicological critical endpoint for butanal: irritation (squamous metaplasia of the nasal cavity). 
 
 The key assumption underlying the read across of the EU-LCI value from butanal to heptanal is that both 
compounds have the same critical endpoint (irritation) and this is caused by the common functional 
group (and not by the additional CH2 group). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
Heptanal  114.18  ?   
(read-across to be used) 
 
900 µg/m³ 
Butanal 
 
72.11 650 µg/m3 
(de novo protocol)  
Unrounded value:  
662.1 µg/m³ or 223.2 ppb 
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 Unrounded EU-LCI value butanal: 662.1 µg/m³  to be used for read-across EU-LCI of heptanal. 
        Cut-off rule in place: difference in change length between the two homologue compounds is larger than   
two CH2 groups per aliphatic chain.  cut-off to hexanal.  
 Thus, EU-LCI value for heptanal is 662.1 µg/m3.  After MW conversion at 23 °C and 1.013 atm (+ cut-off 
rule at 2C): EU-LCI heptanal = 662.1 µg/m3 x 1.39 = 920.3 µg/m³  rounded to 900 µg/m³. 
 
The EU-LCI is above the odour detection threshold of ~ 2 µg/m³.  
 
References 
Nagata Y. (2003). Measurement of odor threshold by triangle odor bag method. Odor Measurement Rev 118-
127. 
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A.15 n-Octanal (read-across from n-Butanal) 
 
Compound n-Octanal 
(read-across from n-Butanal) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 900 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX  
EC-Nr. 5  EINECS – ELINCS – NLP  
CAS-Nr. 6 Chemical Abstract Service number 124-13-0 
Harmonised CLP classification 7 Human health risk related classification  Not harmonized 
Molar mass  8 [g/mol] 128.21 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 
Read across compound 10 Where applicable n-Butanal 
Species 11 Rat,… human  
Route/type of study 12 Inhalation, oral feed, …  
Study length  13 Days, subchronic, chronic  
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of   
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 
POD  Value  17 [mg/m³] or [ppm]  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
 
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
 
Molar adjustment factor  29 Used in read-across (100.16/72) 1.39 
Rounded value  30 [µg/m3] 
(662.1 µg/m3 x 1.39 = 920.3 µg/m3) 
900 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Rationale for read-across  
 Data poor compound: no adequate toxicological data for octanal exist from which an EU-LCI value could 
be derived directly using the de novo procedure. 
 Read-across from EU-LCI value of butanal: within the chemical class ‘saturated aldehydes’, butanal is the 
closest homologue compound with an EU-LCI value: four additional CH2 group in the aliphatic side chain 
of octanal. 
 Toxicological critical endpoint for butanal: irritation (squamous metaplasia of the nasal cavity). 
 
 The key assumption underlying the read-across of the EU-LCI value from butanal to octanal is that both 
compounds have the same critical endpoint (irritation) and this is caused by the common functional 
group (and not by the additional CH2 group). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
Octanal 
 
128.21  ?   
(read-across to be used) 
 
900 µg/m³ 
Butanal 
 
72.11 650 µg/m3 
(de novo protocol)  
Unrounded value:  
662.1 µg/m³ or 223.2 ppb 
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 Unrounded EU-LCI value for butanal: 662.1 µg/m³  to be used for read-across EU-LCI of octanal. 
        Cut-off rule in place: difference in change length between the two homologue compounds is larger than  
two CH2 groups per aliphatic chain.  cut-off to hexanal.  
 Thus, EU-LCI value for octanal is 662.1 µg/m3.  After MW conversion at 23 °C and 1.013 atm (+ cut-off 
rule at 2C): EU-LCI octanal = 662.1 µg/m3 x 1.39 = 920.3 µg/m³  rounded to 900 µg/m³. 
 
The EU-LCI is above the odour detection threshold of  ~ 2 µg/m³ (Cometto-Muniz 2010). 
 
References 
Cometto-Muniz JE, Abraham MH (2010). Odor detection by humans of lineal aliphatic aldehydes and helional 
as gauged by dose-response functions. Chem Senses 35:289-299. 
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A.16 n-Nonanal (read-across from n-Butanal) 
 
Compound n-Nonanal 
(read-across from n-Butanal) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 900 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX  
EC-Nr. 5  EINECS – ELINCS – NLP 204-688-5 
CAS-Nr. 6 Chemical Abstract Service number 124-19-6 
Harmonised CLP classification 7 Human health risk related classification  Not harmonized 
Molar mass  8 [g/mol] 142.23 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 
Read across compound 10 Where applicable n-Butanal 
Species 11 Rat,… human  
Route/type of study 12 Inhalation, oral feed, …  
Study length  13 Days, subchronic, chronic  
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of   
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 
POD  Value  17 [mg/m³] or [ppm]  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
 
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
 
Molar adjustment factor  29 Used in read-across (100.16/72) 1.39 
Rounded value  30 [µg/m3] 
(662.1 µg/m3 x 1.39 = 920.3 µg/m3) 
900 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Rationale for read-across  
 Data poor compound: no adequate toxicological data for nonanal exist from which an EU-LCI value could 
be derived directly using the de novo procedure. 
 Read-across from EU-LCI value of butanal: within the chemical class ‘saturated aldehydes’, butanal is the 
closest homologue compound with an EU-LCI value: five additional CH2 group in the aliphatic side chain 
of nonanal. 
 Toxicological critical endpoint for butanal: irritation (squamous metaplasia of the nasal cavity). 
 
 The key assumption underlying the read-across of the EU-LCI value from butanal to nonanal is that both 
compounds have the same critical endpoint (irritation) and this is caused by the common functional 
group (and not by the additional CH2 group). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
Nonanal 
 
142.23  ?   
(read-across to be used) 
 
900 µg/m³ 
Butanal 
 
72.11 650 µg/m3 
(de novo protocol)  
Unrounded value:  
662.1 µg/m³ or 223.2 ppb 
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 Unrounded EU-LCI value for butanal: 662.1 µg/m³  to be used for read-across EU-LCI of nonanal. 
       Cut-off rule in place: difference in change length between the two homologue compounds is larger than   
two CH2 groups per aliphatic chain.  cut-off to hexanal.  
 Thus, EU-LCI value for nonanal is 662.1 µg/m3.  After MW conversion at 23 °C and 1.013 atm (+ cut-off 
rule at 2C): EU-LCI nonanal = 662.1 µg/m3 x 1.39 = 920.3 µg/m3   rounded to 900 µg/m³. 
 
The EU-LCI is above the odour detection threshold of  ~ 3 µg/m³ (Cometto-Muniz 2010). 
 
References 
Cometto-Muniz JE, Abraham MH (2010). Odor detection by humans of lineal aliphatic aldehydes and helional 
as gauged by dose-response functions. Chem Senses 35:289-299. 
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A.17 n-Decanal (read-across from n-Butanal) 
 
Compound n-Decanal 
(read-across from n-Butanal) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 900 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX  
EC-Nr. 5  EINECS – ELINCS – NLP 203-957-4 
CAS-Nr. 6 Chemical Abstract Service number 112-31-2 
Harmonised CLP classification 7 Human health risk related classification  not harmonized 
Molar mass  8 [g/mol] 156.2 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 
Read across compound 10 Where applicable n-Butanal 
Species 11 Rat,… human  
Route/type of study 12 Inhalation, oral feed, …  
Study length  13 Days, subchronic, chronic  
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of   
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 
POD  Value  17 [mg/m³] or [ppm]  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
 
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
 
Molar adjustment factor  29 Used in read-across (100.16/72) 1.39 
Rounded value  30 [µg/m3] 
(662.1 µg/m3 x 1.39 = 920.3 µg/m3) 
900 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Rationale for read across  
 Data poor compound: no adequate toxicological data for decanal exist from which an EU-LCI value could 
be derived directly using the de novo procedure. 
 Read-across from EU-LCI value of butanal: within the chemical class ‘saturated aldehydes’, butanal is the 
closest homologue compound with an EU-LCI value: six additional CH2 group in the aliphatic side chain 
of decanal. 
 Toxicological critical endpoint for butanal: irritation (squamous metaplasia of the nasal cavity). 
 
 The key assumption underlying the read-across of the EU-LCI value from butanal to decanal is that both 
compounds have the same critical endpoint (irritation) and this is caused by the common functional 
group (and not by the additional CH2 group). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
Decanal 
 
156.2  ?   
(read-across to be used) 
 
900 µg/m³ 
Butanal 
 
72.11 650 µg/m3 
(de novo protocol)  
Unrounded value:  
662.1 µg/m³ or 223.2 ppb 
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 Unrounded EU-LCI value for butanal: 662.1 µg/m³  to be used for read-across EU-LCI of decanal. 
        Cut-off rule in place: difference in change length between the two homologue compounds is larger than  
two CH2 groups per aliphatic chain.  cut-off to hexanal.  
 Thus, EU-LCI value for decanal is 662.1 µg/m3.  After MW conversion at 23 °C and 1.013 atm (+ cut-off 
rule at 2C): EU-LCI decanal = 662.1 µg/m3 x 1.39 = 920.3 µg/m3   rounded to 900 µg/m³. 
The EU-LCI is above the odour detection threshold of ~3  µg/m³ (Nagata 2003). 
References 
Nagata Y (2003). Measurement of odor threshold by triangle odor bag method. Odor Measurement Rev 118-
127. 
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A.18 2-Ethyl hexanal (read-across from n-Butanal) 
 
Compound 2-Ethyl hexanal 
(read-across from n-Butanal) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 900 
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX  
EC-Nr. 5  EINECS – ELINCS – NLP 204-596-5 
CAS-Nr. 6 Chemical Abstract Service number 123-05-07 
Harmonised CLP classification 7 Human health risk related classification  Not harmonized 
Molar mass  8 [g/mol] 128.21 
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
 
Read across compound 10 Where applicable n-Butanal 
Species 11 Rat,… human  
Route/type of study 12 Inhalation, oral feed, …  
Study length  13 Days, subchronic, chronic  
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of   
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
 
POD  Value  17 [mg/m³] or [ppm]  
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
 
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
 
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
 
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)  
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
 
Molar adjustment factor  29 Used in read-across (100.16/72.11) 1.39 
Rounded value  30 [µg/m3] 
(6.1 µg/m3 x 1.39 = 920.3 µg/m3) 
900 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Rationale for read-across  
 Data poor compound: no adequate toxicological data for 2-ethyl hexanal exist from which an EU-LCI 
value could be derived directly using the de novo procedure. 
 Read-across from EU-LCI value of butanal: within the chemical class ‘saturated aldehydes’, butanal is the 
closest homologue compound with an EU-LCI value: two additional CH2 group in the aliphatic main side 
chain of 2-ethyl hexanal, and one in the second minor side chain. 
 Toxicological critical endpoint for butanal: irritation (squamous metaplasia of the nasal cavity). 
 
 The key assumption underlying the read-across of the EU-LCI value from butanal to 2-ethyl hexanal is 
that both compounds have the same critical endpoint (irritation) and this is caused by the common 
functional group (and not by the additional CH2 groups). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
2-ethyl hexanal 
 
128.21  ?   
(read-across to be used) 
 
900 µg/m³ 
Butanal 
 
72.11 650 µg/m3 
(de novo protocol)  
Unrounded value:  
662.1 µg/m³ or 223.2 ppb 
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 Unrounded EU-LCI value of butanal: 662.1 µg/m³  to be used for read-across EU-LCI of 2-ethyl hexanal. 
       Cut-off rule in place: difference in change length between the two homologue compounds is larger than  
two CH2 groups per aliphatic chain.  cut-off to hexanal. 
 Thus, EU-LCI value for 2-ethyl hexanal is 662.1 µg/m3.  After MW conversion at 23 °C and 1.013 atm (+ 
cut-off rule at 2C): EU-LCI 2-ethyl hexanal = 662.1 µg/m3 x 1.39 = 920.3 µg/m³  rounded to 900 µg/m³. 
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A.19 n-Propylbenzene (read-across from Ethylbenzene) 
 
Compound n-Propylbenzene 
(read-across from Ethylbenzene) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 950  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX 601-024-00-X 
EC-Nr. 5  EINECS – ELINCS - NLP 203-132-9 
  
CAS-Nr. 6 Chemical Abstract Service number 103-65-1 
Harmonised CLP classification 7 Human health risk related classification  Asp. Tox. 1 
STOT SE 3 
Molar mass  8 [g/mol] 120.19  
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
  
Read across compound 10 Where applicable Ethylbenzene 
Species 11 Rat,… human   
Route/type of study 12 Inhalation, oral feed, …   
Study length  13 Days, subchronic, chronic   
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of    
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
    
POD  Value  17 [mg/m³] or [ppm]  0.860 mg/m³ or 0.197 
ppm 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
  
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)   
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
        860    µg/m3 
           197    ppb 
Molar adjustment factor  29 Used in read-across 1.13 (=120.19/106.17) 
Rounded value  30 [µg/m3] 
(860 µg/m3 x 1.13 = 971.8 µg/m3) 
950 
Additional Comments 31   
 
 
 
 
 
 
Rationale Section 32   
 
 
Rationale for read-across 
 
 Data poor compound: no adequate toxicological data for n-propylbenzene; de novo derivation of EU-LCI 
for n-propylbenzene is not possible. 
 Read-across from EU-LCI value of ethylbenzene: within the chemical class ‘saturated aromatic 
hydrocarbons’, ethylbenzene is the closest homologue compound with an EU-LCI value: one additional 
CH2 group in the aliphatic side chain of n-propylbenzene. 
 Toxicological critical endpoint for ethylbenzene: ototoxicity. 
 The key assumption underlying the read-across of the EU-LCI value from ethylbenzene to propylbenzene 
is that both compounds have the same critical endpoint (ototoxicity) and this is caused by the common 
functional group (and not by the additional CH2 group). 
 
Compound Structure MW 
[g/mol] 
EU-LCI value 
n-Propylbenzene 
 
120.19  ?   
(read-across to be used) 
 
950 µg/m³ 
Ethylbenzene 
 
106.17 850 µg/m3 
(de novo protocol)  
Unrounded value:  
860.6 µg/m³ or 197 ppb 
CH3
H3C
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 Unrounded EU-LCI value for ethylbenzene: 860 µg/m3  to be used for read-across EU-LCI of n-
propylbenzene. 
No cut-off rule in place: difference in change length between the two homologue compounds is smaller 
than two CH2 groups per aliphatic chain. 
 Thus, EU-LCI value for ethylbenzene is 860 µg/m3.  After MW conversion (at 23 °C and 1.013 atm) : EU-
LCI n-propylbenzene = 860 µg/m3 x 1.13 = 971.8 µg/m³  rounded to 950 µg/m³. 
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A.20 Phenyloctane and Isomers (read-across from Ethylbenzene) 
 
Compound Phenyloctane and Isomers 
(read-across from Ethylbenzene) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 1100  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX (Not in Annex IV of CLP 
Regulation 1272/2008)   
EC-Nr. 5  EINECS – ELINCS - NLP 218-582-1  
CAS-Nr. 6 Chemical Abstract Service number 2189-60-8  
Harmonised CLP classification 7 Human health risk related classification   Not harmonized  
Molar mass  8 [g/mol] 190.32  
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
  
Read across compound 10 Where applicable Ethylbenzene 
Species 11 Rat,… human   
Route/type of study 12 Inhalation, oral feed, …   
Study length  13 Days, subchronic, chronic   
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of    
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose, …. 
   
POD  Value  17 [mg/m³] or [ppm]  0.860 mg/m³ or 0.197 ppm 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d)  
Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic  
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Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
  
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)   
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
860   µg/m3 
197   ppb 
Molar adjustment factor  29 Used in read-across 1.264 
Rounded value  30 [µg/m3] 
(860 µg/m3 x 1.264 = 1087 µg/m3) 
1100 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
Rationale for read-across 
 
 Data poor compound: no adequate toxicological data for phenyl octane (and isomers); de novo derivation of 
EU-LCI for phenyl octane is not possible; therefore, read-across from other compounds was applied, and is 
justified below. 
 Read-across candidate compounds for starting value: within the chemical class of ‘saturated aromatic 
hydrocarbons’ ethylbenzene is the closest homologue with an EU-LCI value; phenyl octane having additional 
(CH2)6 groups in the aliphatic chain compared to ethylbenzene. EU-LCI value for ethylbenzene: 197 ppb. 
Chemical structure, molecular weight of phenyl octane and ethylbenzene are listed in the following table: 
Compound Structure MW  
[g/mol] 
EU-LCI value 
Phenyl octane and 
isomers 
 
190.32    
 
Ethylbenzene 
 
106.17 850 µg/m²  
(de novo protocol)-  
Unrounded value: 860.6 µg/m³ or 
197 ppb 
 
 Toxicological critical endpoints for homologue compounds:  
Ethylbenzene: ototoxicity, assuming the critical endpoint for phenyl octane is ototoxicity. 
 
 The key assumption underlying the read-across of the EU-LCI value from ethylbenzene to phenyl octane is 
that both compounds have the same critical endpoint (ototoxicity) and that this endpoint is caused by the 
common functional group (and not by the additional CH2 groups). 
H3C
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 The cut-off rule on the molar adjustment factor is applicable: difference in change length between the two 
homologue compounds is larger than two CH2 groups per aliphatic chain. 
 
 Thus after applying the MW conversion molar weight conversion (at 23°C and 1.013 atm) and applying the 
cut-off rule to butylbenzene: EU LCI phenyl octane= 1087.0 µg/m³  to be rounded to 1100 µg/m³). 
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A.21 Diisopropylbenzene (1,3-, 1,4-)  (read-across from Xylenes) 
 
Compound Diisopropylbenzene (1,3-, 1,4-) 
(read-across from Xylenes) 
Factsheet 
Parameter Note Comments Value / descriptor 
 
EU-LCI Value and Status    
EU-LCI value  1 Mass/volume [µg/m³] 750  
EU-LCI status 2 Interim / Confirmed  Interim 
EU-LCI year of issue 3 Year when the EU-LCI value has been 
issued 
 2013 
General Information    
CLP-INDEX-Nr.  4  INDEX (Not in Annex VI of CLP 
Regulation 
1272/2008)   
EC-Nr. 5  EINECS – ELINCS - NLP 202-773-1 for (1,3-) 
202-826-9 for (1,4-) 
  
CAS-Nr. 6 Chemical Abstract Service number 99-62-7 for (1,3-) 
100-18-5 for (1,4-) 
Harmonised CLP classification 7 Human health risk related classification   Not harmonized  
  
Molar mass  8 [g/mol] 162.27  
Key Data / Database    
Key study, 
Author(s), 
Year  
9 Critical study with lowest relevant effect 
level 
  
Read across compound 10 Where applicable Xylene 
Species 11 Rat,… human   
Route/type of study 12 Inhalation, oral feed,…   
Study length  13 Days, subchronic, chronic   
Exposure duration 14 Hrs/day, days/week  
Critical endpoint 15 Effect(s), site of    
Point of departure (POD) 16 LOAEC*L, NOAEC*L, NOEC*L, 
Benchmark dose,…. 
 
POD  Value  17 [mg/m³] or [ppm]  0.492 mg/m³ or 0.1126 
ppm 
Assessment Factors (AF) 18   
Adjustment for exposure 
duration 
19 Study exposure 
hrs/day, days/week 
 
AF 
Study Length 
20 sa sc c  
(R8-5) 
 
Route-to-route extrapolation 
factor 
21   
AF  
Dose-response  
22 a Reliability of dose-response,  
LOAEL  NOAEL  
  
 22 b Severity of effect (R 8-6d)  
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Interspecies differences 23 a Allometric  
Metabolic rate (R8-3) 
  
 23 b Kinetic + dynamic  
Intraspecies differences 24 Kinetic + dynamic 
Worker - General population 
  
AF (sensitive population) 25 Children or other sensitive groups   
Other adjustment factors 
Quality of whole database 
26 Completeness and consistency 
Reliability of alternative data (R8-6 d,e) 
 
Result    
Summary of assessment 
factors 
27 Total Assessment Factor (TAF)   
POD/TAF 28 Calculated value (µg/m3 and ppb) 
 
492    µg/m3 
112.6    ppb 
Molar adjustment factor  29 Used in read-across 1.526 (=162.27/106.17) 
Rounded value  30 [µg/m3] 750 
Additional Comments 31   
 
 
 
 
 
Rationale Section 32   
 
 
Rationale for read-across 
 
 Data poor compound: no adequate toxicological data for diisopropylbenzene (1,3-, 1,4-); de novo 
derivation of EU-LCI for diisopropylbenzene is not possible. 
 Read-across candidate compounds for starting value: within the chemical class of ‘saturated aromatic 
hydrocarbons’ xylene and ethylbenzene are two compounds with  EU-LCI values and having similar 
‘closest homologue’ to diisopropylbenzene (1,3-, 1,4). Cumene (=isopropylbenzene) is another possible 
homologue, but it has no EU-LCI value. 
 Toxicological critical endpoints for homologue compounds:  
o xylene: effects on central nervous system (CNS) (and irritation);  
o ethylbenzene: ototoxicity. 
 Of these compounds, xylene has the lowest EU-LCI value (112.6 ppb). Thus, as a conservative approach, 
xylene is used as the most appropriate homologue compound to start the read-across. 
 The key assumption underlying the read-across of the EU-LCI value from xylene to diisopropylbenzene 
(1,3-, 1,4-) is that both compounds have the same critical endpoint (CNS effects) and this endpoint is 
caused by the common functional group (and not by the additional CH2 groups). 
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Compounds Structure MW 
[g/mol] 
EU-LCI value 
Diisopropylbenzene 
(1,3-, 1,4-) 
 
162.27 ?   
(read-across to be 
used) 
750 µg/m³ 
 
Xylene  106.17 500 µg/m³ 
(de novo protocol) 
Unrounded value: 
491.9 µg/m³ or 112.6 
ppb  
Ethylbenzene 
 
106.17 850 µg/m3  
(de novo protocol)  
Unrounded value: 
860.6 µg/m³ or 197 
ppb 
 
 
 No cut-off rule in place: difference in change length between the two homologue compounds is smaller 
than two CH2 groups per aliphatic chain. 
 Thus, the unrounded EU-LCI value for diisopropylbenzene (1,3-, 1,4-) is 492 µg/m3. After MW conversion 
(at 23 °C and 1.013 atm): EU-LCI diisopropylbenzene (1,3-, 1,4-) = 492 µg/m3 x 1.526 = 750.8 µg/m³ to 
be rounded to 750 µg/m³. 
 
 
H3C
CH3
CH3
CH3
H3C
CH3 CH3 CH3
CH3
CH3
CH3
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Abstract 
 
The health based evaluation of chemical emissions from construction products is an integral part of the harmonisation framework for indoor 
products labelling schemes in the EU. The harmonisation process for the health based evaluation of gas-phase chemical emissions from 
construction products in Europe, is based on the LCI (‘Lowest Concentration of Interest’) approach and is described fully in this report.  
The work was co-ordinated by the European Commission’ Directorate General Joint Research Centre (DG JRC) and performed in the context 
of the PILOT INDOOR AIR MONIT administrative arrangement with the Directorate General for Health and Consumers (SANCO) in liaison 
with experts from the EU Member States and the Directorate General for Enterprise and Industry (DG ENTR). 
This EU-LCI development work outlined in the present report builds on firm foundations of the exisiting national labelling schemes 
established by AgBB in Germany and ANSES in France that currently apply the LCI concept, as well as those in Finland, Denmark and 
Belgium. Ultimately, the harmonisation process and procedures described here will allow voluntary and mandatory labelling schemes to 
evaluate product emissions in the same way by using a robust health-based procedure. This work also supports the establishment of future 
emission classes for CE marking under the European Construction Products Regulation ((EU) No 305/2011) with a harmonised list of LCI 
values (EU-LCIs).  
In the EU-LCI work performed to date, only volatile organic compounds (VOCs) have been considered. Very volatile (VVOCs) with the 
exception of acetaldehyde and formaldehyde, semi-volatile organic compounds (SVOCs) and carcinogens were not considered at this stage of 
the process.   
This phase of the EU-LCI harmonisation process has established:  
1. A robust protocol for establishing a harmonised list of compounds and their associated EU-LCI values which takes into account 
existing procedures used in some EU Member States. This procedure, based on sound toxicological and risk assessment principles, 
represents an appropriate health-protective, science-based and transparent yet pragmatic approach for the evaluation of chemical 
emissions from construction products. 
2. A list of interim EU-LCI values for 82 compounds, which includes some of the compounds most relevant to DG ENTR’s ad hoc group 
on emission classes (i.e., acetaldehyde, toluene, xylene, 1,2,4-trimethylbenzene, 1,4-dichlorobenzene, ethylbenzene, 2-butoxyethanol 
and styrene) and two compounds shaded of recent concern in Germany (ε-caprolactam) and Belgium (α-Pinene).   
3. A flexible framework that enables future revision of the content of the EU-LCI list in terms of both the type and number of 
compounds included and their associated EU-LCI values. The framework provides the possibility of taking into account new 
knowledge (e.g. data resulting from the REACH implementation process or compounds identified and suggested by EU national 
authorities). 
The protocol also provides guidance on applying a harmonised application of read-across and assessment factors in EU-LCI derivation. 
Through application of the principles and rationale developed for the establishment of EU-LCI values, EU-LCI values have been established 
for a number of priority compounds. The EU-LCI WG compiled an EU-LCI master list containing a total of 177 compounds and subdivided 
into two groups, the first containing 82 compounds with agreed interim EU-LCI values and the second containing 95 compounds for which 
EU-LCI values are still to be derived.   
The practical application of the EU-LCI values and the necessary consideration of multiple sources that are normally present in real building 
scenarios are discussed and potential harmonisation issues related to the overall evaluation of emissions from construction products (for 
example, common criteria and threshold values for TVOC, SVOC, sensory evaluation and the sum of “not-yet-assessable” compounds) are 
identified. 
Finally, developments concerning policies at both EU and national levels that have explicitly or implicitly considered and/or referred to the 
work of the EU-LCI WG are reported. 
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Mission of the JRC 
 
As the Commission’s in-house science service, the Joint Research Centre’s mission is to 
provide EU policies with independent, evidence-based scientific and technical support 
throughout the whole policy cycle. 
 
Working in close cooperation with policy Directorates-General, the JRC addresses key 
societal challenges while stimulating innovation through developing new standards, 
methods and tools, and sharing and transferring its know-how to the Member States 
and international community. 
 
Key policy areas include: environment and climate change; energy and transport; 
agriculture and food security; health and consumer protection; information society and 
digital agenda; safety and security including nuclear; all supported through a cross-
cutting and multi-disciplinary approach. 
 
 
 
 
L
B
- N
A
- 2
6
1
6
8
- E
N
- N
 
   
